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ABSTRACT OF DISSERTATION 
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF INHIBITORS 
AGAINST BOTH HUMAN AND MOUSE MICROSOMAL PROSTAGLANDIN E2 
SYNTHASE-1 ENZYMES 
As the principal pro-inflammatory prostanoid, prostaglandin E2 (PGE2) serves as 
mediator of pain and fever in inflammatory reactions.  The biosynthesis of PGE2 starts 
from arachidonic acid (AA). Cyclooxygenase (COX)-1 and/or COX-2 converts AA to 
prostaglandin H2 (PGH2), and PGE2 synthases transform PGH2 to PGE2. Current 
mainstream approach for treating inflammation-related symptoms remains the application 
of traditional non-steroidal anti-inflammatory drugs (tNSAIDs) and selective COX-2 
inhibitors (coxibs). As both categories shut down the biosynthesis of all downstream 
prostanoids, their application renders several deleterious effects including 
gastrointestinalulceration and cardiovascular risk. Microsomal prostaglandin E2 synthase-
1 (mPGES-1) inhibitors, specifically blocking the production of inflammation-related 
PGE2, are expected to reduce the adverse effects while retain the anti-inflammation 
activity. Although several compounds have been reported, only a few have entered clinical 
trials and none was on the market. Particularly, most of the reported human mPGES-1 
inhibitors were not active for wild-type mouse/rat mPGES-1 enzymes, which prevents 
using the well-established mouse/rat models of inflammation in preclinical studies. 
Therefore, we expect our designed inhibitors to also be potent against mouse mPGES-1 
and thus is suitable for preclinical testing in wild-type mice. 
KEYWORDS: anti-inflammatory drugs, mPGES-1 inhibitors, selectivity, isatin 
derivatives, benzylidenebarbituric acid, carrageenan air-pouch. 
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 Introduction 
1.1 Prostaglandin E2: mediator in inflammation 
The prostaglandins are biologically active lipids released from phospholipid membranes 
by the action of phospholipase A2 (PLA2). Structurally, prostaglandins are derivatives of 
arachidonic acid and other polyunsaturated fatty acids. Among various prostaglandins, 
prostaglandin E2 (PGE2) is widely recognized as a pro-inflammatory mediator. It tends to 
be over-produced at pathological sites of inflammation; it triggers two prominent 
characteristics of inflammation: fever and pain;[2] and its production can be largely induced 
by pro-inflammatory stimuli such as lipopolysaccharide (LPS) and interleukin-1β (IL-
1β).[3] Moreover, recent research revealed that PGE2 could be closely involved in many 
types of cancers as it was believed to regulate crucial steps in tumorigenesis by stimulating 
cancer cell proliferation, enhancing angiogenesis, preventing apoptosis and inducing 
metastasis.[4] 
However, the physiological functions as the positive sides of PGE2 should not be ignored, 
especially its protective function of gastrointestinal system in the promotion of duodenal 
bicarbonate secretion and in the suppression of gastric acid production.[5] 
1.2 The biosynthetic pathway of PGE2 
PGE2 is biosynthesized from arachidonic acid (AA) liberated by phospholipase A2 (PLA2) 
from membrane phospholipids, followed by several enzymatic transformations known as 
one of the pathways of arachidonic cascade,[6] as shown in Scheme 1-1. In the first step, 
AA is converted into prostaglandin H2 (PGH2) by the action cyclooxygenases (COX-1 and 
COX-2) that are also known as PGH2 synthases. COX isozymes catalyze both of the two 
successive steps in the formation of PGH2: the foregoing cyclooxidization at the 
cyclooxygenase site to generate the endoperoxide prostaglandin G2 (PGG2), and the 
subsequent reduction of the unstable intermediate PGG2 at the peroxidase site of COXs to 
form PGH2.[7] 
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PGH2 acts as the common precursor for various prostanoids such as PGD2, PGE2, PGF2α, 
prostacyclin (PGI2) and thromboxane A2 (TXA2), depending on the action of specific distal 
synthases. Among these terminal synthases, PGE2 synthases are responsible for the final 
step in the biosynthesis of PGE2: the isomerization COXs-derived peroxide PGH2 to 
PGE2.[8] Three distinct PGE2 synthases have been cloned and characterized in recent 
decades: microsomal prostaglandin E2 synthase-1 (mPGES-1), microsomal prostaglandin 
E2 synthase-2 (mPGES-2) and cytosolic prostaglandin E2 synthase (cPGES). 
Arachidonic Acid (AA)
CO2H
PGG2
O
O
CO2H
OOH
PGH2
O
O
CO2H
OH
COX-1 COX-2
mPGES-1
mPGES-1
cPGES
PGE2
CO2H
OH
O
HO
Specific
distal
synthases
PGI2
PGF2
PGD2
TXA2
PLA2
Membrane
 
Scheme 1-1. Biosynthetic pathway of prostaglandin E2. 
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1.3 Anti-inflammatory strategies 
1.3.1 Traditional non-steroidal anti-inflammatory drugs (tNSAIDs) 
For decades, traditional non-steroidal anti-inflammatory drugs (tNSAIDs), including 
ibuprofen and indomethacin (structures shown in Fig. 1-1), have been the mainstay to 
diminish inflammation and to treat inflammation-related symptoms by non-selectively 
inhibiting either COX-1 or COX-2 or both.[9] However, COX-1 and COX-2, despite their 
similarities in molecular weights and 3D structures,[10] behave and function distinctly. 
COX-1 is ubiquitous and constitutively expressed with a relatively stable concentration in 
the body, whereas COX-2 is absent from most cell types. The expression of COX-2 is 
highly inducible in response to inflammatory stimuli.[11] COX-1 primarily produces 
prostanoids for “housekeeping” homeostatic functions such as stomach mucosal protection 
and kidney water excretion, while COX-2, on the other hand, is responsible for the 
prostanoids associated with inflammation, fever and pain.[12] The application of tNSAIDs 
is believed to exert anti-inflammatory activity through the inhibition of only COX-2. 
However, the unwanted adverse effects of tNSAID application, including ulcers and 
bleeding within the gastrointestinal (GI) tract[13] are believed to result from the interference 
of COX-1-derived protective function in GI tract as homeostatic PGE2 produced by COX-
1 promotes duodenal bicarbonate secretion and suppresses gastric acid production.[5]  
CO2H
Me
Me
Me
N
MeO
Me
CO2H
O
Cl
Ibuprofen Indomethacin  
Fig. 1-1. Structures of selected tNSAIDs: ibuprofen and indomethacin. 
1.3.2 Coxibs 
Due to the adverse effects associated with the application of non-selective tNSAIDs, a 
major effort has been deployed in the development of selective COX-2 inhibitors[14] so as 
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to preserve the regular housekeeping function of COX-1. While tNSAIDs are considered 
as the 1st generation, selective COX-2 inhibitors, also known as coxibs, represent the 2nd 
generation of non-steroidal anti-inflammatory drugs. Indeed, celecoxib and rofecoxib 
(structures shown in Fig. 1-2) did exhibit comparable anti-inflammatory efficacy with 
enhanced gastrointestinal tolerance as compared to non-selective tNSAIDs. Unexpectedly, 
coxib application were later observed with increased risk of cardiovascular events, 
including myocardial infarction, stroke, pulmonary hypertension and congestive heart 
failure.[15] These severe deleterious effects eventually resulted in the withdrawal of 
rofecoxib from the US market in 2004, leaving celecoxib the only FDA-approved selective 
COX-2 inhibitor on US market with the warning of cardiovascular risk. 
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Fig. 1-2. Structures of selected coxibs: celecoxib and rofecoxib. 
The biological mechanism behind the cardiovascular consequences associated with coxib 
application may result from the disruption of the crucial balance between COX-1 derived 
TXA2 and COX-2 produced PGI2, in which the former is vasoconstrictive and pro-
thrombotic while the latter is vasodilative and anti-platelet.[16] For example, celecoxib was 
discovered to suppress PGI2 synthesis (from COX-2) without simultaneous blocking the 
TXA2 production (from COX-1), from which the cardiovascular effects arise.[17] 
1.3.3 Potent mPGES-1 inhibitors 
From the biosynthetic pathway of PGE2 as shown in Scheme 1-1, the terminal step of the 
isomerization of PGH2 to PGE2 is catalyzed by three distinct PGE2 synthases, including 
two microsomal enzymes, mPGES-1and mPGES-2, and a cytosolic enzyme cPGES. 
Recent reports indicated the specific inhibition of mPGES-1, which only blocks the yield 
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of inflammation-related PGE2 without affecting the normal production of other prostanoids 
and homeostatic PGE2 downstream COX-2 (as shown in Scheme 1-2), provides promising 
perspective in the exploration of a next generation of drugs in the treatment of 
inflammation-associated symptoms.[18] 
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Scheme 1-2. Biosynthetic pathway of PGE2 and anti-inflammatory roles of tNSAIDs, 
coxibs and mPGES-1 inhibitors. 
First, both cPGES and mPGES-2 are constitutively expressed enzymes in which cPGES is 
functionally coupled with COX-1 and mPGES-2 with both COX-1 and COX-2. 
Specifically, cPGES receives the substrate PGH2 from COX-1 and mPGES-2 receives 
PGH2 from either COX-1 or COX-2 without selectivity, and they together provide basal 
level of PGE2 for physiological homeostasis.[19] However, mPGES-1, first identified in 
1999,[20] is pro-inflammatory stimuli-dependent and preferentially uses COX-2-derived 
PGH2 as a substrate to produce PGE2 related to inflammation, fever, and pain, as shown in 
Scheme 1-3.[19] 
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In addition, the knockout (KO) studies in various animal models of diseases including 
collagen-induced arthritis,[21] atherosclerosis,[22] LPS-stimulated pyresis[23] and pain 
hypersensitivity[24] confirmed the involvement of mPGES-1 enzyme. Specifically, 
ischemic stroke induced in mPGES-1 knockout mice showed significantly reduced infarct 
size and volume[25] and a decrease in inflammation response was observed in a collagen-
induced arthritis model. In human, enhanced mPGES-1 expression and PGE2 production 
have been observed in several pathologies such as rheumatoid arthritis,[26] myositis,[27] 
atherosclerosis,[28] inflammatory bowel disease,[29] cancer[30] and Alzheimer’s disease.[31] 
Altogether, these encouraging findings provided a firm rationale for targeting this enzyme 
in the development of new generation of anti-inflammatory drugs. 
COX-1
COX-2
PGH2
PGH2
AA
cPGES
mPGES-2 Constitutive PGE2
mPGES-1 Inducible PGE2
mPGES-2
Homeostasis:
Gastrointestinal protection
Renal system protection
......
Inflammation
Fever
Pain
......  
Scheme 1-3. Functional coupling of PGES with COXs. 
1.4  Structure of mPGES-1 
Several crystal structures of human mPGES-1 enzyme have been disclosed in recent years. 
The first two-dimensional (2D) low resolution crystal structure (PDB ID: 3DWW)[32] 
derived from transmission electron microscope represents the closed conformation. Our 
group proposed an mPGES-1 model in the open conformation derived from the crystal 
structures of microsomal glutathione S-transferase-1 (mGST-1) and ba3-cytochrome c 
oxidase.[33] The first three-dimensional (3D) high resolution structure provided by X-ray 
experiments (PDB ID: 4AL0)[34] and the first crystal structure of this enzyme in complex 
with an inhibitor (PDB ID: 4BPM)[35] were disclosed recently. These crystal structures, 
especially the last two with high crystallographic resolution, provide detailed structural 
information of human mPGES-1 enzyme, which is of great importance in the rational 
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design of the corresponding inhibitors. 
Human mPGES-1, a member of the membrane-associated protein involved in eicosanoid 
and glutathione metabolism (MAPEG) family, is a membrane-bound homotrimeric protein 
with a molecular weight of 16 kDa. The homotrimer has three active-site cavities within 
the transmembrane region at each monomer interface.[34] Each monomer consists of four 
transmembrane helices (TM I-IV) and encloses an inner cavity with a funnel-shaped 
opening toward the cytoplasm. The essential cofactor glutathione (GSH) adopts a 
horseshoe U-shaped conformation because of the strong interactions of the two terminal 
carboxylic groups with the positively charged region of the enzyme.[32] In fact, the GSH 
interacts with the enzyme structure by hydrogen bonds with amino acid residues R73, N74, 
E77, H113, Y117, R126 and S127 from helices II and IV and amino acid residue R38 from 
helix I. The thiol (-SH) group on GSH was proposed to attack the peroxide of PGH2 at the 
active site during catalytic cycle.[36] R126, located near the thiol group of GSH was 
suggested to be catalytic residue based on extensive computational studies in our group[18, 
33a, 37] and reported mutation studies.[36b] Mutation R126Q change the function of the 
enzyme from an isomerase to a reductase. R52 and H53 are likely to have an effect on 
species differences. 
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Scheme 1-4. Suggested mechanism of mPGES-1 catalyzed isomerization of PGH2 to PGE2. 
(1) The hydroxyl group of S127 helps forming and stabilizing the thiolate anion of GSH. 
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This thiolate anion nucleophilically attack one of the endoperoxide oxygen atom at C-9 
carbon of PGH2, producing the mixed sulfide intermediate. (2) D49 is responsible for the 
proton attraction at C-9 carbon, facilitating the S-O bond cleavage. The bidentate complex 
of D49 with R126 promotes the basicity of carboxylate of D49, which increases the 
effectiveness of proton transfer. (3) PGE2 is produced and the reactive thiolate anion is 
regenerated. 
The suggested mechanism of the isomerization of PGH2 to PGE2 by the action of mPGES-
1 including a nucleophilic attack of the thiolate anion of GSH at one of the peroxide oxygen 
atoms to form a mixed sulfide, followed by the deprotonation on C-9 and the cleavage of 
S-O bond. The hydroxyl group of S127 is suggested to promote the formation and 
stabilization of the GSH thiolate anion, facilitating the nucleophilic attack in the first step. 
D49 is the residue considered acting as base to deprive the proton on C-9. The putative role 
of R126 is the alteration of the pKa of D49 to promote the proton abstraction in the second 
step and to prevent the reduction of the intermediate. The plausible mechanism of mPGES-
1 catalyzed isomerization of PGH2 to PGE2 is suggested in Scheme 1-4. 
1.5 Recent progress in the development of potent mPGES-1 inhibitors 
1.5.1 Early unselective inhibitors 
A number of coxibs including celecoxib (IC50 = 22 µM) and lumiracoxib (IC50 = 33 µM),[38] 
and PGH2 structural analogs such as arachidonic acid (IC50 = 0.3 µM)[39] and 15-Δ12,14-
PGJ2 (IC50 = 0.3 µM)[39] were among the first bunch of compounds identified to be potent 
against mPGES-1 enzyme, although these compounds were rather  not selective for 
mPGES-1.[39] The structures of these early inhibitors are shown in Figure 1-3.  
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Fig. 1-3. Unselective mPGES-1 inhibitors. 
1.5.2 MK-886, MF-63 and their analogs by Merck 
Merck Frosst Centre for Therapeutic Research has been a productive leading group in the 
discovery of potent mPGES-1 inhibitors in the recent decades. A 5-lipoxygenase-activating 
protein (FLAP) inhibitor,[40] MK-886, was identified to inhibit human recombinant 
mPGES-1 enzyme with low micromolar potency (IC50 = 2.4 µM).[41] MK-886 was then 
used as the lead structure for the design of a series of potent and selective mPGES-1 
inhibitors with the scaffold of indole-2-proponionic acid.[42] The introduction of biphenyl 
substituent at indole-5-position led to the discovery of inhibitors 1 (IC50 = 7 nM) and 2 
(IC50 = 3 nM) with low nanomolar potencies. The molecular structures of MK-886 and its 
analogs 1 and 2 are outlined in Fig. 1-4. Both 1 and 2 showed negligible activity toward 
FLAP (target enzyme of the lead MK-886) and acceptable selectivity for mPGES-1 over 
mPGES-2 (IC50 > 1 µM) and TXA2 synthase (IC50 = 1 µM). However, the remarkable loss 
of inhibitory efficacy in both cell-based assays and human whole blood (HWB) assays 
prohibited these series of compounds from entering preclinical evaluation. 
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Fig. 1-4. MK-886 and structurally related indole-2-proponionic acid derivatives. 
Unsatisfied with the poor whole cell potency of indole carboxylic acid compounds 
mentioned above, Merck scientists developed a novel class of phenanthreneimidazoles and 
their heterocyclic derivatives from the lead compound azaphenanthrenone,[43] a JAK kinase 
inhibitor also suppressing mPGES-1 (IC50 = 0.14 µM). MF-63 was obtained through the 
replacement of azaphenanthrenone by phenanthrene with a 2,6-dicyanophenyl substituent 
at 2-position and alternation of 6-fluoro by chorine.[44] MF-63 not only exhibited excellent 
activity in cell-free assays (IC50 = 1 nM), but also showed markedly better inhibitory 
efficacy in whole cells and (IC50 = 0.05-0.42 µM) with high selectivity for mPGES-1 over 
other recombinant prostanoid synthases and isolated JAK isoenzymes. However, MF-63 
was active against neither mouse nor rat mPGES-1 enzyme, which prevents using well-
established mouse and rat models of inflammation in preclinical studies. Therefore, human 
mPGES-1 knock-in (KI) mice and guinea pigs were used as the alternatives (IC50 = 0.9 nM 
against guinea pig mPGES-1). Using these animal models, MF-63 was observed to 
suppress LPS-induced thermal hyperalgesia, iodoacetate-induced osteoarthritis pain, and 
LPS-induced pyresis.[45] 
Further structural modification generated the disubstituted phenanthreneimidazole 
derivatives 3 and 4 with IC50 value of 1 nM each. These compounds showed comparably 
potency as compared to MF-63, but were much more potent in human whole blood (IC50 = 
0.20 µM and 0.14 µM, respectively). Compound 4, with a rat half-life of 2.3 h, was 
encouragingly observed anti-analgesic effect in an LPS-stimulated guinea pig hyperalgesia 
model.[46] 
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Fig. 1-5. Molecular structures of the lead azaphenanthrenone, designed inhibitor MF-63 
and structurally related inhibitors 3–5. 
Residing in the structure of MF-63, a new biarylimidazole scaffold was then reported by 
Merck. The extensive SAR studies led to the discovery of 5, a highly potent mPGES-1 
inhibitor with an IC50 value of 1 nM in cell-free assay. Compound 5 was also active in 
A549 cells and HWB assays (IC50 = 13~160 nM and 1.6 µM, respectively). The rat 
pharmacokinetic study with this compound gave a clinical relevant half-life of 4.8 h and a 
bioavailability of 127%.[47] The structures of azaphenanthrenone, MF-63, and other 
structural analogs 3–5 are shown in Fig. 1-5. 
1.5.3 Oxicam and benzoxazole derivatives by Pfizer 
A series of compounds with oxicam template were identified as human mPGES-1 
inhibitors by high throughput screening of Pfizer chemical files. The subsequent extensive 
SAR studies led to the discovery of 6, a low nanomolar (IC50 = 0.016 µM)  inhibitor  against 
mPGES-1 with desired selectivity for mPGES-1 over COX-2 (>238 folds).[48]  
Pfizer scientists also developed a class of potent inhibitors with a benzoxazole scaffold. 
Based on detailed synthesis and the first round of SAR study, PF-0469362 (IC50 = 3.0 nM) 
was discovered as a promising mPGES-1 inhibitor with low nanomolar potency.[49] 
Unsatisfied with the poor aqueous solubility and non-detectable half-life, Pfizer scientists 
conducted a new round of SAR study, from which compounds 7 (IC50 = 8.3 nM) and 8 
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(IC50 = 19 nM) were identified as comparably potent human mPGES-1 inhibitors with 
improved water solubility and longer rat half-life (4.5 h and 17 h, respectively). The 
molecular structures of 6, PF-0469362, and 7–8 are shown in Fig. 1-6. 
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Fig. 1-6. The molecular structures of compound derived from oxicam template 6, 
benzoxazole derivatives PF-0469362, and 7–8. 
1.5.4 Dual mPGES-1/5-LO inhibitors 
As part of arachidonic acid cascade, AA released by PLA2 is transferred to 5-lipoxygenase 
(5-LO) via FLAP. Enzyme 5-LO converts AA into arachidonic acid 5-hydroperoxide (5-
HPETE), which is then further metabolized to leukotriene A4 (LTA4). LTA4 is converted 
into a series of cysteinyl-leukotrienes (LTC4, LTD4 and LTE4) and is hydrolyzed into 
LTB4.[11, 50] Leukotrienes are also important lipid mediators in inflammation that play a role 
in cancers and cardiovascular diseases.[51] Dual 5-LO and mPGES-1 inhibitors, blocking 
the biosynthesis of both PGE2 and leukotrienes, might be more efficient in diminishing 
inflammation while less afflicted with GI and cardiovascular deleterious effects.[50] 
Werz group from University of Tuebingen, Germany discovered a series of benzo[g]indol-
3-carboxylate derivatives as potent dual mPGES-1/5-LO inhibitors.[52] Compound 9 was 
identified to inhibit both mPGES-1 (IC50 = 0.6 µM) and 5-LO (IC50 = 0.086 µM) with 
submicromolar potencies in cell-free assays.[52] The low percentages of inhibition against 
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both COX-1 and COX-2 at a concentration of 10 µM of compound 9 (12% and 33%, 
respectively) demonstrated the high selectivity for mPGES-1 over COX isozymes. In vivo 
intraperitoneal administration of 9 significantly reduced PGE2 levels in pleural exudates of 
carrageenan-treated rats.[53] 
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Fig. 1-7. Molecular strucutres of dual mPGES-1/5-LO inhibitors: benzo[g]indol-3-
carboxylate derivative 9, triazole-based compound 10, indomethacin derivative 11 and 
lonazolac derivative 12. 
As continued effort, Werz group designed, synthesized and biologically evaluated another 
series of triazole-based compounds.[54] Several compounds, including 10 (IC50 = 1.2 µM 
and 2.0 µM against mPGES-1 and 5-LO, respectively), were identified as low micromolar 
inhibitors against both mPGES-1 and 5-LO. 
By structurally modifying acidic NSAIDs, Werz et al. also identified several potent dual 
mPGES-1/5-LO inhibitors among a variety of synthetic molecules.[55] Compounds 11 (IC50 
= 6.4 µM against mPGES-1 and IC50 = 2.9 µM against 5-LO) and 12 (IC50 = 3.4 µM against 
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mPGES-1 and IC50 = 2.5 µM against 5-LO), derived from indomethacin and lonazolac, 
respectively, were identified to inhibit both enzymes with comparable low micromolar 
potency. The structures of these dual mPGES-1/5-LO inhibitors are depicted in Fig. 1-7. 
1.5.5 Inhibitors discovered by virtual screening 
Although high-throughput screening has been used to identify new leads in drug discovery 
for decades, it remains an expensive and time-consuming procedure. Virtual screening has 
emerged as an alternative approach widely used in modern rational drug design. Using the 
structural model of the active conformation derived from newly disclosed crystal structures 
of MAPEG family proteins, Lai group (Peking University, China) identified highly potent 
mPGES-1 inhibitors via virtual screening.[56] Some of the molecules, with novel scaffolds, 
such as compounds 13 and 14 (Fig. 1-8) exhibited submicromolar inhibitory potencies 
against mPGES-1 in both cell-free assays (IC50 = 0.0040 µM and 0.0093 µM for 
compounds 13 and 14, respectively) and HWB assays (IC50 = 0.3 µM and 0.7 µM, 
respectively). 
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Fig. 1-8. Structures of compounds 13–14 identified from virtual screening. 
1.5.6 Other synthetic compounds as potent mPGES-1 inhibitors 
Bruno et al. characterized the function of mPGES-1 toward PGH2 metabolism in LPS-
treated human monocytes and human whole blood by analyzing the biosynthesis of 
prostanoids downstream PGES and expression of COXs in the presence of inhibition by 
the novel selective mPGES-1 inhibitor AF-3442 they prepared.[57] Compound AF-3442 is 
a carbazole derivative  with an IC50 value of 0.06 µM against human recombinant mPGES-
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1. This compound was reported to suppress PGE2 biosynthesis in LPS-stimulated human 
monocyte with an IC50 value of 0.41 µM although it was not quite potent in HWB assays 
(IC50 = 29 µM). 
A novel class of compounds based on imidazolequinoline core, which was structurally 
analogous with phenanthreneimidazole series,[44] were reported by Shiro et al. as potent 
mPGES-1 inhibitors. Compound 15, as an example, was identified as an mPGES-1 
inhibitor with low nanomolar potency (IC50 = 9.1 nM) and a 1000-fold selectivity for 
mPGES-1 over COX isoenzymes.[58] 
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Fig. 1-9. Structures of carbazole derivative AF-3442, imidazolequinoline derivative 15, 
dihydorpyrimidin-2(1H)-one derivative 16–17 and pyrazolone derivative 18. 
Terracciano et al. reported the rational structural optimization of dihydorpyrimidin-2(1H)-
one lead compound 16 (IC50 = 4.16 µM) based on the simulated binding mode of 16 with 
recently disclosed crystal structure of human mPGES-1 (PDB ID: 4BPM).[35] By 
introducing hydrophilic group and altering the dimensions of hydrophobic moiety, 
compound 17 was designed and synthesized, with a 10-fold improved potency against 
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human mPGES-1 (IC50 = 0.41 µM).[59] 
Although several compounds have been reported to inhibit human mPGES-1 with low 
nanomolar activity, these compounds were either inactive or insignificantly active for 
mouse or rat mPGES-1 enzyme. The lack of mouse/rat animal models often precluded 
preclinical study. Leclerc group from Karolinska Institute, Sweden characterized the 
pyrazolone derivative 18 as dual human/rat mPGES-1 inhibitor (IC50 = 1.8 and 0.62 µM, 
for human and rat mPGES-1 enzymes, respectively).[60] A number of in vivo studies were 
conducted to evaluate PGE2 production in rat peritoneal macrophages and rat carrageenan 
air-pouch, which supported the effectiveness of 18 in these rat models. For example, in rat 
carrageenan air-pouch model, treatment of rats with 18 at 75 mg/kg intraperitoneally 
reduced PGE2 production by 62% relative to vehicle control. The structures of AF-3442 
and 15–18 are shown in Fig. 1-9. 
1.5.7 Natural products as potent mPGES-1 inhibitors 
Curcumin, an antioxidant polyphenolic β-diketone from turmeric with anti-carcinogenic 
and anti-inflammatory activities, is a major component of the curry spice turmeric. Werz 
group identified mPGES-1 as a predominant target of curcumin in the mechanism of 
suppressing PGE2 biosynthesis.[61] Curcumin was observed to reversibly inhibit the 
isomerization of PGH2 to PGE2 by mPGES-1 in microsomes of IL-1β-stimulated A549 
lung carcinoma cells (IC50 = 0.2–0.3 µM). In addition, neither isolated ovine COX-1 nor 
human recombinant COX-2 was inhibited by curcumin at a concentration as high as 30 
µM. In addition, curcumin was also identified to inhibit 5-LO with an IC50 value of 0.7 µM. 
A few other natural products such as mytucommulone (from myrle),[62] hyperforin (from 
St. John’s wort),[63] garcinal (from the rind of guttiferae)[64] and arzanol (from Helichrysum 
italicum)[65], sharing no structural similarities except an acylphloroglucinol, were identified 
as dual mPGES-1 (IC50 = 0.3~1.3 µM) and 5-LO (IC50 = 1~3 µM) inhibitors. At higher 
concentrations, these natural products also showed inhibitory potency against COX-1 (IC50 > 
12 µM). The structures of these natural products are described in Fig. 1-10. 
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Fig. 1-10. Structures of natural products active against human mPGES-1 enzyme: 
curcumin, mytucommulone, garcinol, hyperforin and arzanol. 
1.6 Summary 
Human mPGES-1 has emerged as prospective target in the exploration of a next-generation 
of anti-inflammatory drugs, as specific mPGES-1 inhibitors are expected to 
discriminatively suppress the production of induced PGE2 without blocking the normal 
biosynthesis of other prostanoids including homeostatic PGE2. Therefore, this therapeutic 
approach is believed to reduce the adverse effects associated with the application of 
tNSAIDs and selective COX-2 inhibitors (coxibs). Although great effort has been deployed 
in the exploration of mPGES-1 inhibitors, be it from virtual screening, synthesis and natural 
products,[42, 44-49, 52, 54, 57-58, 59, 66] only a few have entered clinical trials[67] and none has made 
it to market so far. In particular, most of the reported human mPGES-1 inhibitors are not 
active for wild-type mouse or rat mPGES-1 enzyme, which prevents using the well-
established mouse/rat models of inflammation in preclinical studies. Therefore, we expect 
that our designed inhibitors to be potent for both human and mouse mPGES-1 enzymes 
and thus can be preclinically evaulated using mouse models of inflammation, such as 
carrageenan air-pouch and paw edema models. In the following chapters, the strategies for 
the design and structural optimization, the chemical synthesis and the biological evaluation 
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of two series of compounds are descibed in detail.
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 Structure-based discovery of substituted benzylidenebarbituric acid 
derivatives as mPGES-1 inhibitors suitable for preclinical testing in wild-type mice 
Part of the results described in this chapter has been published (“Structure-based discovery 
of mPGES-1 inhibitors suitable for preclinical testing in wild-type mice as a new 
generation of anti-inflammatory drugs” Sci. Rep. 2018, 8, 5205). 
2.1 mPGES-1 as a more promising anti-inflammation target 
The first generation of nonsteroidal anti-inflammatory drugs (tNSAIDs) used to treat pain 
and reduce fever or inflammation, such as ibuprofen, inhibit both COX-1 and COX-2 
without selectivity, and the second generation of NSAIDs (Coxibs), including celecoxib 
(Celebrex), rofecoxib (Vioxx) and valdecoxib (Bextra), selectively inhibit COX-2. The 
COX-2 specific inhibitors still have a number of serious side effects, such as increasing the 
risk of fatal heart attack or stroke and causing stomach or intestinal bleeding. The serious 
side effects led to the withdrawal of rofecoxib and valdecoxib, although celecoxib still 
remains in clinical use. The serious side effects are due to the fact that the synthesis of all 
physiologically needed prostaglandins downstream of PGH2 are inhibited by the action of 
the COX-1/2 inhibitors. For example, blocking the production of PGI2 will cause 
significant cardiovascular problems.[68]  
The mPGES-1 expression in most tissues including heart and brain is low, but abundant in 
a limited number of organs including kidney[69] and reproductive organs.[70] Enzyme 
mPGES-1 in human is related to various diseases associated with inflammation. For 
example, up-regulation of mPGES-1 was detected in heart tissue after myocardial 
infarction and in Alzheimer’s disease tissues.[31, 71]  Unlike the COX-1/2 inhibition, 
inhibition of terminal mPGES-1 will only block the production of PGE2 without affecting 
the normal production of other prostaglandins including PGI2. Therefore, mPGES-1, an 
inducible enzyme, is a more promising target for anti-inflammatory drugs. Reported knock-
out studies identified mPGES-1 as an essential central switch in pyresis.[72] The mPGES-1 
knock-out studies also revealed a decrease in inflammatory response in a collagen-induced 
arthritis model.[73] In contrast to COX-2, mPGES-1-deficient mice were reported to be 
viable, fertile and have normal phenotype.[73] Ischemic stroke induced in mPGES-1 null 
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mice was reported to show significant reduction in the infarct size and volume.[74] Thus, 
mPGES-1 inhibitors are expected to retain the anti-inflammatory effect of COX-1/2 
inhibitors, but without the side effects caused by the COX-1/2 inhibition. For development 
of a next generation of anti-inflammatory drugs, various mPGES-1 inhibitors have been 
reported in the literature.[42, 44, 46-49, 52, 54, 57-59, 66-67, 75]  
Unfortunately, none of the reported potent inhibitors of human mPGES-1 has shown to be 
also a potent inhibitor of mouse or rat mPGES-1, which prevents using the well-established 
mouse/rat models of inflammation-related diseases for preclinical studies. Here we present 
the discovery of a novel type of mPGES-1 inhibitors potent for both human and mouse 
mPGES-1 enzymes through structure-based rational design. These inhibitors are also 
highly selective for mPGES-1 over COX-1/2 and orally bioavailable, enabling preclinical 
testing using the well-established wild-type mouse models of inflammation-related 
diseases through oral administration. 
2.2 Design of dual inhibitors of human and mouse mPGES-1 enzymes 
Our rational design of novel mPGES-1 inhibitors started from molecular modeling of 
various human mPGES-1 inhibitors, including MF63,[75] 19[76] and its scaffold structure 
(20) depicted in Fig. 2-1A and Fig. 2-2A, for their binding with human and mouse mPGES-
1 enzymes, and aimed to design a modified, novel compound which can favorably bind 
with both human and mouse mPGES-1 enzymes at the active site. To design a compound 
which can favorably bind with both human and mouse mPGES-1 enzymes, our strategy 
was to identify a scaffold structure which can bind in the conserved region of the active 
site, ensuring that the scaffold structure can bind with both of the enzymes in a similar 
binding mode. For this purpose, molecular docking was performed to understand the 
binding of known mPGES-1 inhibitors with both human and mouse mPGES-1 enzymes 
based on an X-ray crystal structure (PDB ID: 4BPM)[35] of human mPGES-1 and a 
homology model of mouse mPGES-1 developed by using the human mPGES-1 structure 
as a template.  
As seen in Fig. 2-1B and Fig. 2-1C, compound 19 (identified from virtual screening),[76] 
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which has a unique scaffold structure (20), binds in a conserved region of the active site in 
the human and mouse mPGES-1 enzymes, although 19 has a low binding affinity with 
human mPGES-1 (IC50 = 3.5 µM).[76] The conserved region is nearby S127 and has a 
mainly hydrophobic pocket surrounded by Y28, I32, G35, L39, S127, Y130, T131, L135, 
and A138 for human mPGES-1. In comparison, mouse mPGES-1 differs from human 
mPGES-1 only in residues #32 (which is V32), #131 (which is V131), and #138 (which is 
F138). In Fig. 2-1B, D and E, we mainly highlight the residues of human mPGES-1 that 
are different in mouse mPGES-1, in addition to the most important residues (such as S127) 
for binding. 
On the basis of the scaffold structure 20, we designed a modified scaffold structure (21, 
see Fig. 2-1A) which can more favorably bind in the conserved region of the active site. 
Depicted in Fig. 2-1B to E are the binding structures of human mPGES-1 with 19, 20, and 
21, respectively. The overall binding complex with surface representation of human 
mPGES-1 is shown in Fig. 2-1C. As seen in Fig. 2-1D and E, compared to 20, 21 is a more 
favorable scaffold structure, as a carbonyl oxygen on the barbituric acid head group of 21 
forms a hydrogen bond with the hydroxyl group of S127 side chain. The same hydrogen 
bond is expected to exist in mouse mPGES-1 binding with 21. By using this novel scaffold 
(21), a series of potentially promising new compounds were designed, synthesized, 
characterized and assayed for their in vitro inhibitory activities against human and mouse 
mPGES-1 enzymes.  
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Fig. 2-1. Molecular structures of ligand structure 19, scaffold structures 20–21, and their 
binding with human mPGES-1. (A) Ligand structures; (B) binding with the lead 19; (C) 
binding complex (B) with surface representation of human mPGES-1; (D) binding with 20; 
(E) binding with 21. 
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2.3 Chemistry and SAR study 
2.3.1 SAR on the central benzene ring 
The initial SAR study was the impacts of the substitution pattern of the central benzene 
ring on the inhibitory efficacy. The synthetic protocol is outlined in Scheme 2-1. The 
tosylate 23 derived from commercially available 4-cyclohexyl-1-butanol (22) was reacted 
with various substituted hydroxybenzaldehyde in the presence of excess potassium 
carbonate as acid capturer, yielding aldehyde intermediates (24a–24q). These aldehyde 
intermediates were then condensed with barbituric acid in reflux mixture of EtOH and H2O 
to produce the final products, a series of substituted benzylidenebarbituric acid derivatives 
(25a–25q).  
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25d, X = H, Y = Me;
25e, X = H, Y = OH;
25f, X = H, Y = OMe;
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Scheme 2-1. Synthetic protocol of substituted benzylidenebarbituric acid derivatives with 
various substitution patterns on the central benzene ring. Reagents and conditions: (a) p-
Toluenesulfonyl chloride (1.20 equiv.), 50% KOH aq., DCM, 0 °C→rt, 95%; (b) K2CO3 
(2.0 equiv.), DMF, 80 °C, 74–93%; (c) EtOH/H2O (4:1, v/v), reflux, 71–95%. 
As shown in Table 2-1, we first investigated the impact of substitution on the central 
benzene ring on the inhibitory potency with fixed 4-cyclohexyl-1-butyl group as the 
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hydrocarbon tail. Without a substituent, as for 25a (X = H, Y = H), the inhibitory potency 
of the compound against both human and mouse mPGES-1 enzymes was greatly impaired.  
Table 2-1. Variation on the Central Benzene Ring. 
Compound 
Inhibition of  mPGES-1 
IC50 (human, nM)a IC50 (mouse, nM) 
25a 622±121 7087±627 
25b 33±3 157±31 
25c 45±8 917±321 
25d 82±10 n.d.b (25)c 
25e 116±17 2900±293 
25f 121±20 1458±209 
25g 186±26 2410±339 
25h 67±20 698±97 
25i 22±7 360±56 
25j 69±16 292±47 
25k 54±12 359±50 
25l 155±23 727±109 
25m 87±27 n.d. (28) 
25n 96±14 n.d. (38) 
25o 135±18 n.d. (54) 
25p 154±18 n.d. (46) 
25q 171±34 3699±562 
aData are expressed as means ± SD of single determinations obtained in triplicate. bn.d. = 
not detected. cThe % inhibition of the compound at a concentration of 10 µM against 
mPGES-1. The IC50 values were determined if the compound cause significant inhibition 
at 10 µM (≥ 70%). 
Secondly, both electro-withdrawing and electro-donating groups were tolerated, although 
the former resulted in greater inhibition. Di-substitution on the central benzene ring, as 
investigated in the structures of 25i–25k, resulted in compounds with comparable 
inhibitory efficacy as those mono-substituted.  The central benzene ring of 25l was 
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originated from isovanillin. As compared with the vanillin derivative 25f, compound 25l 
was comparably potent against human mPGES-1 (IC50 = 121 nM and 155 nM for 25f and 
25l, respectively) whereas 2-fold more potent against the mouse enzyme (IC50 = 1458 nM 
and 727 nM for 25f and 25l, respectively). In compound group 25m–25o, the central 
benzene ring was originated from salicylaldehyde with chlorine, bromine and iodine 
substituted at 5-position. These compounds were active against human mPGES-1 with 
submicromolar potencies (IC50 = 87 nM, 96 nM and 135 nM for 25m, 25n and 25o, 
respectively) but surprisingly not effective against the mouse enzyme. Naphthalene, 
instead of benzene, was used to form the “linker” in compounds 25p–25q. Compared with 
the most potent compound 25b, the inhibition against mouse mPGES-1 was markedly 
decreased while that against the human enzyme was mostly retained (IC50 = 154 nM and 
171 nM for 25p and 25q, respectively). 
2.3.2 SAR on the barbituric acid moiety 
In the next round of SAR study, variations were made on the barbituric acid “head”. We 
fixed the substitution on the central benzene ring as electro-withdrawing groups (Cl, Br 
and NO2) and the aliphatic “tail” as 4-cyclohexyl-1-butyl group. Instead of barbituric acid, 
1,3-dimethylbarbituric acid and 2-thiobarbituric acid were introduced to the structure as 
polar “head”, respectively. As shown in Scheme 2-2, the aldehyde intermediates 24b, 24c 
and 24h (with Cl, Br and NO2 substituted, respectively) were condensed with either 1,3-
dimethylbarbituric acid (26) or 2-thiobarbituric acid (28). The final products 1,3-
dimethylbarbituric acid derivatives 27a–27c and 2-thiobarbituric acid derivatives 29a–29c, 
were thus prepared. Compared with the normal barbituric acid “head” (25b, 25c and 25h), 
the substitution of methyl group (as in compounds 27a–27c) significantly impaired the 
inhibitory efficacy against human mPGES-1 with 8, 9 and 9 folds. The inhibitory potency 
against the mouse enzyme was also decreased. However, the replacement of O with S (as 
in compounds 29a–29c) generally slightly improved the inhibition for human mPGES-1. 
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Scheme 2-2. Synthetic protocol of substituted benzylidenebarbituric acid derivatives with 
variation on the barbituric acid moiety. Reagents and conditions: (a) EtOH/H2O (4:1, v/v), 
reflux, 83–95%. 
Table 2-2. SAR on the barbituric acid moiety. 
Compound 
Inhibition of  mPGES-1 
IC50 (human, nM)a IC50 (mouse, nM) 
27a 272±30 n.d.b (8)c 
27b 427±55 n.d. (24) 
27c 561±55 n.d. (15) 
29a 28±3 239±72 
29b 20±5 415±21 
29c 53±14 n.d. (49) 
aData are expressed as means ± SD of single determinations obtained in triplicate. bn.d. = 
not detected. cThe data in the parentheses refer to the % inhibition of the compound at a 
concentration of 10 µM against mPGES-1. The IC50 values were determined if the 
compound cause significant inhibition at 10 µM (≥ 70%). 
2.3.3 SAR on the side chain 
The length, shape and the substitution pattern of the aliphatic side chain were also 
investigated. The terminal cyclohexyl or cyclohexylmethyl group in 25b was replaced by 
phenyl (31) and aryloxy groups (34a–34c). Compound 31 remained active against human 
mPGES-1 but lost the potency against the mouse enzyme by 18 folds. The presence of 
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terminal aryloxy groups on the side chain was remarkably detrimental to the maintenance 
of the inhibitory activity. A plausible explanation is that the presence of oxygen atom on 
the side chain impairs the hydrophobic interaction of the compound with the enzyme, as 
discussed later in the computational part. The impact of “tail” length on the mPGES-1 
inhibition was investigated in compound group of 25h and 37a–37c (IC50 = 67 nM, 156 
nM, 517 nM and 1114 nM for compounds 25h, 37a, 37b and 37c respectively). One 
methylene group (CH2) was “cut off” from the former on the side chain of each compound. 
The rank order of potency was in accordance with the length of the “tail”: greater inhibition 
favored longer “tail”. Similarly, compounds with linear side chains (37d–37f) also 
followed the rank order, as shown Table 2-3. The synthetic protocol of these compounds 
with a range of side chains are described in Scheme 2-3. 
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Scheme 2-3. Synthetic protocol of substituted benzylidenebarbituric acid derivatives with 
various aliphatic side chains. Reagents and conditions: (a) K2CO3 (2.0 equiv.), acetone, 
reflux, 89–92%; (b) K2CO3 (2.0 equiv.), DMF, 80 °C, 71–96%; (c) EtOH/H2O (4:1, v/v), 
reflux, 78–95%; (d) p-Toluenesulfonyl chloride (1.20 equiv.), 50% KOH aq., DCM, 
0 °C→rt, 67%. 
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Table 2-3. SAR on the aliphatic side chain. 
Compound 
Inhibition of mPGES-1 
IC50 (Human, nM)a IC50 (Mouse, nM) 
31 73±10 2788±525 
34a 349±40 n.db (52)c 
34b 337±34 n.d (17) 
34c 365±59 n.d. (19) 
37a 156±30 373±51 
37b 517±68 2395±425 
37c 1114±104 n.d. (42) 
37d 460±64 n.d. (62) 
37e 232±54 734±119 
37f 188±43 1303±163 
aData are expressed as means ± SD of single determinations obtained in triplicate. bn.d. = 
not detected. cThe data in the parentheses refer to the % inhibition of the compound at a 
concentration of 10 µM against mPGES-1. The IC50 values were determined if the 
compound cause significant inhibition at 10 µM (≥ 70%). 
2.4 In vitro activities and selectivity 
All the synthesized compounds were first screened at a single concentration of 10 µM for 
the calculation of percentage of inhibition against both human and mouse mPGES-1 
enzymes. Compounds caused significant inhibition (≥ 70%) were further tested for their 
IC50 values. MK-886,  a well-recognized human mPGES-1 inhibitor, was used as a 
reference compound for which we obtained IC50 = 2.6 ± 0.6 µM, which is close to the 
previously reported IC50 values (IC50 = 1.6 µM,[42] and 2.4±0.3 µM[66a]) without significant 
inhibition of mouse mPGES-1.The concentration-dependent curves of compound 25b 
against human and mouse mPGES-1 enzymes are shown in Fig. 2-2. 
29 
 
 
Fig. 2-2. Concentration-dependent curves of compound 25b against human and mouse 
mPGES-1 enzymes. (A) Concentration-dependent inhibition of human mPGES-1 (n = 3); 
(B) Concentration-dependent inhibition of mouse mPGES-1 (n = 3). 
Next we wanted to know whether these compounds have significant inhibitory activities 
against either COX-1 or COX-2. For this purpose, some of the more potent compounds 
with IC50 valuesless than 100 nM) were assayed for their potential inhibitory activities 
against mixed COX-1 and COX-2 (denoted as COX-1/2) with equal amounts of COX-1 
and COX-2 in terms of the enzyme activities. The protein preparation and purification and 
the protocol for in vitro activity assays followed our previous reports.[76-77] The data shown 
in Table 2-4 demonstrated that among all the 14 compounds tested, only 25c, 25m, 25n, 
29d, 29e and 31 caused an inhibition greater than 50%  at a concentration as high as 100 
µM, most of these compounds caused less than 50% inhibition, including the most potent 
compounds 25b (4.3%) and 25i (2.6%). 
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Table 2-4. Inhibition against COX-1/2 of selected compounds. 
Compound % Inhibition at 100 µMa 
25b 4 ±6 
25c 63±1 
25d 9±7 
25h 43±3 
25i 3±7 
25j 17±5 
25k 15±3 
25m 56±4 
25n 71±5 
29d 93±2 
29e 79±3 
29f 18±1 
31 53±4 
aThe % inhibition of the compound at a concentration of 100 µM against the COX-1/2 
(mixed COX-1 and COX-2). The enzyme mixture contained equal amounts of COX-1 and 
COX-2 in terms of their enzyme activities. In this way, when a compound can significantly 
inhibit either COX-1 or COX-2, it will show significant inhibitory effects against the mixed 
COX-1 and COX-2. The error bars were given by the program of GraphPad Prism 7. 
2.5 Enzyme-inhibitor binding modes 
To further elucidate the SAR of this series of compounds, we performed molecular docking 
study of 25b, one of the most potent barbituric acid derivative inhibiting both human and 
mouse mPGES-1 enzymes with nanomolar potencies without significant inhibition against 
COX isozymes,  using the AutoDock 4.2 program.[78] The binding modes of 25b with both 
human and mouse mPGES-1 enzymes were investigated, as depicted in Fig. 2-3B and Fig. 
2-3C, respectively. As predicted, compound 25b binds in a conserved region of the active 
site of both human and mouse mPGES-1 enzymes. For human mPGES-1 (PDB ID: 4BPM), 
the conserved region is nearby S127 and has a hydrophobic pocket surrounded by Y28, I32, 
G35, L39, Y130, T131, L135, and A138. Only a few amino acid residues in mouse 
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mPGES-1 differentiate from the human enzyme in this conserved region, where V32, V131, 
and F138 take over I32, T131, and A138 respectively. The hydrogen bonding interaction 
between the barbituric acid carbonyl group and the hydroxyl groups of S127 is crucial for 
the compound to maintain the inhibitory potency. As discussed in the SAR study, 
replacement of the amide hydrogens on the barbituric acid with two methyl groups 
significantly lowers the inhibitory potency, which might result from the impairment of 
hydrogen bonding. The substituted alkoxy on the side chain occupies the hydrophobic 
groove where the long hydrocarbon “tail” of PGH2 locates. The longer and bulkier side 
chains are favored as they match the size and shape of the hydrophobic pocket better. 
Aryloxy substitution on the side chain greatly lowers the inhibition not only because of 
oxygen atom that impairs the hydrophobic interaction, but also the rigidity of aryl groups 
that hampers structural complementarity. 
In addition, we obtained IC50 = 1.5 nM for MF63 against human mPGES-1 and MF63 at 
10 µM had no significant inhibition against mouse mPGES-1, which is consistent with the 
previously reported data showing that MF63 potently inhibited human mPGES-1 (IC50 = 
1.3 nM) without significant activity against the mouse or rat enzyme.[45] For comparison, 
we also investigated the binding of MF63 with mPGES-1 and tried to propose a plausible 
explanation of this selectivity. As predicted in Fig. 2-3D, the NH group on the imidazole 
ring of H53 of human mPGES-1 forms a hydrogen bond with one aromatic nitrogen atom 
on MF63. As we transferred the structure of MF63 from Fig. 2-3D to mouse mPGES-1 
(Fig. 2-3E), the same hydrogen bond between H53 and MF63 does not exist as amino acid 
residue R53 in mouse mPGES-1 (which is H53 in the human enzyme) almost overlap with 
the ligand structure. The binding of MF63 with unique residue in human mPGES-1 makes 
it inactive against the mouse enzyme. 
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Fig. 2-3. Molecular structures of 25b and MF63 and their binding with human and mouse 
mPGES-1 enzymes. (A) Ligand structures of 25b and MF63; (B) binding of 25b with 
human mPGES-1; (C) binding of 25b with mouse mPGES-1; (D) binding of MF63 with 
human mPGES-1; (E) hypothetical binding structure of mouse mPGES-1 with MF63 after 
human mPGES-1 structure in panel D is replaced by mouse mPGES-1 structure. 
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2.6  In vivo anti-inflammatory activity 
 
Fig. 2-4. Data from in vivo assays using the mouse carrageenan air-pouch model of 
inflammation (n = 4 each group) with 25b or celecoxib dosed orally. (A) the effectiveness 
of 25b in reducing PGE2 level in air-pouch fluid; (B) the effectiveness of 25b in reducing 
PGE2 level in kidney (assayed for PGE2 by ELISA and expressed as Mean ± SEM). 
Statistical results from the one-way ANOVA analysis of the data in panel A with post hoc 
tests: p = 0.0003 for Vehicle Control vs 20 mg/kg 25b (p.o., bid); p < 0.0001 for Vehicle 
Control vs 10 mg/kg 25b (p.o., bid); and p < 0.0001 for Vehicle Control vs 50 mg/kg 
celecoxib (p.o., pid). Statistical results from the one-way ANOVA analysis of the data in 
panel A with post hoc tests: p < 0.0001 for Vehicle Control vs 20 mg/kg 25b (p.o., bid); p 
< 0.0001 for Vehicle Control vs 10 mg/kg 25b (p.o., bid); and p < 0.0001 for Vehicle 
Control vs 50 mg/kg celecoxib (p.o., pid). 
To examine the anti-inflammatory potential of 25b, we determined the in vivo effectiveness 
of 25b in the most popularly used mouse air-pouch model of inflammation in comparison 
with celecoxib. The air-pouch model of inflammation is widely used for determining the 
in vivo effectiveness of inhibitors of prostaglandin synthesis. Air pouches were produced 
by duplicate injections of 3 mL of sterile air under the skin on the back of mice. After the 
formation of the air-pouch, a single injection of the inflammatory reagent λ-carrageenan 
into the pouch resulted in the recruitment of inflammatory cells and the production of a 
fluid exudate containing significant levels of PGE2 (an inflammatory marker) produced 
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primarily by activities of COX-2 and mPGES-1. Then, the mice were orally administered 
with a single dose of 25b, celecoxib, or vehicle for 24 hours prior to collection of air-pouch 
fluid and the kidney samples. The air-pouch fluid and kidney samples were analyzed for 
PGE2 by the same ELISA method used in the in vitro enzyme activity assay mentioned 
above. As mPGES-1 is more abundant in kidney, we examined the effects of 25b and 
celecoxib on the PGE2 level in kidney. Depicted in Fig. 2-4A and Fig. 2-4B are the 
measured PGE2 levels in air-pouch fluid samples and kidney extract samples. 
As shown in Fig. 2-4A, compound 25b administered p.o. at each dose (20 or 10 mg/kg) 
condition significantly decreased the PGE2 levels in the mouse air-pouch fluid samples (p 
= 0.0003, p < 0.0001, and p < 0.0001, respectively), although the effectiveness was not as 
good as 50 mg/kg celecoxib with the same dosing method. Further, according to Fig. 2-4B, 
compound 25b was also capable of reducing the PGE2 levels in kidney (p < 0.0001, p < 
0.0001, and p < 0.0001, respectively) as compared to vehicle control. Although the dose-
dependence was not quite obvious, no significant difference was observed between 20 
mg/kg 25b with 50 mg/kg celecoxib and between 10 mg/kg 25b with 50 mg/kg celecoxib, 
respectively (p = 0.9994 and p = 0.2244). 
2.7 Acute toxicity/safety of 25b 
Finally, we also tested acute toxicity/safety of 25b in comparison with celecoxib. In fact, 
50 mg/kg celecoxib administered p.o. were very toxic for stomach and other issues of mice, 
and bleeding ulcer was observed at gastric mucosa. In comparison, a high dose (up to 1 
g/kg) of 25b administered p.o. did not cause any toxic sign in mice during our observation 
for 14 days. Depicted in Fig. 2-5 are representative images of the stomach tissues collected 
from mice at 24 hour after the PO administration of vehicle or 25b or celecoxib. For all 
mice in the vehicle, the stomach samples were used as standard for comparison with 25b 
dosed and celecoxib dosed groups. In the 2nd group dosed with a high dose of 25b (1 g/kg), 
we did not detect any bleeding spot on the inner side of stomach samples. Meanwhile, for 
each mouse in the celecoxib group, we were able to clearly see at least one bleeding spot, 
as labeled in red circles.  
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Fig. 2-5. Representative images of stomach tissues collected from mice at 24 h after oral 
administration of (A) vehicle (oil) or (B) 25b (1 g/kg in oil) or (C) celecoxib (50 mg/kg in 
oil). For all mice in the vehicle and 25b groups, we did not find any bleeding spot on the 
inner side of stomach samples. Meanwhile, for each mouse in the celecoxib group, we were 
able to clearly see at least one bleeding spot; the bleeding points are labeled in red circles.  
2.8 Conclusion 
As well known, inflammation is related to many types of diseases, and mPGES-1 was 
recognized as the most promising target for developing the highly desirable next generation 
of anti-inflammatory drugs without the adverse side effects of currently used COX 
inhibitors. The promise of mPGES-1 as the target was based on understanding of the 
physiological process and biosynthesis of the pro-inflammatory compound PGE2, and was 
supported strongly by the mPGES-1 gene knock-out studies. It is well known that 
mouse/rat models of inflammation-related diseases have been well-established, enabling 
to test a potentially promising anti-inflammatory drug candidate in the established 
mouse/rat models of inflammation-related diseases. Unfortunately, despite of extensive 
efforts to design and discover various human mPGES-1 inhibitors and the fact that 
numerous potent inhibitors of human mPGES-1 have already been reported in the literature, 
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the promise of mPGES-1 as a target for the next generation of anti-inflammatory drugs has 
never been demonstrated in any wild-type mouse/rat model using an inhibitor of mPGES-
1 because none of the previously discovered human mPGES-1 inhibitors can potently 
inhibit mouse/rat mPGES-1. Without a dual inhibitor (against both human and mouse 
mPGES-1 enzymes) available, one has to explore alternative animal models by using either 
other animal species that are less popular for use as animal models of inflammation-related 
diseases or mPGES-1 gene knock-out/knock-in mice expressing human mPGES-1 instead 
of mouse mPGES-1. For example, Merck developed the first strain of mPGES-1 gene 
knock-out/knock-in mice expressing human mPGES-1 instead of mouse mPGES-1. But 
interpretation of the animal data with the knock-in mice is complicated due to the difference 
between the original mouse gene and knock-in gene in the localization and amount. So, 
there is still no clinically useful mPGES-1 inhibitor developed so far. Reported here is the 
first demonstration that a potent human mPGES-1 inhibitor has potent in vivo activity in 
wild-type mice-based air-pouch model of inflammation. So, we are able to demonstrate in 
wild-type mice that mPGES-1 is truly a promising target for the next generation of anti-
inflammatory drugs. 
In this study, we successfully designed, synthesized and conducted biological evaluation 
of a series of substituted benzylidenebarbituric acid derivatives as inhibitors against both 
human and mouse mPGES-1 enzymes. A number of the compounds were prepared were 
capable of inhibiting both enzymes with submicromolar potency without concomitant 
inhibition against COX isozymes. In addition, selected compound 25b was further 
evaluated using wild-type based mouse models of inflammation, the carrageenan air-pouch 
experiment and the results showed that 25b administered orally with both doses (20 mg/kg 
and 10 mg/kg) significantly reduced the PGE2 levels in both air-pouch fluid and kidney 
extract samples. The computational chemistry including the generation of simulated 3D 
structure of mouse mPGES-1 and the docking study were performed by Shuo Zhou and Dr. 
Yaxia Yuan. The in vitro assays were conducted by Dr. Ziyuan Zhou. Animal procedures 
were performed according to Dr. Charles Loftin’s guidance and assisted by Xirong Zheng, 
Drs. Ting Zhang and Jianzhong Chen. 
In general, a traditional drug discovery and development effort is usually focused on 
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identification of ligands of a human protein target without accounting for the species 
difference in target protein during the early drug design and discovery stage before finding 
out that the ligands identified in vitro are actually inactive in the in vivo animal models. 
Our study demonstrates a more effective strategy of drug design and discovery to rationally 
design a dual inhibitor of human and animal target proteins. The general strategy of our 
structure-based rational design of a dual inhibitor of the human and mouse mPGES-1 
enzymes may also be used for other drug targets with significant species differences in the 
binding pocket.
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 (Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-2,4-dione derivatives as potent 
inhibitors against both human and mouse mPGES-1 enzymes: rational design, 
synthesis, in vitro assays and in vivo evaluation 
Part of the results described in this chapter has been submitted for consideration of 
publication (“(Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-2,4-dione derivatives as potent 
inhibitors against both human and mouse mPGES-1 enzymes: rational design, synthesis, 
in vitro assays and in vivo evaluation”, to be published). 
3.1 Dual human/mouse mPGES-1 inhibitors enabling preclinical testing in wild-type 
mice 
Currently available treatments for inflammation-related symptoms rely heavily on 
traditional non-steroidal anti-inflammatory drugs (tNSAIDs) and coxibs, by either non-
selectively inhibiting COX isozymes,[9] or specifically inhibiting COX-2,[10b] respectively. 
Both categories of drugs exert anti-inflammatory efficacy by indirectly modulating the 
production of PGE2. However, long-term application of tNSAIDs cause ulceration and 
bleeding in the gastrointestinal (GI) tract due to disturbance of the COX-1-derived 
protective function.[79] Coxib application, on the other hand, interferes with the intrinsic 
balance between vasodilative prostacyclin and vasoconstrictive thromboxane A2 and thus 
renders cardiovascular risk.[14, 80] As several coxibs were withdrawn from the US market,[9] 
the direct modulation of PGE2 production, specifically the inhibition of inducible mPGES-
1, has emerged as an attractive therapeutic approach in the development of a new 
generation of anti-inflammatory drugs. As continued efforts in the development of dual 
human/mouse mPGES-1 inhibitors, we further designed, synthesized, and biologically 
evaluated of a series of (Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-2,4-dione (isatin-
thiazolidine-2,4-dione backbone) derivatives as potent inhibitors against both human and 
mouse mPGES-1 enzymes. Some of the compounds, such as 44d (IC50 = 121 nM and 947 
nM for human and mouse mPGES-1 enzymes, respectively) and 52e ((IC50 = 25 nM and 
685 nM, respectively), were capable of inhibiting both enzymes with submicromolar 
potency without concomitant inhibition of COX isozymes (≤ 50 % inhibition at a 
concentration of 100 µM). Following in vitro assays, 52e was selected as a candidate for 
in vivo evaluation in mice. A pilot mouse carrageenan air-pouch experiment was performed 
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with double doses of 52e in its meglumine salt form (52e-MEG), which indicated that 52e 
was effective in reducing PGE2 levels in both air-pouch fluid and kidney extract as 
compared to negative vehicle control. 
3.2 Design of the (Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-2,4-dione (isati-
thiazolidine-2,4-dione backbone) derivatives 
The design of novel inhibitors also started from the molecular docking of compound 19 
(Fig. 3-1A) with the human mPGES-1 crystal structure (PDB ID: 4BPM).[35] The (Z)-5-
benzylidene-2-iminothiazolidine-4-one derivative 19 was identified as an active human 
mPGES-1 inhibitor through structure-based virtual screening in our previous work.[76] 
Although with moderate inhibitory potency (IC50 = 3.5 µM), it is suggested to bind in a 
conserved region of the active site in both human and mouse mPGES-1 enzymes, as 
predicted by the binding mode (Fig. 3-1B). This conserved region is close to amino acid 
residues S127, side chains of Y28, I32, G35, L39, Y130, T131, L135 and A138 constitute 
the major hydrophobic pocket in human mPGES-1. In the mouse enzyme, only a few amino 
acid residues differ from human mPGES-1, where I32, T131 and A138 are replaced by 
V32, V131 and F138, respectively. Instead of replacing the thiazolidine-2,4-dione with 
barbituric acid as we did in our previous reports,[77a, 77b] we kept thiazolidine-2,4-dione N-
acetic acid in order to maintain the polar interaction with the enzyme while removing the 
phenyl from the original structure as it might hamper the hydrogen-bond formation. Isatin 
(2,3-indolinedione) was introduced as the central core not only because of its existence as 
a substructure in many bioactive molecules, but also its versatility for multi-
functionalization.[81] Similarly, a flexible hydrophobic “tail” was attached to the central 
isatin, as we did in the previous series of inhibitors.[77a, 77b] Compounds with isatin-
thiazolidine-2,4-dione backbone were thus designed, in which 44d was selected as an 
example structure for the docking study. As shown in Fig. 3-1C, compound 44d binds in a 
similar region as 19, and this region is largely conserved in mouse mPGES-1, indicating 
that the designed inhibitors might also inhibit the mouse enzyme. In addition, while 19 
binds with human mPGES-1 with moderate affinity, compound 44d is predicted to bind 
more favorably with the enzyme, as a hydrogen bond is observed between the carboxylic 
carbonyl group of 44d with the NH group of R52. 
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Fig. 3-1. Molecular structures of the lead 19, designed inhibitor 44d and their binding with 
human mPGES-1. (A) Ligand structures; (B) binding with the lead 19; (C) binding with 
44d. 
3.3 Chemistry and SAR study 
3.3.1 SAR on 1-substituted isatin derivatives 
In the SAR study, we mainly investigated the substitution at isatin-1(N)-position and its 
impact on inhibitory potency. The synthetic protocol of these compounds with a range of 
side chains is outlined in Scheme 3-1. Commercially available thiazolidine-2,4-dione (38) 
and isatin (41) were used as starting materials to construct the building blocks of 2-(2,4-
dioxothiazolidin-3-yl)acetic acid (2,4-thiazolidinedione N-acetic acid 40) and1-substuted 
isatins (43a–43m). After treating 38 with excess potassium hydroxide in hot ethanol, the 
potassium salt of 38 was precipitated and filtered off.[82] This salt was reacted with tert-
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butyl bromoacetate for N-substitution. The cleavage of the tert-butyl ester (39) in 
trifluoroacetic acid/dichloromethane (1:1, v/v) at room temperature led to the formation of 
the important thiazolidine-2,4-dione based building block (40).[83] The 1-substituted isatins 
were prepared by the reaction of isatin with alkyl bromides, alcohol tosylates (23 and 35)[84] 
and alkyl chlorides (34a and 34b)[85] in the presence of excess potassium carbonate as acid 
capturer. The obtained 1-substituted isatins (43a–43m) and isatin (41) were then condensed 
with 40 catalyzed by ammonium acetate in glacial acetic acid at 108°C, yielding the final 
products (44a–44m and 42) with isatin-thiazolidine-2,4-dione backbone. 
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Scheme 3-1. Synthesis of 1-substituted isatin derivatives. Reagents and conditions: (a) 
KOH, EtOH, 55 °C, 74%; (b) acetone, reflux, 82%; (c) TFA/DCM (1;1, v/v), rt, 97%; (d) 
50% KOH, aq., DCM, 0 °C→rt, 83–90%; (e) acetone, reflux, 89–92%; (f) K2CO3, DMF, 
rt, 70–87%; (g) NH4OAc, glacial AcOH, 108 °C, 38–85%. 
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Table 3-1. SAR on 1-Substituted isatin derivatives. 
Compound 
Inhibition of mPGES-1 
IC50 (Human, nM)a IC50 (Mouse, nM) 
42 n.d.b (5)c n.d. (10) 
44a 1269±104 2728±422 
44b 494±32 n.d. (39) 
44c 253±30 1518±317 
44d 121±25 947±183 
44e 963±87 n.d. (61) 
44f 805±100 n.d. (41) 
44g 1681±168 1023±131 
44h 1661±168 n.d. (35) 
44i 1073±116 n.d. (57) 
44j 324±44 n.d. (67) 
44k 314±44 2676±302 
44l 199±32 1398±217 
44m 217±30 935±135 
48a 2560±442 n.d. (64) 
48b 962±159 n.d. (44) 
aData are expressed as means ± SD of single determinations obtained in triplicate. bn.d. = 
not determined. cThe values in the parentheses refer to the % inhibition of the compound 
at a concentration of 10 µM against the mPGES-1 enzyme (IC50 values were determined 
only for the compounds that showed ≥70% inhibition at 10 µM). 
The inhibitory potencies against human and mouse mPGES-1 enzymes are shown in Table 
3-1. The presence of a hydrophobic substituent at isatin-1-position is of great importance 
for the compound to gain inhibitory efficacy. Without a substituent, compound 40 was not 
active against either enzyme. In compound group 44a–44d, one methylene group (CH2) 
was “inserted” into the alkyl chain, with the same cyclohexyl as terminal group. The 
increased length of the side chain was in accordance with the progressively enhanced 
inhibitory potency against human and mouse mPGES-1. With bulky cyclohexylbutyl 
substituted at isatin-1-position, compound 44d was capable of inhibiting both human and 
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mouse mPGES-1 enzymes with submicromolar potency (IC50 = 121 nM and 947 nM for 
human and mouse mPGES-1 enzymes, respectively). With phenyl, phenoxy and 2-
naphthoxy replacing the terminal cyclohexyl or cyclohexylmethyl groups, compounds 44e, 
44f and 44g resulted in an 8-fold, 7-fold, and 14-fold decrease in inhibitory potency as 
compared with 44d, respectively. Substitution with linear side chains were also 
investigated in compound group 44h–44m. In general, the rank order of inhibitory potency 
was in accordance with the length of the side chain. But compounds with an extremely 
long aliphatic side chain, such as 44l and 44m with nonyl and decyl substitution, were 
comparable in potency against human mPGES-1 (IC50 = 199 nM and 217 nM, respectively). 
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Scheme 3-2. Synthesis of 1-substituted isatin derivatives with reversed polarity. Reagents 
and conditions: (a) K2CO3, DMF, rt, 77%; (b) TFA/DCM (1;1, v/v), rt, 99%; (c) KOH, 
EtOH, 55 °C, 72%; (d) acetone, reflux, 82–89%; (e) NH4OAc, glacial AcOH, 108 °C, 68–
74%. 
We also tried to switch the positions of hydrophilic “head” and hydrophobic “tail”. In this 
case, isatin-based building block 2-(2,3-dioxoindolin-1-yl)acetic acid (isatin-N-acetic acid 
46)[86] and N-substituted thiazolidine-2,4-diones (47a–47b)[87] were prepared respectively. 
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These two building blocks were then condensed in the presence of ammonium acetate in 
glacial acetic acid at 108°C to accomplish the preparation of the final products (48a–48b) 
with reversed positions of hydrophobic and hydrophilic moieties. The synthetic protocol 
of 48a–48b is depicted in Scheme 3-2. Compared to the “standard” compound 44d, 
compound 48a was 20 times less potent against human mPGES-1. Although 48b was 
comparably potent as compared to 44e in inhibiting human mPGES-1, both 48a and 48b 
were not quite as active for the mouse enzyme. We still focused on the structure as 44d. 
3.3.2 SAR on 1,5-disubstituted isatin derivatives 
In the aforementioned SAR study, we successfully identified two compounds (44d and 
44m) inhibiting both human and mouse mPGES-1 enzymes with submicromolar potency. 
As we carefully analyzed the binding mode of 44d with the human mPGES-1 crystal 
structure (Fig. 3-1C), we discovered a substantial unoccupied area at the active site, 
specifically the small hydrophobic pocket above the cofactor glutathione (GSH) of the 
enzyme and around the central isatin ring of the inhibitor. Therefore, another substituted 
group at isatin-5-position was introduced to occupy this small hydrophobic pocket. With 
the same thiazolidine-2,4-dione N-acetic acid (40) as polar “head” and cyclohexylmethyl 
as 1-substituent, we varied the substituent at isatin-5-position. The synthetic protocol of 
these compounds is outlined in Scheme 3-3. Commercially available 5-iodoisatin (49) was 
used as starting material to prepare the building block of 1,5-disubstituted isatins (52a–
52e). The 1-substitution was first carried out by the reaction of 49 with 
(bromomethyl)cyclohexane in the presence of excess potassium carbonate as acid 
capturer.[88] The resulting 1-substituted-5-iodoisatin (50) was then coupled with various 
aryl boronic acids via Suzuki coupling (51a–51c),[89] or with terminal alkynes via 
Sonogashira coupling (51d–51e),[90] respectively. The final products, 1,5-disubstituted 
isatin derivatives (52a–52e) were prepared by the ammonium acetate-catalyzed 
condensation of isatin-based building blocks (51a–51e) with thiazolidine-2,4-dione-based 
building block 40. The inhibitory potency data were summarized in Table 3-2. Compared 
with the corresponding 1-substituted isatin derivative 44a, the introduction of all phenyl, 
4-biphenyl and 2-naphthyl groups at the 5-position enhanced the inhibitory potency against 
human mPGES-1 by about 6-, 8-, and 2-fold. Moreover, compounds with phenylethynyl 
45 
 
(52d) and cyclohexylethynyl (52e) substituted at isatin-5-position were identified as low 
nanomolar human mPGES-1 inhibitors (IC50 = 91 nM and 25 nM, respectively). In the 
follow-up SAR study, we fixed phenyl as the 5-substituent and varied the substitution at 
isatin-1-position. The synthetic protocol was slightly modified, with Suzuki coupling of 5-
iodoisatin (49) and phenylboronic acid (5-substitution) as the first step, followed by the 
substitution at isatin-1-position, and the subsequent condensation with 40. Without 
substitution at the 1-position, the inhibitory potency was greatly impaired. Compared to 
44a, compound 54 was 36-fold less potent against human mPGES-1. In compound group 
52a, and 55a–55c, one methylene (CH2) group was “inserted” into the former structure in 
the side chain, the inhibitory potency was enhanced along with the increased length of the 
side chain. With 4-cyclohexylbutyl substituted at isatin-1-position, compound 55c was 
identified as human mPGES-1 inhibitor with low nanomolar potency (IC50 = 13 nM). 
While with 4-chlorophenyl substitution at the same position, compound 55d, was potent 
against human mPGES-1 (IC50 = 54 nM), it was not effective in inhibiting the mouse 
enzyme (IC50 = 13236 nM). 
Table 3-2. SAR on 1,5-Diubstituted isatin derivatives. 
Compound 
Inhibition of mPGES-1 
IC50 (Human, nM)a IC50 (Mouse, nM) 
52a 221±47 394±58 
52b 154±20 1020±162 
52c 531±90 244±31 
52d 91±23 1960±348 
52e 25±5 685±406 
24 8023±1050 n.d.b (63)c 
55a 32±6 777±364 
55b 16±4 1220±430 
55c 13±3 1130±244 
55d 54±14 13236±5081 
aData are expressed as means ± SD of single determinations obtained in triplicate. bn.d. = 
not determined. cThe value in the parenthesis refers to the % inhibition of the compound at 
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a concentration of 10 µM against the mPGES-1 enzyme (IC50 values were determined only 
for the compounds that showed ≥70% inhibition at 10 µM). 
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Scheme 3-3. Synthesis of 1,5-disubstituted isatin derivatives. Reagents and conditions: (a) 
K2CO3, DMF, 80 °C, 73–90%; (b) Pd(dppf)2Cl2·CH2Cl2, NaHCO3, DME/H2O (4:1, v/v), 
reflux, N2 atmosphere, 62–76%; (c) Pd(dppf)2Cl2·CH2Cl2, CuI, DIPEA, DMF, rt, N2 
atmosphere, 84–90%; (d) NH4OAc, glacial AcOH, 108 °C, 47–73%.  
3.4 Structural analysis 
X-ray diffraction analysis of single crystals of compound 42 revealed the double bond 
between isatin and thiazolidine-2,4-dione moieties adopts the Z configuration. The crystal 
structure of 42 is depicted in Fig. 3-2 and the crystallographic data is given in the 
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experimental section (Chapter 4). 
 
Fig. 3-2. Crystal structure of 42. Crystals of 42 were non-merohedric twins and crystallized 
as a DMSO solvate. For the sake of clarity, the DMSO, which was disordered over two 
orientations, is not shown. 
3.5 In vitro assays 
The synthesized compounds were initially screened at a concentration of 10 µM to 
calculate the percentages of inhibition against human and mouse mPGES-1 enzymes. 
Compounds that  showed significant inhibition (≥ 70%) were further tested for their IC50 
values. Depicted in Table 3-1 and Table 3-2 are the in vitro inhibitory data for human and 
mouse mPGES-1 enzymes. As predicted, a number of these compounds did effectively, but 
not equally inhibit both enzymes. We also investigated whether these mPGES-1 inhibitors 
have significant inhibitory efficacy against either COX-1 or COX-2. For this purpose, some 
of the more potent compounds (IC50 ≤ 100 nM for human mPGES-1) were assayed for 
their potential inhibitory activities against mixed COXs (denoted as COX-1/2) with equal 
amounts of COX-1 and COX-2 in terms of enzyme activities. As shown in Table 3-3, at a 
concentration as high as 100 µM, only 55d resulted in an inhibition greater than 50 % and 
all the other compounds investigated (52d–52e and 55a–55c) did not cause significant 
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inhibition (≤ 30%). The protocol for the protein preparation and purification, and the 
procedure for in vitro activity assays were the same, as described in our previous reports.[33b, 
76-77] 
Table 3-3. Inhibition against COX-1/2 of selected compounds. 
Compound % Inhibition at 100 µMa 
52d 1±3 
52e 5±1 
55a 20±2 
55b 17±0 
55c 23±3 
55d 78±1 
aThe % inhibition of the compound at a concentration of 100 µM against the COX-1/2 
(mixed COX-1 and COX-2). The enzyme mixture contained equal amounts of COX-1 and 
COX-2 in terms of their enzyme activities. In this way, when a compound can significantly 
inhibit either COX-1 or COX-2, it will show significant inhibitory effects against the mixed 
COX-1 and COX-2. The error bars were given by the program of GraphPad Prism 7. 
 
3.6 Enzyme-inhibitor binding modes 
Knowing the possible binding mode of the inhibitor with the target protein is of great 
importance in structure optimization. To further elucidate the SAR of these synthesized 
compounds, as well as to enlighten the design of new inhibitors, we selected compounds 
52e and 55c as candidates for molecular docking studies, as these compounds were among 
the most potent inhibitors against both human and mouse mPGES-1 enzymes. The 
AutoDock Vina[91] program was employed as molecular docking tool to investigate the 
binding modes of these compounds with both human and mouse mPGES-1 enzymes. As 
depicted in Fig. 3-3B and Fig. 3-3C, the cyclohexylmethyl group at the isatin-1-postion of 
52e occupies the hydrophobic groove accommodating the long hydrocarbon “tail” of the 
substrate PGH2, and the cyclohexylethynyl substituent at isatin-5-position inserts into the 
membrane structure. Part of thiazolidine-2,4-dione N-acetic acid moiety fits into the small 
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pocket above GSH, and this polar “head” also interacts with S127 and R52 by building 
hydrogen bonds between the amide carbonyl (of 52e) with the hydroxyl group (OH of 
S127), and between the carboxyl carbonyl (of 52e) with the amine group (NH of R52). 
However, with 4-cyclohexyl-1-butyl and phenyl groups occupying 1- and 5-positions of 
isatin respectively, compound 55c shows a different binding mode with human mPGES-1. 
As shown in Fig. 3-3F and 3-3G, the smaller 5-substituent (phenyl) fits into the smaller 
pocket above GSH, and the bulkier 5-substituent (4-cyclohexyl-1-butyl) occupies the larger 
hydrophobic groove that holds the PGH2 aliphatic “tail”. The carboxyl carbonyl group of 
thiazolidine-2,4-dione N-acetic acid forms a hydrogen bond with the amino group of R52.  
In human mPGES-1, the major hydrophobic pocket is surrounded by I32, G35, L39, Y130, 
T131, L135 and A138. As shown in Fig. 3-3E and Fig 3-3I, this hydrophobic pocket is 
largely conserved in the mouse enzyme, with only a few amino acid residues altered from 
human mPGES-1, i.e., V32, V131 and F138 replace I32, T131 and A138, respectively. 
Both 52e and 55c bind in a similar region in mouse mPGES-1 as in the human enzyme, 
with substituents at isatin-1-position fitting into this major hydrophobic pocket. The most 
significant differences appear in the upper part of the mouse enzyme, where mutants K52 
and R53 take over R52 and H53. The amide carbonyl group of both 52e and carboxyl 
carbonyl group of 55c can also form a hydrogen bond with S127-OH and K52-NH, 
respectively, ensuring the inhibitory potencies of these compounds against mouse mPGES-
1. However, the much greater dimension of R53 (in mouse mPGES-1) than H53 (in human 
mPGES-1) makes in a steric clash with the ligand structure, resulting in lower affinity of 
these inhibitors with mouse mPGES-1. 
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Fig. 3-3. Molecular structures of 52e and 55c and their binding with human and mouse 
mPGES-1 enzymes. (A) Ligand structures; (B) binding of 52e with human mPGES-1; (C) 
surface representation of human mPGES-1 using the same orientation as in (B); (D) 
binding of 52e with mouse mPGES-1; (E) surface representation of mouse mPGES-1 using 
the same orientation as in (D); (F) binding of 55c with human mPGES-1; (G) surface 
representation of human mPGES-1 using the same orientation as in (F); (H) binding of 55c 
with mouse mPGES-1; (I) surface representation of mouse mPGES-1 using the same 
orientation as in (H).  
3.7 In vivo anti-inflammatory efficacy  
Compound 52e was selected as candidate for in vivo evaluation because of its 
submicromolar potency against both human and mouse mPGES-1 enzymes. However, 
although possessing a carboxylic acid group, this compound was barely soluble in distilled 
water, and so was its sodium salt. We screened a number of conjugate amines and found 
out the meglumine (N-methyl-D-glucamine) salt[92] of 52e (denoted as 52e-MEG, 
synthetic protocol shown in Scheme 3-4) showed excellent aqueous solubility in distilled 
water (≥ 25 mg/mL). Meglumine has been used as pH modifier and/or counterion in a 
number of FDA-approved drugs.  
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Scheme 3-4. Preparation of meglumine salt of 52e. Reagent and conditions: (a) N-methyl-
glucamine, EtOH, reflux, 81%. 
Mouse carrageenan air-pouch model of inflammation is widely employed for determining 
the in vivo effectiveness of inhibitors in reducing prostaglandin biosynthesis. Thus, to 
investigate the anti-inflammatory potential of 52e-MEG, we performed a pilot mouse 
carrageenan air-pouch experiment.[93] The effectiveness of 52e-MEG was in comparison 
with the same dose of celecoxib for their capability in reducing PGE2 levels. Air-pouches 
were generated by duplicate injection of sterile air under the skin on the back of mice. A 
single injection of inflammation reagent λ-carrageenan directly into the pouch was 
followed to induce local inflammation and stimulate PGE2 biosynthesis. Inflammatory 
cells were recruited and fluid exudate containing substantial amounts of PGE2 was 
produced in response to carrageenan. Then the mice were orally administered with double 
doses of 52e-MEG, celecoxib and vehicle for 24 hours before they were sacrificed for the 
collection of air-pouch fluid and kidney samples. As PGE2 is more abundant in kidney, we 
also investigated the effects of 52e-MEG and celecoxib on the PGE2 levels in kidney. The 
air-pouch fluid and kidney samples were assayed for PGE2 levels and the results were 
summarized in Fig. 3-4. As shown in Fig. 3-4A, compound 52e-MEG administered orally 
with double doses of 100 mg/kg in 24 h significantly decreased the PGE2 levels in mice (p 
= 0.0001). In addition, no significant difference was observed in the in vivo potency 
between 100 mg/kg 52e-MEG and the same dose of celecoxib (p = 0.4974). The 
corresponding data in kidney extract was similar as compared to air-pouch fluid, as outlined 
in Fig. 3-4B. 
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3.8 Conclusions 
By modifying the chemical scaffold of the lead 19, we have designed, synthesized and 
conducted biological evaluation of a series of (Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-
2,4-dione derivatives (42, 44a–44m, 48a–48b, 52a–52e, 54, and 55a–55d). The structures 
of the potent inhibitors were rationally optimized in light of molecular docking by focusing 
on the unoccupied area in the conserved region of the active site in both human and mouse 
mPGES-1 enzymes. As expected, a number of these compounds, especially those with 1,5-
disubstituted isatin substructures (52a–52e and 55a–55d), were capable of inhibiting both 
human and mouse mPGES-1 enzymes. Some of the more potent compounds were also 
tested for their selectivity of mPGES-1 over COX isozymes. It was observed at a 
concentration of 100 µM, compounds 52d–52e and 55a–55c did not cause significant 
inhibition against COX isozymes. Furthermore, compound 52e was selected as candidate 
for in vivo pharmacological evaluation. We improved the solubility by preparing the 52e-
meglumine salt (52e-MEG) and performed the rat PK study with 52e-MEG administered 
both intravenously and orally. A pilot mouse carrageenan air-pouch experiment was carried 
out with double doses of 52e-MEG administered orally. The results shown in Fig. 3-5 
demonstrated this compound was effective in reducing PGE2 levels in both air-pouch fluid 
and kidney extract as compared to vehicle control. Based on the above-mentioned studies, 
compound 52e is worthy of further research as a candidate for animal models of 
inflammation and as a new lead in the design of novel mPGES-1 inhibitors. In the research 
described in this chapter, Shuo Zhou and Dr. Yaxia Yuan performed the docking study. Dr. 
Ziyuan Zhou determined the IC50 values by conducting in vitro assays. Dr. Charles Loftin 
directed the air-pouch experiment process, which was assisted by Xirong Zheng and Dr. 
Jianzhong Chen. 
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Fig. 3-4. Data from in vivo assays using the mouse carrageenan air-pouch model of 
inflammation (n = 3 for control and 52e-MEG groups and n = 4 for celecoxib group) with 
52e-MEG or celecoxib dosed orally. (A) the effectiveness of 52e-MEG in reducing PGE2 
level in air-pouch fluid; (B) the effectiveness of 52e-MEG in reducing PGE2 level in 
kidney (assayed for PGE2 by ELISA and expressed as Mean ± SEM). Statistical results 
from the one-way ANOVA analysis of the data in panel B with post hoc tests: p = 0.0001 
for Vehicle Control vs 100 mg/kg 52e-MEG (p.o., bid); p < 0.0001 for Vehicle Control vs 
100 mg/kg celecoxib (p.o., bid); and p = 0.4974 for 100 mg/kg 20e-MEG (p.o., bid) vs 100 
mg/kg celecoxib (p.o., bid). Statistical results from the one-way ANOVA analysis of the 
data in panel B with post hoc tests: p = 0.0386 for Vehicle Control vs. 100 mg/kg 52e-
MEG (p.o., bid); p = 0.0122 for Vehicle Control vs 100 mg/kg celecoxib (p.o., bid); and p 
= 0.7978 for 100 mg/kg 52e-MEG (p.o., bid) vs 100 mg/kg celecoxib (p.o., bid). 
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 Experimental Section 
4.1 Computational studies 
4.1.1 Trimer structure of human mPGES-1 
The trimer structure of human mPGES-1 was generated by the symmetry operation via 
PyMol,[94] based on the X-ray crystal structure of the monomer unit for human mPGES-1 
(PDB ID: 4BPM).[34-35] 
4.1.2 Trimer structure of mouse mPGES-1 
As there is no available X-ray crystal structure of mouse mPGES-1, homology modeling 
was performed to model the structure of mouse mPGES-1. Sequence alignment was 
performed on the amino acid sequence of human mPGES-1 (accession number of O14684) 
and mouse mPGES-1 (accession number of Q9JM51) by using the Basic Local Alignment 
Search Tool (BLAST) of Uniprot server (http://www.uniprot.org/align/).[95] The aligned 
sequence indicates that human mPGES-1 is highly homologous to mouse mPGES-1, with 
the sequence identity being 79% and the sequence similarity being 84%. As 40% sequence 
identity between a template protein and a target protein is considered to be sufficient for 
constructing a satisfactory homology model,[96] we built the  trimer structure of mouse 
mPGES-1 based on the aforementioned trimer structure of human mPGES-1 by using the 
Modeller module[96a] of Discovery Studio 2.5.5.[97] The GSH cofactor in human mPGES-
1 structure was directly transferred to the mouse mPGES-1 model. The final structure was 
selected from 50 candidate models according to the DOPE score.[98] 
4.1.3 Molecular docking 
In order to explore the binding mode of the presented compounds with human and mouse 
mPGES-1, molecular docking was performed by using the program of AutoDock 4.2[78]. 
During the process of molecular docking, Lamarckian genetic algorithm was applied to 
treat the intermolecular interactions between ligand and protein. The number of the runs 
was set to 200, and the number of individuals for each run was set to 300. The maximum 
number of energy evaluations was set to 25,000,000, and the maximum number of 
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generations to 300,000. The size of grid box was 80 × 80 × 80 points along each axis and 
the grid spacing was 0.2 Å. All of the candidates generated from the docking operations 
were evaluated and ranked in terms of binding free energies by using the standard energy 
score function implemented in the AutoDock 4.2 program. The largest one of the docked 
binding structure clusters was selected as the finally chosen initial mPGES-1-ligand 
complex structure, based on the lowest binding free energy (i.e. the best energy score from 
the AutoDock 4.2 scoring function) along with good geometric matching quality with the 
surrounding residues in the binding site of mPGES-1. Molecular docking was also 
performed by using the program of AutoDock Vina.[91] 
4.2 Chemistry 
4.2.1 General 
All the starting chemicals were purchased from Sigma-Aldrich (St. Louis, MO), Oakwood 
Chemical (Estill, SC), Alfa Aesar (Haverhill, MA), Frontier Scientific (Logan, UT) or 
Fisher Scientific (Hampton, NH) and used without further purification. Compounds were 
purified by SiO2 flash chromatography (Flash silica gel 32-63 u, Dynamic Adsorbents Inc., 
Norcross, GA). 1H and 13C NMR spectra were recorded on a Varian Unity Inova 400 MHz 
spectrometer (Palo Alto, CA) at ambient temperature using 99.8% CDCl3 and 99.9% 
DMSO-d6 (Cambridge Isotope Laboratories, Tewksbury, MA). 1H and 13C chemical shifts 
were referenced to internal solvent resonances and reported in parts per million (ppm), with 
coupling constants J given in Hz. HR-ESI-MS spectra were recorded on AB SCIEX Triple 
TOF 5600 system (AB Sciex, Framingham, MA). 
4.2.2 Preparation of tosylates 23 and 35 
Preparation of 23. To the solution of 4-cyclohexyl-1-butanol (22, 1.05 g, 6.72 mmol, 1.00 
equiv.) in dichloromethane (40 mL) was added aqueous KOH solution (50 %, 20 mL). The 
mixture was brought to 0~5 oC using ice-bath and p-toluenesulfonyl chloride (1.54 g, 8.06 
mmol, 1.20 equiv.) was added portionwise over a period of 30 min. The resulting reaction 
mixture was stirred at room temperature for 5 h and partitioned between CH2Cl2 (30 mL) 
and water (30 mL). The organic layer was isolated and the aqueous layer was extracted 
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with CH2Cl2 (30 mL × 3). The combined organic phase was washed sequentially with water 
(30 mL) saturated NaHCO3 solution (30 mL) and brine (30 mL), dried over anhydrous 
Na2SO4, and evaporated under reduced pressure. The residue was dried under high vacuum 
using oil pump overnight to afford the tosylate 23 as white wax in high purity (Yield: 1.98 
g, 95 %). The tosylation (synthesis of 35) of 3-cyclohexyl-1-propanol followed the same 
protocol as described. 
OTs
 4-cyclohexylbutyl 4-methylbenzenesulfonate (23). Yield: 95 %. 
White wax-like solid. 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 
6.3 Hz, 2H), 4.02 (t, 2H), 2.45 (d, J = 2.0 Hz, 3H), 1.71 – 1.58 (m, 7H), 1.58 – 0.82 (m, 
14H), 0.82 – 0.36 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 144.75, 133.36, 129.93, 128.03, 
70.87, 37.57, 36.82, 33.39, 29.23, 26.79, 26.48, 22.76, 21.78. HRMS (ESI+) m/z calcd for 
C16H25O3S [M+H]+: 297.1519, found: 297.1522. 
 
OTs
3-Cyclohexylpropyl 4-methylbenzenesulfonate (35). Compound 35 
was prepared from 3-cyclohexyl-1-propanol and p-toluenesulfonyl chloride followed the 
same method as described in the preparation of 23. Yield: 67 %. Colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.79 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 4.00 (t, J = 6.6 Hz, 
2H), 2.44 (s, 3H), 1.71 – 1.55 (m, 7H), 1.25 – 1.04 (m, 6H), 0.88 – 0.71 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 144.67, 133.12, 129.80, 127.85, 71.07, 36.96, 33.08, 32.83, 26.52, 
26.21, 26.17, 21.61. HRMS (ESI+) m/z calcd for C17H27O3S [M+NH4]+: 328.1941, found: 
328.1945. 
4.2.3 Preparation of the chlorides 32a–32c 
Preparation 32a. The suspension of phenol (1.89 g, 20.1 mmol, 1.00 equiv.), 1-bromo-3-
chloropropane (1.50 equiv., 30.1 mmol, 4.74 g), K2CO3 (2.00 equiv., 40.2 mmol, 5.55 g) 
in acetone was stirred at reflux. The reaction mixture was cooled to room temperature after 
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TLC indicating the total consumption of phenol (~6 h). The solid was removed by filtration 
and the filtrate was concentrated under reduced pressure.[85] The residue was dried under 
vacuum overnight to give 32a as a colorless oil (4.57 g, 26.8 mmol, 89% yield). Compound 
32b and 32c was prepared using the same method with 2-naphthol as starting material. 
O Cl
  (3-Chloropropoxy)benzene (32a). Yield: 89%. Colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 7.40 – 7.28 (m, 2H), 7.05 – 6.85 (m, 3H), 4.14 (t, J = 5.8 Hz, 
2H), 3.78 (t, J = 6.4 Hz, 2H), 2.26 (p, J = 6.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 
158.78, 129.59, 120.99, 114.58, 64.22, 41.68, 32.40. 
O Cl
 2-(3-Chloropropoxy)naphthalene (32b). Compound 32b was 
prepared from 2-naphthol and 1-bromo-3-chloropropane with the same method as 
described in the preparation of 32a. Yield: 92%. White solid. 1H NMR (400 MHz, CDCl3) 
δ 7.76 (dd, J = 16.1, 7.3 Hz, 3H), 7.50 – 7.40 (m, 1H), 7.40 – 7.30 (m, 1H), 7.21 – 7.11 (m, 
2H), 4.25 (t, J = 5.9 Hz, 2H), 3.80 (t, J = 6.3 Hz, 2H), 2.31 (p, J = 6.1 Hz, 2H). 13C NMR 
(101 MHz, CDCl3) δ 156.76, 134.64, 129.58, 129.15, 127.78, 126.88, 126.54, 123.83, 
118.92, 106.83, 64.42, 41.75, 32.39. HRMS (ESI+) m/z calcd for C13H14ClO [M+H]+: 
221.0728, found: 221.0724. 
O Cl
 4-(3-Chloropropoxy)biphenyl (32c). Compound 32c was 
prepared from 4-phenylphenol and 1-bromo-3-chloropropane with the same method as 
described in the preparation of 32a. Yield: 92%. 1H NMR (400 MHz, CDCl3) δ 7.65 – 7.53 
(m, 4H), 7.53 – 7.29 (m, 3H), 7.00 (d, J = 8.7 Hz, 2H), 4.18 (t, J = 5.8 Hz, 2H), 3.78 (t, J 
= 6.3 Hz, 2H), 2.28 (p, J = 6.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 158.40, 140.89, 
134.15, 128.86, 128.32, 126.87, 126.83, 114.93, 64.50, 41.67, 32.44. 
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4.2.4 Preparation of the aldehyde intermediates 24a–24q, 30, 33a–33c and 36a–36e 
Preparation of 24b. The suspension of 3-chloro-4-hydroxybenzaldehyde (0.32 g, 2.04 
mmol, 1.00 equiv.), 4-cyclohexyl-1-butanol tosylate (23) (0.63 g, 2.04 mmol, 1.00 equiv.) 
and potassium carbonate (0.56 g, 4.09 mmol, 2.00 equiv.) in DMF (10 mL) was heated at 
80 oC for 12 h (or overnight). The reaction mixture was then diluted with water (20 mL) 
and extracted with ethyl acetate (30 mL × 3). The combined organic phase was washed 
sequentially with saturated NaHCO3 solution (30 mL), water (30 mL) and brine (30 mL), 
dried over anhydrous Na2SO4, evaporated under reduced pressure and dried under vacuum 
at room temperature. The crude product was used in subsequent step without further 
purification. However, the analytical sample can be obtained as light yellow oil by flash 
chromatography on silica gel using a mixture of hexanes and EtOAc (4:1) as eluent. The 
preparation of other aldehyde intermediates (24a, 24c–24q, 30, 33a–33c and 36a–36e) 
followed the similar protocol as described, with different starting materials. 
O
CHO 4-(4-Cyclohexylbutoxy)benzaldehyde (24a). 
Obtained from the reaction of 4-hydroxybenzaldehyde and 23. Yield: 76 %. Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 9.86 (s, 1H), 7.80 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.6 Hz, 
2H), 4.02 (t, J = 6.5 Hz, 2H), 1.81 – 1.60 (m, 7H), 1.50 – 1.41 (m, 2H), 1.26 – 1.07 (m, 
6H), 0.92 – 0.81 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 191.14, 164.67, 132.36, 130.15, 
115.15, 68.84, 37.99, 37.54, 33.77, 29.76, 27.11, 26.81, 23.65. 
O
CHOCl 3-Chloro-4-(4-cyclohexylbutoxy)benzaldehyde 
(24b). Obtained from the reaction of 3-chloro-4-hydroxybenzaldehyde and 23. Yield: 88 %. 
Light yellow oil. 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.72 
(dd, J = 8.5, 2.0 Hz, 1H), 6.99 (d, J = 8.5 Hz, 1H), 4.09 (t, J = 6.5 Hz, 2H), 1.87 – 1.79 (m, 
2H), 1.73 – 1.59 (m, 5H), 1.54 – 1.45 (m, 2H), 1.28 – 1.07 (m, 6H), 0.92 – 0.80 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 189.75, 159.58, 131.26, 130.52, 130.08, 124.02, 112.55, 
69.61, 37.60, 37.13, 33.43, 29.24, 26.79, 26.48, 23.22. 
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O
CHOBr  3-Bromo-4-(4-cyclohexylbutoxy)benzaldehyde (24c). 
Obtained from the reaction of 3-bromo-4-hydroxybenzaldehyde and 23. Yield: 86%. 
Yellow oil. 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 8.06 (d, J = 1.9 Hz, 1H), 7.78 (dd, 
J = 8.5, 1.8 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 4.10 (t, J = 6.4 Hz, 2H), 1.89 – 1.79 (m, 2H), 
1.74 – 1.60 (m, 5H), 1.56 – 1.46 (m, 2H), 1.28 – 1.04 (m, 6H), 0.95 – 0.80 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 189.69, 160.41, 134.67, 131.18, 130.54, 113.08, 112.40, 69.70, 
37.61, 37.15, 33.45, 29.24, 26.81, 26.51, 23.26. 
O
CHOMe  4-(4-Cyclohexylbutoxy)-3-methylbenzaldehyde (24d). 
Obtained from the reaction of 4-hydroxy-3-methylbenzaldehyde and 23. Yield: 82 %. 
Orange oil. 1H NMR (400 MHz, CDCl3) δ 9.84 (s, 1H), 7.68 (d, J = 7.3 Hz, 2H), 6.89 (d, J 
= 7.7 Hz, 1H), 4.04 (t, J = 5.5 Hz, 2H), 2.26 (s, 3H), 1.86 – 1.77 (m, 2H), 1.74 – 1.62 (m, 
5H), 1.54 – 1.44 (m, 2H), 1.28 – 1.11 (m, 6H), 0.93 – 0.80 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 191.31, 162.64, 131.57, 130.79, 129.31, 127.83, 110.48, 68.46, 37.70, 37.26, 
33.49, 29.50, 26.84, 26.54, 23.43, 16.38. 
O
CHOHO 4-(4-Cyclohexylbutoxy)-3-hydroxybenzaldehyde (24e). 
Obtained from the reaction of 3,4-dihydroxybenzaldehyde and 23. Yield: 74 %. White solid. 
1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 7.47 – 7.36 (m, 2H), 6.94 (d, J = 8.2 Hz, 1H), 
4.12 (t, J = 6.6 Hz, 2H), 1.87 – 1.77 (m, 2H), 1.73 – 1.61 (m, 5H), 1.51 – 1.41 (m, 2H), 
1.26 – 1.11 (m, 6H), 0.93 – 0.83 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 191.14, 151.45, 
146.32, 130.55, 124.62, 114.17, 111.02, 69.44, 37.68, 37.21, 33.46, 29.40, 26.78, 26.49, 
23.32. 
O
CHOMeO  4-(4-Cyclohexylbutoxy)-3-methoxybenzaldehyde 
(24f). Obtained from the reaction of vanillin and 23. Yield: 78 %. Colorless oil. 1H NMR 
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(400 MHz, CDCl3) δ 9.82 (s, 1H), 7.44 – 7.35 (m, 2H), 6.94 (d, J = 8.1 Hz, 1H), 4.07 (t, J 
= 6.8 Hz, 2H), 3.90 (s, 3H), 1.88 – 1.79 (m, 2H), 1.71 – 1.58 (m, 5H), 1.50 – 1.40 (m, 2H), 
1.25 – 1.05 (m, 6H), 0.91 – 0.80 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 190.92, 154.29, 
149.93, 129.94, 126.83, 111.48, 109.38, 69.28, 56.09, 37.59, 37.18, 33.42, 29.27, 26.77, 
26.47, 23.24. 
O
CHOEtO  4-(4-Cyclohexylbutoxy)-3-ethoxybenzaldehyde (24g). 
Obtained from the reaction of 3-ethoxy-4-hydroxybenzaldehyde and 23. Yield: 76 %. 
Colorless oil. 1H NMR (400 MHz, CDCl3) δ 9.83 (s, 1H), 7.45 – 7.34 (m, 2H), 6.95 (d, J 
= 6.1 Hz, 1H), 4.19 – 4.02 (m, 4H), 1.89 – 1.80 (m, 2H), 1.76 – 1.60 (m, 5H), 1.52 – 1.42 
(m, 5H), 1.28 – 1.10 (m, 6H), 0.93 – 0.84 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 191.06, 
154.68, 149.29, 129.98, 126.73, 111.85, 111.04, 69.30, 64.69, 37.64, 37.21, 33.46, 33.29, 
29.30, 26.83, 26.52, 23.26, 14.80. 
O
O2N CHO  4-(4-Cyclohexylbutoxy)-3-nitrobenzaldehyde (24h). 
Obtained from the reaction of 4-hydroxy-3-nitrobenzaldehyde and 23. Yield: 93 %. Yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 9.91 (s, 1H), 8.32 (s, 1H), 8.05 (d, J = 7.3 Hz, 1H), 7.20 
(d, J = 8.7 Hz, 1H), 4.19 (t, J = 6.4 Hz, 2H), 1.88 – 1.79 (m, 2H), 1.71 – 1.55 (m, 6H), 1.27 
– 1.09 (m, 7H), 0.91 – 0.79 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 188.93, 156.91, 140.03, 
134.67, 128.79, 127.51, 114.60, 70.49, 37.58, 37.07, 33.42, 29.11, 26.78, 26.48, 23.11. 
O
CHOCl
OMe
 3-Chloro-4-(4-cyclohexylbutoxy)-5-
methoxybenzaldehyde (24i). Obtained from the reaction of 3-chloro-4-hydroxy-5-
methoxybenzaldehyde and 23. Yield: 83 %. Light yellow oil. 1H NMR (400 MHz, CDCl3) 
δ 9.81 (s, 1H), 7.46 (d, J = 1.8 Hz, 1H), 7.31 (d, J = 1.8 Hz, 1H), 4.09 (t, J = 6.6 Hz, 2H), 
3.90 (s, 3H), 1.79 – 1.60 (m, 7H), 1.52 – 1.42 (m, 2H), 1.25 – 1.10 (m, 6H), 0.91 – 0.79 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 190.04, 154.47, 150.37, 132.23, 129.07, 125.89, 
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109.46, 74.05, 56.29, 37.69, 37.27, 33.47, 30.56, 26.81, 26.50, 23.16. 
O
CHOBr
OMe
 3-Bromo-4-(4-cyclohexylbutoxy)-5-
methoxybenzaldehyde (24j). Obtained from the reaction of 3-bromo-4-hydroxy-5-
methoxybenzaldehyde and 23. Yield: 82 %. Yellow oil. 1H NMR (400 MHz, CDCl3) δ 9.82 
(d, J = 0.9 Hz, 1H), 7.64 (dd, J = 1.8, 0.8 Hz, 1H), 7.36 (d, J = 1.8 Hz, 1H), 4.09 (t, J = 6.6 
Hz, 2H), 3.91 (s, 3H), 1.82 – 1.60 (m, 7H), 1.54 – 1.43 (m, 2H), 1.27 – 1.08 (m, 6H), 0.92 
– 0.81 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 190.00, 154.30, 151.47, 132.86, 129.02, 
118.27, 110.12, 74.02, 56.32, 37.75, 37.33, 33.53, 30.62, 26.85, 26.55, 23.27. 
O
CHOI
OMe
 4-(4-Cyclohexylbutoxy)-3-iodo-5-
methoxybenzaldehyde (24k). Obtained from the reaction of 4-hydroxy-3-iodo-5-
methoxybenzaldehyde and 23. Yield: 76 %. Brown oil. 1H NMR (400 MHz, CDCl3) δ 9.80 
(s, 1H), 7.84 (d, J = 1.8 Hz, 1H), 7.38 (d, J = 1.8 Hz, 1H), 4.09 (t, J = 6.6 Hz, 2H), 3.89 (s, 
3H), 1.85 – 1.60 (m, 7H), 1.56 – 1.44 (m, 2H), 1.28 – 1.10 (m, 6H), 1.01 – 0.78 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 189.83, 153.87, 153.02, 135.02, 133.74, 111.12, 92.62, 
73.89, 56.19, 37.74, 37.33, 33.53, 30.70, 26.85, 26.55, 23.41. 
O
MeO
CHO
3-(4-Cyclohexylbutoxy)-4-methoxybenzaldehyde (24l). 
Obtained from the reaction of isovanillin and 23. Yield: 79 %. Colorless oil. 1H NMR (400 
MHz, CDCl3) δ 9.83 (s, 1H), 7.46 – 7.36 (m, 2H), 6.96 (d, J = 8.2 Hz, 1H), 4.05 (t, J = 6.9 
Hz, 2H), 3.93 (s, 3H), 1.87 – 1.78 (m, 2H), 1.73 – 1.59 (m, 5H), 1.45 (dt, J = 9.4, 8.0 Hz, 
2H), 1.27 – 1.06 (m, 6H), 0.92 – 0.80 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 191.05, 
154.95, 149.27, 130.19, 126.67, 110.69, 110.40, 69.21, 56.26, 37.64, 37.22, 33.46, 29.36, 
26.82, 26.52, 23.30. 
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O
CHO
Cl   5-Chloro-2-(4-cyclohexylbutoxy)benzaldehyde (24m). 
Obtained from the reaction of 5-chlorosalicylaldehyde and 23. Yield: 75 %. Yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 10.41 (s, 1H), 7.74 (d, J = 2.8 Hz, 1H), 7.44 (dd, J = 8.9, 2.8 
Hz, 1H), 6.91 (d, J = 8.9 Hz, 1H), 4.04 (t, J = 6.4 Hz, 2H), 1.87 – 1.75 (m, 2H), 1.72 – 1.58 
(m, 5H), 1.51 – 1.41 (m, 2H), 1.26 – 1.07 (m, 6H), 0.92 – 0.81 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 188.59, 160.08, 135.44, 127.79, 126.19, 125.81, 114.26, 69.13, 37.64, 
37.19, 33.45, 29.39, 26.78, 26.47, 23.35. 
O
CHO
Br  5-Bromo-2-(4-cyclohexylbutoxy)benzaldehyde (24n). 
Obtained from the reaction of 5-bromosalicylaldehyde and 23. Yield: 85 %. Yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 10.39 (s, 1H), 7.88 (d, J = 2.6 Hz, 1H), 7.63 – 7.52 (m, 1H), 
6.86 (d, J = 8.9 Hz, 1H), 4.03 (t, J = 6.4 Hz, 2H), 1.85 – 1.77 (m, 2H), 1.72 – 1.59 (m, 6H), 
1.51 – 1.41 (m, 2H), 1.26 – 1.10 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 188.51, 160.50, 
138.33, 130.81, 126.15, 114.63, 113.26, 69.04, 37.61, 37.19, 33.43, 29.35, 26.76, 26.47, 
23.34. 
O
CHO
I  2-(4-Cyclohexylbutoxy)-5-iodobenzaldehyde (24o). 
Obtained from the reaction of 5-iodosalicylaldehyde and 23. Yield: 81 %. Yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 10.36 (s, 1H), 8.08 (s, 1H), 7.81 – 7.72 (m, 1H), 6.76 (d, J = 
8.8 Hz, 1H), 4.04 (t, J = 6.4 Hz, 2H), 1.85 – 1.77 (m, 2H), 1.73 – 1.61 (m, 6H), 1.52 – 1.42 
(m, 2H), 1.28 – 1.09 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 188.50, 161.23, 144.19, 
136.90, 126.65, 115.10, 82.83, 68.95, 37.64, 37.21, 33.46, 29.35, 26.79, 26.49, 23.36. 
O
CHO
 2-(4-Cyclohexylbutoxy)-1-naphthaldehyde (24p). 
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Obtained from the reaction of 2-hydroxy-1-naphthaldehyde and 23. Yield: 76 %. White 
wax-like solid. 1H NMR (400 MHz, CDCl3) δ 10.92 (s, 1H), 9.29 (d, J = 8.7 Hz, 1H), 8.08 
– 7.97 (m, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.65 – 7.56 (m, 1H), 7.45 – 7.36 (m, 1H), 7.24 (s, 
1H), 4.19 (t, J = 6.5 Hz, 2H), 1.90 – 1.80 (m, 2H), 1.72 – 1.63 (m, 6H), 1.28 – 1.17 (m, 
7H), 0.91 – 0.84 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 192.23, 163.85, 161.30, 137.60, 
131.69, 129.90, 128.49, 128.29, 125.02, 124.76, 116.78, 113.66, 69.70, 37.67, 33.47, 33.43, 
29.70, 26.80, 26.50, 23.43. 
O
CHO
4-(4-Phenylbutoxy)-1-naphthaldehyde (24q). Obtained 
from the reaction of 4-hydroxy-1-naphthaldehyde and 23. Yield: 86 %. White wax-like 
solid. 1H NMR (400 MHz, CDCl3) δ 10.19 (s, 1H), 9.31 (d, J = 8.6 Hz, 1H), 8.35 (d, J = 
8.3 Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.74 – 7.65 (m, 1H), 7.57 (t, J = 7.6 Hz, 1H), 6.90 
(d, J = 8.1 Hz, 1H), 4.23 (t, J = 6.4 Hz, 2H), 1.99 – 1.90 (m, 2H), 1.77 – 1.55 (m, 7H), 1.34 
– 1.13 (m, 6H), 0.96 – 0.85 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 192.62, 160.79, 140.17, 
132.35, 129.85, 126.67, 126.01, 125.24, 125.11, 122.84, 103.91, 69.19, 37.97, 37.55, 33.78, 
29.72, 27.10, 26.80, 23.83. 
O
Cl CHO  3-Chloro-4-(4-phenylbutoxy)benzaldehyde (30). 
Obtained from the reaction of 3-chloro-4-hydroxybenzaldehyde and 1-bromo-4-
phenylbutane. Yield: 96 %. Yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.84 (s, 1H), 7.90 
(d, J = 1.4 Hz, 1H), 7.74 (dd, J = 8.5, 1.4 Hz, 1H), 7.32 – 7.18 (m, 4H), 6.99 (d, J = 8.5 Hz, 
1H), 4.12 (t, J = 5.8 Hz, 2H), 2.73 (t, J = 7.1 Hz, 2H), 1.99 – 1.83 (m, 4H). 13C NMR (101 
MHz, CDCl3) δ 189.82, 159.45, 141.98, 131.29, 130.53, 130.09, 128.49, 128.45, 125.97, 
123.96, 112.50, 69.32, 35.49, 28.45, 27.63. 
OO
Cl CHO  3-Chloro-4-(3-phenoxypropoxy)benzaldehyde (33a). 
Obtained from the reaction of 3-chloro-4-hydroxybenzaldehyde and 32a. Yield: 71 %. 
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Yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.84 (s, 1H), 7.90 (d, J = 1.2 Hz, 1H), 7.75 
(dd, J = 8.5, 1.2 Hz, 1H), 7.29 (t, J = 7.7 Hz, 2H), 7.06 (d, J = 8.5 Hz, 1H), 6.94 (dd, J = 
14.9, 8.0 Hz, 3H), 4.33 (t, J = 6.0 Hz, 2H), 4.22 (t, J = 5.9 Hz, 2H), 2.36 (p, J = 5.9 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ 189.88, 159.31, 158.75, 131.36, 130.62, 130.33, 
129.64, 124.06, 121.02, 114.56, 112.65, 66.02, 63.83, 29.17. 
O O
Cl CHO  3-Chloro-4-(3-(naphthalen-2-
yloxy)propoxy)benzaldehyde (33b). Obtained from the reaction of 3-chloro-4-
hydroxybenzaldehyde and 32b. Yield: 70 %. Yellow solid. 1H NMR (400 MHz, CDCl3) δ 
9.84 (s, 1H), 7.91 (d, J = 1.9 Hz, 1H), 7.81 – 7.68 (m, 4H), 7.44 (t, J = 7.4 Hz, 1H), 7.34 
(t, J = 7.5 Hz, 1H), 7.21 – 7.11 (m, 2H), 7.07 (d, J = 8.5 Hz, 1H), 4.36 (dt, J = 8.6, 6.0 Hz, 
4H), 2.43 (p, J = 5.9 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 189.83, 159.33, 156.75, 
134.65, 131.41, 130.59, 130.41, 129.60, 129.16, 127.77, 126.88, 126.57, 124.14, 123.86, 
118.87, 112.71, 106.90, 66.11, 64.08, 29.20. 
O O
Cl CHO
 4-(3-([1,1'-Biphenyl]-4-yloxy)propoxy)-3-
chlorobenzaldehyde (33c). Obtained from the reaction of 3-chloro-4-
hydroxybenzaldehyde and 32c. Yield: 75 %. Yellow solid. 1H NMR (400 MHz, CDCl3) δ 
9.85 (s, 1H), 7.94 – 7.89 (m, 1H), 7.76 (dd, J = 8.5, 0.7 Hz, 1H), 7.53 (t, J = 8.1 Hz, 4H), 
7.42 (t, J = 7.5 Hz, 2H), 7.31 (dd, J = 11.3, 4.5 Hz, 1H), 7.07 (d, J = 8.5 Hz, 1H), 7.00 (d, 
J = 7.9 Hz, 2H), 4.33 (t, 2H), 4.27 (t, J = 5.8 Hz, 2H), 2.39 (p, J = 5.8 Hz, 2H). 13C NMR 
(101 MHz, CDCl3) δ 189.87, 159.32, 158.35, 140.84, 134.16, 131.40, 130.62, 130.39, 
128.87, 128.34, 126.86, 124.11, 114.89, 112.68, 110.15, 66.00, 64.08, 29.20. 
O
CHOO2N  3-Nitro-4-(3-cyclohexylpropoxy)benzaldehyde (36a). 
Obtained from the reaction of 4-hydroxy-3-nitrobenzaldehyde and 35. Yield: 93 %. Yellow 
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wax-like solid. 1H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 8.33 (d, J = 2.1 Hz, 1H), 8.05 
(dd, J = 8.7, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 4.18 (t, J = 6.5 Hz, 2H), 1.91 – 1.83 (m, 
2H), 1.75 – 1.63 (m, 5H), 1.36 – 1.16 (m, 6H), 0.96 – 0.85 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 188.94, 156.93, 140.06, 134.66, 128.81, 127.59, 114.61, 70.89, 37.38, 33.49, 
33.36, 26.71, 26.42, 26.27. 
O
O2N CHO  4-(2-cyclohexylethoxy)-3-nitrobenzaldehyde (36b). 
Obtained from the reaction of 4-hydroxy-3-nitrobenzaldehyde and 1-bromo-2-
cyclohexylethane. Yield: 91 %. Yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.91 (s, 1H), 
8.31 (d, J = 2.1 Hz, 1H), 8.04 (dd, J = 8.7, 2.1 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 4.23 (t, J 
= 6.6 Hz, 2H), 1.78 – 1.62 (m, 7H), 1.59 – 1.46 (m, 1H), 1.31 – 1.09 (m, 3H), 1.03 – 0.90 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 188.92, 156.87, 140.06, 134.68, 128.77, 127.43, 
114.59, 68.59, 36.04, 34.38, 33.20, 26.50, 26.20. 
O
O2N CHO 4-(Cyclohexylmethoxy)-3-nitrobenzaldehyde (36c). Obtained 
from the reaction of 4-hydroxy-3-nitrobenzaldehyde and (bromomethyl)cyclohexane. 
Yield: 97 %. White solid. 1H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 8.33 (d, J = 2.1 Hz, 
1H), 8.05 (dd, J = 8.7, 2.1 Hz, 1H), 7.19 (d, J = 8.7 Hz, 1H), 3.99 (d, J = 5.9 Hz, 2H), 1.93 
– 1.67 (m, 6H), 1.38 – 1.05 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 188.93, 157.08, 134.66, 
128.79, 127.58, 114.61, 75.65, 37.52, 29.64, 26.40, 25.79. 
O
O2N CHO
Me
 3-Nitro-4-(pentyloxy)benzaldehyde (36d) Obtained from 
the reaction of 4-hydroxy-3-nitrobenzaldehyde and 1-bromopentane. Yield: 96 %. Yellow 
solid. 1H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.05 (dd, J = 
8.7, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 4.20 (t, J = 6.5 Hz, 2H), 1.92 – 1.80 (m, 2H), 
1.53 – 1.32 (m, 4H), 0.93 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 188.94, 156.91, 
140.07, 134.68, 128.81, 127.52, 114.59, 70.50, 28.55, 28.00, 22.40, 14.06. 
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O
O2N CHO
Me
4-(Heptyloxy)-3-nitrobenzaldehyde (36e). Obtained 
from the reaction of 4-hydroxy-3-nitrobenzaldehyde and 1-bromoheptane. Yield: 92 %. 
Yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 8.32 (d, J = 1.9 Hz, 1H), 8.09 – 
8.01 (m, 1H), 7.20 (d, J = 8.7 Hz, 1H), 4.20 (t, J = 6.4 Hz, 2H), 1.93 – 1.78 (m, 2H), 1.52 
– 1.43 (m, 2H), 1.39 – 1.24 (m, 6H), 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 188.94, 156.92, 140.07, 134.67, 128.81, 127.53, 114.60, 70.52, 31.78, 28.98, 28.86, 25.83, 
22.69, 14.19. 
O
O2N CHO
Me
 3-Nitro-4-(nonyloxy)benzaldehyde (36f). 
Obtained from the reaction of 4-hydroxy-3-nitrobenzaldehyde and 1-bromoheptane. Yield: 
87 %. Yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.91 (s, 1H), 8.31 (d, J = 2.0 Hz, 1H), 
8.04 (dd, J = 8.7, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 4.19 (t, J = 6.4 Hz, 2H), 1.92 – 
1.79 (m, 2H), 1.52 – 1.42 (m, 2H), 1.36 – 1.21 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 188.93, 156.89, 140.04, 134.69, 128.78, 127.48, 114.59, 70.50, 31.94, 
29.53, 29.31, 29.30, 28.83, 25.84, 22.76, 14.21. 
4.2.5 Preparation of the benzylidenenbarbituric acid derivatives 25a–25q, 27a–27c, 
29a–29c, 31, 34a–34c and 37a–37f 
Preparation of 25b. The suspension of 24b (0.30 g, 1.02 mmol, 1.00 equiv.) and barbituric 
acid (0.13 g, 1.02 mmol, 1.00 equiv.) in absolute ethanol and distilled water (4:1, v/v) was 
heated at reflux for 5 h and the reaction mixture was cooled to room temperature. The 
precipitate was filtered off, washed with hot water and ethanol, and dried under vacuum to 
afford the product as yellow powders in high purity (0.37 g, 90 %). The analytical sample 
was obtained by recrystallization from a mixture of ethanol and DMF. The synthesis for 
other benzylidenebarbituric acid derivatives followed the same protocol as described, but 
with different starting materials. 
67 
 
O
NH
H
NO O
O  5-(4-(4-
Cyclohexylbutoxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25a). Obtained 
from the condensation of 24a with barbituric acid. Yield: 86 %. Yellow solid. 1H NMR 
(400 MHz, DMSO) δ 11.29 (s, 1H), 11.16 (s, 1H), 8.36 (d, J = 8.1 Hz, 2H), 8.24 (s, 1H), 
7.04 (d, J = 8.0 Hz, 2H), 4.09 (t, J = 6.4 Hz, 2H), 1.75 – 1.55 (m, 7H), 1.47 – 1.36 (m, 2H), 
1.25 – 1.06 (m, 6H), 0.92 – 0.75 (m, 2H). 13C NMR (101 MHz, DMSO) δ 163.90, 162.96, 
162.16, 154.95, 150.17, 137.54, 124.98, 115.37, 114.32, 68.02, 36.98, 36.53, 32.82, 28.77, 
26.20, 25.83, 22.68. HRMS (ESI+) m/z calcd for C21H27N2O4 (MH)+: 371.1965, found: 
371.1971. 
O
NH
H
NO O
O
Cl
 5-(3-Chloro-4-(4-
cyclohexylbutoxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25b). Obtained 
from the condensation of 24b with barbituric acid. Yield: 90 %. Yellow solid. 1H NMR 
(400 MHz, DMSO) δ 11.34 (s, 1H), 11.23 (s, 1H), 8.66 (d, J = 2.1 Hz, 1H), 8.20 (s, 1H), 
8.15 (dd, J = 9.1, 2.2 Hz, 1H), 7.25 (d, J = 8.9 Hz, 1H), 4.18 (t, J = 6.4 Hz, 2H), 1.82 – 
1.49 (m, 7H), 1.49 – 1.36 (m, 2H), 1.30 – 1.02 (m, 6H), 0.97 – 0.73 (m, 2H). 13C NMR 
(101 MHz, DMSO) δ 163.58, 162.12, 157.54, 153.26, 150.13, 136.54, 135.20, 125.66, 
120.96, 116.92, 112.94, 69.09, 36.94, 36.41, 32.80, 28.57, 26.20, 25.83, 22.59. HRMS 
(ESI+) m/z calcd for C21H26BrN2O4 (MH)+: 405.1576, found: 405.1574. 
O
NH
H
NO O
O
Br
 5-(3-Bromo-4-(4-
cyclohexylbutoxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25c). Obtained 
from the condensation of 24c with barbituric acid. Yield: 92 %. Yellow solid. 1H NMR (400 
MHz, DMSO) δ 11.34 (s, 1H), 11.22 (s, 1H), 8.81 (d, J = 2.1 Hz, 1H), 8.19 (dd, J = 8.2, 
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2.7 Hz, 2H), 7.21 (d, J = 8.9 Hz, 1H), 4.17 (t, J = 6.3 Hz, 2H), 1.78 – 1.58 (m, 7H), 1.50 – 
1.41 (m, 2H), 1.26 – 1.05 (m, 6H), 0.90 – 0.79 (m, 2H). 13C NMR (101 MHz, DMSO) δ 
163.57, 162.12, 158.38, 153.15, 150.13, 138.34, 137.09, 126.19, 116.87, 112.73, 110.60, 
69.14, 36.95, 36.40, 32.80, 28.57, 26.20, 25.83, 22.61. HRMS (ESI+) m/z calcd for 
C21H26BrN2O4 (MH)+: 449.1070, found: 449.1059. 
O
NH
H
NO O
O
Me
 5-(4-(4-Cyclohexylbutoxy)-3-
methylbenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25d) Obtained from the 
condensation of 24d with barbituric acid. Yield: 82 %. Orange solid. 1H NMR (400 MHz, 
DMSO) δ 11.27 (s, 1H), 11.14 (s, 1H), 8.30 (dd, J = 8.8, 2.1 Hz, 1H), 8.21 (s, 2H), 7.05 (d, 
J = 8.8 Hz, 1H), 4.10 (t, J = 6.3 Hz, 2H), 2.17 (s, 3H), 1.77 – 1.57 (m, 7H), 1.49 – 1.39 (m, 
2H), 1.25 – 1.04 (m, 6H), 0.90 – 0.79 (m, 2H). 13C NMR (101 MHz, DMSO) δ 163.96, 
162.15, 161.34, 155.30, 150.19, 137.51, 135.98, 125.63, 124.56, 114.97, 110.88, 68.00, 
36.95, 36.50, 32.81, 28.77, 26.20, 25.84, 22.72, 15.88. HRMS (ESI+) m/z calcd for 
C22H29N2O4 (MH)+: 385.2122, found: 385.2125. 
O
HO
NH
H
NO O
O  5-(4-(4-Cyclohexylbutoxy)-3-
hydroxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25e) Obtained from the 
condensation of 24e with barbituric acid. Yield: 86 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.26 (s, 1H), 11.14 (s, 1H), 9.32 (s, 1H), 8.14 (d, J = 4.9 Hz, 2H), 7.71 (d, J = 
8.5 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 4.08 (t, J = 5.6 Hz, 2H), 1.78 – 1.57 (m, 7H), 1.49 – 
1.38 (m, 2H), 1.28 – 1.05 (m, 6H), 0.93 – 0.79 (m, 2H). 13C NMR (101 MHz, DMSO) δ 
164.00, 162.11, 155.55, 152.39, 150.19, 145.86, 130.37, 125.18, 120.49, 114.86, 112.05, 
68.32, 37.04, 36.59, 32.84, 28.84, 26.21, 25.85, 22.70. HRMS (ESI+) m/z calcd for 
C21H27N2O5 (MH)+: 387.1914, found: 387.1920. 
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O
NH
H
NO
O
O
MeO
 5-(4-(4-Cyclohexylbutoxy)-3-
methoxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25f) Obtained from the 
condensation of 24f with barbituric acid. Yield: 95 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.30 (s, 1H), 11.17 (s, 1H), 8.41 (s, 1H), 8.24 (s, 1H), 7.87 (d, J = 8.5 Hz, 1H), 
7.08 (d, J = 8.5 Hz, 1H), 4.07 (t, J = 5.9 Hz, 2H), 3.81 (s, 3H), 1.77 – 1.54 (m, 7H), 1.46 – 
1.03 (m, 8H), 0.92 – 0.77 (m, 2H). 13C NMR (101 MHz, DMSO) δ 163.99, 162.36, 155.50, 
153.19, 150.17, 147.87, 131.80, 125.11, 117.04, 115.06, 111.79, 68.43, 55.45, 36.99, 36.53, 
32.83, 28.77, 26.22, 25.85, 22.73. HRMS (ESI+) m/z calcd for C22H29N2O5 (MH)+: 
401.2071, found: 401.2074. 
O
NH
H
NO
O
O
EtO
 5-(4-(4-Cyclohexylbutoxy)-3-
ethoxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25g) Obtained from the 
condensation of 24g with barbituric acid. Yield: 92 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.28 (d, J = 1.3 Hz, 1H), 11.16 (d, J = 1.4 Hz, 1H), 8.42 (d, J = 2.1 Hz, 1H), 
8.23 (s, 1H), 7.82 (dd, J = 8.7, 2.0 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 4.12 – 4.02 (m, 4H), 
1.75 – 1.56 (m, 7H), 1.46 – 1.32 (m, 5H), 1.25 – 1.03 (m, 6H), 0.96 – 0.72 (m, 2H). 13C 
NMR (101 MHz, DMSO) δ 163.96, 162.35, 155.53, 153.46, 150.14, 147.07, 131.88, 
125.12, 118.29, 114.99, 112.05, 68.39, 63.82, 36.95, 36.46, 32.79, 28.70, 26.21, 25.84, 
22.64, 14.58. HRMS (ESI+) m/z calcd for C23H31N2O5 (MH)+: 415.2227, found: 415.2231. 
O
O2N
NH
H
NO O
O  5-(4-(4-Cyclohexylbutoxy)-3-
nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25h) Obtained from the 
condensation of 24h with barbituric acid. Yield: 94 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.40 (s, 1H), 11.29 (s, 1H), 8.99 (d, J = 2.1 Hz, 1H), 8.37 (dd, J = 9.2, 2.2 Hz, 
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1H), 8.25 (s, 1H), 7.45 (d, J = 9.0 Hz, 1H), 4.26 (t, J = 6.3 Hz, 2H), 1.75 – 1.56 (m, 7H), 
1.47 – 1.37 (m, 2H), 1.25 – 1.06 (m, 6H), 0.84 (dd, J = 20.8, 10.4 Hz, 2H). 13C NMR (101 
MHz, DMSO) δ 163.73, 162.48, 154.62, 152.44, 150.57, 141.09, 139.09, 130.47, 124.99, 
118.90, 114.90, 70.22, 37.36, 36.77, 33.21, 28.87, 26.64, 26.26, 22.89. HRMS (ESI+) m/z 
calcd for C21H29N4O6 (M+NH4)+: 433.2082, found: 433.2084. 
O
NH
H
NO
O
O
Cl
OMe
 5-(3-Chloro-4-(4-cyclohexylbutoxy)-5-
methoxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25i) Obtained from the 
condensation of 24i with barbituric acid. Yield: 75 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.40 (s, 1H), 11.27 (s, 1H), 8.20 (s, 1H), 8.06 (s, 1H), 7.99 (s, 1H), 4.07 (t, J = 
6.3 Hz, 2H), 3.85 (s, 3H), 1.77 – 1.52 (m, 7H), 1.52 – 1.32 (m, 2H), 1.32 – 1.01 (m, 6H), 
0.98 – 0.52 (m, 2H). 13C NMR (101 MHz, DMSO) δ 163.36, 161.89, 152.98, 152.40, 
150.11, 147.27, 128.51, 127.50, 126.32, 118.70, 117.56, 73.20, 56.27, 37.00, 36.54, 32.84, 
29.94, 26.21, 25.85, 22.58. HRMS (ESI+) m/z calcd for C21H28ClN2O4 (MH)+: 435.1681, 
found: 435.1681. 
O
NH
H
NO
O
O
Br
OMe
 5-(3-Bromo-4-(4-cyclohexylbutoxy)-5-
methoxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25j) Obtained from the 
condensation of 24j with barbituric acid. Yield: 76 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.40 (s, 1H), 11.27 (s, 1H), 8.23 – 8.16 (m, 2H), 8.02 (d, J = 1.8 Hz, 1H), 4.06 
(t, J = 6.4 Hz, 2H), 3.85 (s, 3H), 1.73 – 1.57 (m, 7H), 1.50 – 1.40 (m, 2H), 1.27 – 1.05 (m, 
6H), 0.92 – 0.78 (m, 2H). 13C NMR (101 MHz, DMSO) δ 163.36, 161.90, 152.85, 152.15, 
150.11, 148.27, 130.37, 129.20, 118.67, 118.13, 116.04, 73.11, 56.25, 36.99, 36.57, 32.85, 
29.96, 26.21, 25.85, 22.65. HRMS (ESI+) m/z calcd for C22H31BrN3O5 (M+NH4)+: 
496.1442, found: 496.1438. 
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O
I
OMe
NH
H
NO
O
O
 5-(4-(4-Cyclohexylbutoxy)-3-iodo-5-
methoxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25k) Obtained from the 
condensation of 24k with barbituric acid. Yield: 72 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.38 (s, 1H), 11.25 (s, 1H), 8.33 (d, J = 1.7 Hz, 1H), 8.18 (s, 1H), 8.05 (d, J = 
1.8 Hz, 1H), 4.04 (t, J = 6.4 Hz, 2H), 3.83 (s, 3H), 1.78 – 1.48 (m, 7H), 1.48 – 1.38 (m, 
2H), 1.36 – 0.97 (m, 6H), 0.97 – 0.73 (m, 2H). 13C NMR (101 MHz, DMSO) δ 163.38, 
161.91, 152.87, 150.93, 150.86, 150.11, 136.51, 130.03, 118.85, 118.31, 92.17, 72.92, 
56.07, 36.99, 36.61, 32.86, 30.07, 26.22, 25.86, 22.82. HRMS (ESI+) m/z calcd for 
C21H28IN2O4 (MH)+: 527.1037, found: 527.1034. 
O
N
H
NH
MeO O
O
O
5-(3-(4-Cyclohexylbutoxy)-4-
methoxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25l) Obtained from the 
condensation of 24l with barbituric acid. Yield: 83 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.29 (s, 1H), 11.16 (s, 1H), 8.40 (d, J = 1.9 Hz, 1H), 8.24 (s, 1H), 7.86 (dd, J = 
8.6, 1.8 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 3.99 (t, J = 6.5 Hz, 2H), 3.88 (s, 3H), 1.80 – 1.47 
(m, 7H), 1.47 – 1.32 (m, 2H), 1.32 – 1.00 (m, 6H), 0.97 – 0.73 (m, 2H). 13C NMR (101 
MHz, DMSO) δ 163.96, 162.34, 155.53, 153.86, 150.14, 147.15, 131.66, 125.26, 117.84, 
115.14, 111.19, 68.15, 55.86, 36.98, 36.56, 32.83, 28.85, 26.21, 25.85, 22.79. HRMS 
(ESI+) m/z calcd for C22H29N2O5 (MH)+: 401.2071, found: 401.2076. 
O
Cl
NH
H
NO
O
O
5-(5-Chloro-2-(4-
cyclohexylbutoxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25m)  Obtained 
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from the condensation of 24m with barbituric acid. Yield: 73 %. Yellow solid. 1H NMR 
(400 MHz, DMSO) δ 11.39 (s, 1H), 11.21 (s, 1H), 8.38 (s, 1H), 8.00 (d, J = 2.6 Hz, 1H), 
7.50 (dd, J = 8.9, 2.7 Hz, 1H), 7.12 (d, J = 9.0 Hz, 1H), 4.07 (t, J = 6.3 Hz, 2H), 1.79 – 
1.47 (m, 7H), 1.47 – 1.32 (m, 2H), 1.32 – 0.97 (m, 6H), 0.96 – 0.72 (m, 2H). 13C NMR 
(101 MHz, DMSO) δ 162.98, 161.41, 156.96, 150.17, 147.86, 132.78, 131.31, 123.31, 
123.14, 119.98, 113.72, 68.75, 36.95, 36.48, 32.77, 28.67, 26.20, 25.83, 22.67. HRMS 
(ESI+) m/z calcd for C21H26ClN2O4 (MH)+: 405.1576, found: 405.1578. 
O
Br
NH
H
NO
O
O
 5-(5-Bromo-2-(4-
cyclohexylbutoxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25n) Obtained 
from the condensation of 24n with barbituric acid. Yield: 75 %. Yellow solid. 1H NMR 
(400 MHz, DMSO) δ 11.38 (s, 1H), 11.21 (s, 1H), 8.36 (s, 1H), 8.11 (d, J = 2.1 Hz, 1H), 
7.62 (dd, J = 8.9, 2.6 Hz, 1H), 7.07 (d, J = 9.0 Hz, 1H), 4.07 (t, J = 6.3 Hz, 2H), 1.73 – 
1.56 (m, 7H), 1.46 – 1.35 (m, 2H), 1.24 – 1.06 (m, 6H), 0.89 – 0.77 (m, 2H). 13C NMR 
(101 MHz, DMSO) δ 162.99, 161.43, 157.35, 150.19, 147.74, 135.59, 134.10, 123.85, 
120.01, 114.21, 110.77, 68.69, 36.96, 36.47, 32.78, 28.65, 26.21, 25.83, 22.67. HRMS 
(ESI+) m/z calcd for C21H26BrN2O4 (MH)+: 449.1070, found: 449.1070. 
O
I
NH
H
NO
O
O
 5-(2-(4-Cyclohexylbutoxy)-5-
iodobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (25o) Obtained from the 
condensation of 24o with barbituric acid. Yield: 71 %. Orange solid. 1H NMR (400 MHz, 
DMSO) δ 11.37 (s, 1H), 11.20 (s, 1H), 8.34 (s, 1H), 8.25 (dd, J = 2.3, 0.6 Hz, 1H), 7.75 
(dd, J = 8.8, 2.2 Hz, 1H), 6.93 (d, J = 8.9 Hz, 1H), 4.05 (t, J = 6.3 Hz, 2H), 1.78 – 1.47 (m, 
7H), 1.47 – 1.30 (m, 2H), 1.30 – 1.01 (m, 6H), 0.96 – 0.48 (m, 2H). 13C NMR (101 MHz, 
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DMSO) δ 162.99, 161.44, 157.94, 150.18, 147.84, 141.40, 139.86, 124.28, 119.74, 114.59, 
81.95, 68.53, 36.95, 36.47, 32.77, 28.64, 26.20, 25.82, 22.66. HRMS (ESI+) m/z calcd for 
C21H26IN2O4 (MH)+: 497.0932, found: 497.0931. 
O
NH
H
NO
O
O
 5-((2-(4-Cyclohexylbutoxy)naphthalen-1-
yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-trione (25p) Obtained from the 
condensation of 24p with barbituric acid. Yield: 73 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.43 (s, 1H), 11.13 (s, 1H), 8.55 (s, 1H), 8.01 (d, J = 9.1 Hz, 1H), 7.89 (d, J = 
8.0 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.51 – 7.34 (m, 3H), 4.13 (t, J = 6.2 Hz, 2H), 1.76 – 
1.50 (m, 7H), 1.50 – 1.16 (m, 5H), 1.16 – 0.93 (m, 3H), 0.93 – 0.67 (m, 2H). 13C NMR 
(101 MHz, DMSO) δ 162.68, 160.77, 154.57, 150.29, 148.68, 132.03, 131.04, 128.32, 
127.92, 127.11, 124.15, 123.75, 122.55, 117.27, 114.08, 68.67, 36.99, 36.61, 32.77, 29.07, 
26.21, 25.83, 22.83. HRMS (ESI+) m/z calcd for C25H29N2O4 (MH)+: 421.2122, found: 
421.2124. 
O
NH
H
NO O
O 5-((4-(4-Cyclohexylbutoxy)naphthalen-1-
yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-trione (25q) Obtained from the 
condensation of 24q with barbituric acid. Yield: 76 %. Orange solid. 1H NMR (400 MHz, 
DMSO) δ 11.37 (s, 1H), 11.13 (s, 1H), 8.86 (s, 1H), 8.28 (dd, J = 19.6, 8.3 Hz, 2H), 7.94 
(d, J = 8.4 Hz, 1H), 7.72 – 7.55 (m, 2H), 7.08 (d, J = 8.5 Hz, 1H), 4.26 (t, J = 6.3 Hz, 2H), 
1.93 – 1.78 (m, 2H), 1.78 – 1.45 (m, 7H), 1.34 – 1.02 (m, 6H), 0.97 – 0.73 (m, 2H). 13C 
NMR (101 MHz, DMSO) δ 163.64, 161.49, 157.99, 151.79, 150.32, 133.34, 132.97, 
128.18, 125.73, 124.42, 123.71, 122.34, 121.55, 118.13, 104.51, 68.38, 36.96, 36.54, 
32.83, 28.77, 26.20, 25.83, 22.89. HRMS (ESI+) m/z calcd for C25H29N2O4 (MH)+: 
421.2122, found: 421.2123. 
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O
N
NO
O
O
Cl
Me
Me
 5-(3-Chloro-4-(4-
cyclohexylbutoxy)benzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione 
(27a). Obtained from the condensation of 24b with 1,3-dimethylbarbituric acid. Yield: 94 
%. Yellow solid. 1H NMR (400 MHz, DMSO) δ 8.63 (d, J = 2.2 Hz, 1H), 8.27 (s, 1H), 8.13 
(dd, J = 9.0, 2.2 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 4.19 (t, J = 6.4 Hz, 2H), 3.22 (d, J = 7.8 
Hz, 6H), 1.82 – 1.49 (m, 7H), 1.49 – 1.38 (m, 2H), 1.31 – 1.04 (m, 6H), 0.97 – 0.75 (m, 
2H). 13C NMR (101 MHz, DMSO) δ 162.31, 160.75, 157.56, 154.08, 151.02, 136.48, 
134.99, 125.68, 120.97, 116.70, 112.93, 69.09, 36.94, 36.41, 32.80, 28.64, 28.56, 28.07, 
26.20, 25.82, 22.58. HRMS (ESI+) m/z calcd for C23H30ClN2O4 (MH)+: 433.1889, found: 
433.1890. 
O
N
NO
O
O
Br
Me
Me
 5-(3-bromo-4-(4-
cyclohexylbutoxy)benzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione 
(27b). Obtained from the condensation of 24c with 1,3-dimethylbarbituric acid. Yield: 91 
%. Yellow solid. 1H NMR (400 MHz, DMSO) δ 8.78 (d, J = 2.1 Hz, 1H), 8.26 (s, 1H), 8.16 
(dd, J = 9.1, 2.1 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 4.18 (t, J = 6.3 Hz, 2H), 3.22 (d, J = 7.4 
Hz, 6H), 1.78 – 1.58 (m, 7H), 1.51 – 1.41 (m, 2H), 1.27 – 1.07 (m, 6H), 0.91 – 0.79 (m, 
2H). 13C NMR (101 MHz, DMSO) δ 162.31, 160.75, 158.42, 154.01, 151.02, 138.16, 
137.09, 126.21, 116.61, 112.72, 110.62, 69.15, 36.96, 36.42, 32.81, 28.65, 28.58, 28.08, 
26.21, 25.84, 22.62. HRMS (ESI+) m/z calcd for C23H30BrN2O4 (MH)+: 477.1383, found: 
477.1380. 
O
N
NO
O
O
O2N
Me
Me
 5-(4-(4-cyclohexylbutoxy)-3-
75 
 
nitrobenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (27c). Obtained 
from the condensation of 24h with 1,3-dimethylbarbituric acid. Yield: 95 %. Yellow solid. 
1H NMR (400 MHz, DMSO) δ 8.94 (d, J = 2.0 Hz, 1H), 8.39 – 8.29 (m, 2H), 7.45 (d, J = 
9.0 Hz, 1H), 4.26 (t, J = 6.3 Hz, 2H), 3.21 (d, J = 13.5 Hz, 6H), 1.77 – 1.57 (m, 7H), 1.47 
– 1.36 (m, 2H), 1.26 – 1.04 (m, 6H), 0.92 – 0.78 (m, 2H). 13C NMR (101 MHz, DMSO) δ 
162.02, 160.64, 154.21, 152.91, 150.97, 140.50, 138.66, 129.87, 124.57, 118.13, 114.45, 
69.80, 36.92, 36.34, 32.77, 28.63, 28.43, 28.08, 26.20, 25.82, 22.45. HRMS (ESI+) m/z 
calcd for C23H30N3O6 (MH)+: 444.2129, found: 444.2130. 
O
NH
H
NO
O
S
Cl
 5-(3-Chloro-4-(4-
cyclohexylbutoxy)benzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (29a) 
Obtained from the condensation of 24b with 2-thiobarbituric acid. Yield: 90 %. Yellow 
solid. 1H NMR (400 MHz, DMSO) δ 12.42 (s, 1H), 12.33 (s, 1H), 8.72 (d, J = 2.0 Hz, 1H), 
8.24 – 8.16 (m, 2H), 7.27 (d, J = 8.9 Hz, 1H), 4.20 (t, J = 6.4 Hz, 2H), 1.82 – 1.49 (m, 7H), 
1.49 – 1.36 (m, 2H), 1.30 – 1.03 (m, 6H), 0.96 – 0.73 (m, 2H). 13C NMR (101 MHz, DMSO) 
δ 178.33, 161.89, 159.92, 157.99, 154.23, 137.05, 135.46, 125.74, 121.09, 116.96, 113.04, 
69.19, 36.93, 36.41, 32.80, 28.55, 26.20, 25.82, 22.57.  HRMS (ESI+) m/z calcd for 
C21H26ClN2O3S (MH)+: 421.1347, found: 421.1348. 
O
NH
H
NO
O
S
Br
 5-(3-Bromo-4-(4-
cyclohexylbutoxy)benzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (29b) 
Obtained from the condensation of 24c with 2-thiobarbituric acid. Yield: 83 %. Yellow 
solid. 1H NMR (400 MHz, DMSO) δ 12.42 (s, 1H), 12.33 (s, 1H), 8.87 (d, J = 2.1 Hz, 1H), 
8.27 – 8.18 (m, 2H), 7.22 (d, J = 8.8 Hz, 1H), 4.18 (t, J = 6.3 Hz, 2H), 1.77 – 1.56 (m, 7H), 
1.50 – 1.40 (m, 2H), 1.26 – 1.06 (m, 6H), 0.90 – 0.78 (m, 2H). 13C NMR (101 MHz, DMSO) 
δ 178.32, 161.88, 159.93, 158.85, 154.15, 138.63, 137.64, 126.28, 116.88, 112.81, 110.74, 
69.24, 36.95, 36.42, 32.81, 28.57, 26.21, 25.84, 22.61. HRMS (ESI+) m/z calcd for 
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C21H26BrN2O3S (MH)+: 465.0842, found: 465.0842. 
O
NH
H
NO
O
S
O2N
 5-(4-(4-Cyclohexylbutoxy)-3-
nitrobenzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (29c). Obtained from 
the condensation of 24h with 2-thiobarbituric acid. Yield: 86 %. Yellow solid. 1H NMR 
(400 MHz, DMSO) δ 12.47 (s, 1H), 12.38 (s, 1H), 9.06 (d, J = 2.0 Hz, 1H), 8.41 (dd, J = 
9.3, 2.3 Hz, 1H), 8.27 (s, 1H), 7.46 (d, J = 9.0 Hz, 1H), 4.28 (t, J = 6.3 Hz, 2H), 1.75 – 1.57 
(m, 7H), 1.47 – 1.38 (m, 2H), 1.26 – 1.07 (m, 6H), 0.90 – 0.79 (m, 2H). 13C NMR (101 
MHz, DMSO) δ 178.44, 161.59, 159.85, 154.55, 152.93, 141.02, 138.70, 130.30, 124.59, 
118.46, 114.56, 69.89, 36.92, 36.33, 32.77, 28.42, 26.20, 25.82, 22.45. HRMS (ESI+) m/z 
calcd for C21H26N3O5S (MH)+: 432.1588, found: 432.1587. 
O
Cl
NH
H
NO O
O  5-(3-chloro-4-(4-
phenylbutoxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (31). Obtained from the 
condensation of 30 with barbituric acid. Yield: 89 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.36 (s, 1H), 11.24 (s, 1H), 8.66 (d, J = 2.1 Hz, 1H), 8.22 – 8.11 (m, 2H), 7.32 
– 7.12 (m, 6H), 4.21 (t, J = 5.6 Hz, 2H), 2.66 (t, J = 7.0 Hz, 2H), 1.91 – 1.51 (m, 4H). 13C 
NMR (101 MHz, DMSO) δ 163.62, 162.16, 157.52, 153.27, 150.18, 141.93, 136.57, 
135.23, 128.30, 125.74, 125.71, 120.97, 116.96, 112.96, 68.94, 34.63, 27.89, 27.22. HRMS 
(ESI+) m/z calcd for C21H20ClN2O4 (MH)+: 399.1106, found:  399.1103. 
O
NH
H
NO
O
OO
Cl
 5-(3-Chloro-4-(3-
phenoxypropoxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (34a) Obtained 
from the condensation of 33a with barbituric acid. Yield: 84 %. White-yellow solid. 1H 
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NMR (400 MHz, DMSO) δ 11.35 (s, 1H), 11.24 (s, 1H), 8.66 (d, J = 2.0 Hz, 1H), 8.23 – 
8.12 (m, 2H), 7.35 – 7.24 (m, 3H), 6.93 (dd, J = 15.3, 7.6 Hz, 3H), 4.36 (t, J = 6.1 Hz, 2H), 
4.16 (t, J = 6.2 Hz, 2H), 2.24 (p, J = 6.1 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 163.58, 
162.13, 158.38, 157.27, 153.16, 150.16, 136.48, 135.20, 129.52, 125.90, 120.99, 120.61, 
117.13, 114.42, 113.00, 65.93, 63.77, 28.37. HRMS (ESI+) m/z calcd for C20H18ClN2O5 
(MH)+: 401.0899, found:  401.0893. 
O O
NH
H
NO O
O
Cl
 5-(3-Chloro-4-(3-(naphthalen-2-
yloxy)propoxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (34b). Obtained from 
the condensation of 33b with barbituric acid. Yield: 78 %. Yellow solid. 1H NMR (400 
MHz, DMSO) δ 11.35 (s, 1H), 11.23 (s, 1H), 8.66 (d, J = 2.0 Hz, 1H), 8.23 – 8.13 (m, 2H), 
7.81 (t, J = 8.6 Hz, 3H), 7.45 (t, J = 7.5 Hz, 1H), 7.38 – 7.29 (m, 3H), 7.18 (dd, J = 8.9, 2.3 
Hz, 1H), 4.41 (t, J = 6.1 Hz, 2H), 4.30 (t, J = 6.2 Hz, 2H), 2.32 (p, J = 6.1 Hz, 2H). 13C 
NMR (101 MHz, DMSO) δ 163.54, 162.10, 157.26, 156.30, 153.14, 150.13, 136.44, 
135.19, 134.25, 129.30, 128.48, 127.47, 126.66, 126.36, 125.91, 123.56, 120.99, 118.68, 
117.12, 113.01, 106.67, 65.97, 64.05, 28.35. HRMS (ESI+) m/z calcd for C24H20ClN2O5 
(MH)+: 451.1055, found:  451.1051. 
O
NH
H
NO
O
OO
Cl
 5-(4-(3-([1,1'-Biphenyl]-4-
yloxy)propoxy)-3-chlorobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (34c). 
Obtained from the condensation of 33c with barbituric acid. Yield: 80 %. Yellow solid. 1H 
NMR (400 MHz, DMSO) δ 11.35 (s, 1H), 11.24 (s, 1H), 8.66 (d, J = 2.1 Hz, 1H), 8.20 (s, 
1H), 8.16 (dd, J = 8.9, 2.0 Hz, 1H), 7.66 – 7.52 (m, 4H), 7.42 (t, J = 7.7 Hz, 2H), 7.37 – 
7.24 (m, 2H), 7.04 (d, J = 8.8 Hz, 2H), 4.38 (t, J = 6.0 Hz, 2H), 4.22 (t, J = 6.1 Hz, 2H), 
2.26 (p, J = 5.9 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 163.56, 162.11, 158.03, 157.28, 
153.18, 150.15, 139.78, 136.47, 135.20, 132.65, 128.83, 127.77, 126.70, 126.15, 125.91, 
121.01, 117.10, 114.90, 113.00, 65.92, 64.03, 28.37. HRMS (ESI+) m/z calcd for 
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C26H22ClN2O5 (MH)+: 477.1212, found:  477.1209. 
O
NH
H
NO
O
O
O2N
 5-(4-(3-Cyclohexylpropoxy)-3-
nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (37a) Obtained from the 
condensation of 36a with barbituric acid. Yield: 95 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.40 (s, 1H), 11.29 (s, 1H), 8.99 (d, J = 2.2 Hz, 1H), 8.37 (dd, J = 9.1, 2.2 Hz, 
1H), 8.25 (s, 1H), 7.45 (d, J = 9.0 Hz, 1H), 4.26 (t, J = 6.3 Hz, 2H), 1.79 – 1.59 (m, 7H), 
1.35 – 1.10 (m, 6H), 0.93 – 0.81 (m, 2H). 13C NMR (101 MHz, DMSO) δ 163.28, 162.03, 
154.17, 152.00, 150.12, 140.63, 138.67, 130.02, 124.56, 118.47, 114.47, 70.15, 36.54, 
32.90, 32.77, 26.14, 25.75, 25.59. HRMS (ESI+) m/z calcd for C20H24N3O6 (MH)+: 
402.1660, found: 402.1656. 
O
O2N
NH
H
NO O
O  5-(4-(2-Cyclohexylethoxy)-3-
nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (37b) Obtained from the 
condensation of 36b with barbituric acid. Yield: 87 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.40 (s, 1H), 11.29 (s, 1H), 8.98 (s, 1H), 8.37 (d, J = 8.1 Hz, 1H), 8.25 (s, 1H), 
7.47 (d, J = 9.0 Hz, 1H), 4.30 (t, J = 6.5 Hz, 2H), 1.76 – 1.59 (m, 7H), 1.51 – 1.41 (m, 1H), 
1.26 – 1.08 (m, 3H), 1.00 – 0.89 (m, 2H). 13C NMR (101 MHz, DMSO) δ 163.28, 162.03, 
154.14, 152.02, 150.12, 140.61, 138.70, 129.98, 124.57, 118.45, 114.50, 68.06, 35.45, 
33.91, 32.50, 25.99, 25.70. HRMS (ESI+) m/z calcd for C19H22N3O6 (MH)+: 388.1503, 
found:  388.1495. 
O
O2N
NH
H
NO O
O  5-(4-(cyclohexylmethoxy)-3-
nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (37c) Obtained from the 
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condensation of 36c with barbituric acid. Yield: 88 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.40 (s, 1H), 11.29 (s, 1H), 9.00 (d, J = 2.1 Hz, 1H), 8.37 (dd, J = 9.2, 2.2 Hz, 
1H), 8.25 (s, 1H), 7.45 (d, J = 9.0 Hz, 1H), 4.08 (d, J = 5.9 Hz, 2H), 1.89 – 1.53 (m, 6H), 
1.35 – 0.95 (m, 5H). 13C NMR (101 MHz, DMSO) δ 163.29, 162.04, 154.29, 152.03, 
150.13, 140.67, 138.59, 130.09, 124.53, 118.44, 114.43, 74.59, 36.78, 28.80, 25.93, 25.14. 
HRMS (ESI+) m/z calcd for C18H20N3O6 (MH)+: 374.1347, found:  374.1338. 
Me
O
O2N
NH
H
NO O
O  5-(3-Nitro-4-(pentyloxy)benzylidene)pyrimidine-
2,4,6(1H,3H,5H)-trione (37d) Obtained from the condensation of 36d with barbituric acid. 
Yield: 92 %. Yellow solid. 1H NMR (400 MHz, DMSO) δ 11.40 (s, 1H), 11.29 (s, 1H), 8.99 
(d, J = 2.2 Hz, 1H), 8.37 (dd, J = 9.2, 2.2 Hz, 1H), 8.25 (s, 1H), 7.46 (d, J = 9.0 Hz, 1H), 
4.27 (t, J = 6.4 Hz, 2H), 1.81 – 1.66 (m, 2H), 1.44 – 1.29 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 163.29, 162.04, 154.18, 152.02, 150.14, 140.64, 138.68, 
130.03, 124.57, 118.48, 114.47, 69.82, 27.88, 27.41, 21.69, 13.87. HRMS (ESI+) m/z calcd 
for C16H18N3O6 (MH)+: 348.1190, found:  348.1191. 
O
Me
O2N
NH
H
NO O
O  5-(4-(heptyloxy)-3-
nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (37e) Obtained from the 
condensation of 36e with barbituric acid. Yield: 86 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.40 (s, 1H), 11.30 (s, 1H), 9.00 (d, J = 2.1 Hz, 1H), 8.36 (dd, J = 9.1, 2.2 Hz, 
1H), 8.24 (s, 1H), 7.44 (d, J = 9.0 Hz, 1H), 4.26 (t, J = 6.3 Hz, 2H), 1.81 – 1.66 (m, 2H), 
1.45 – 1.23 (m, 8H), 0.85 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 163.30, 
162.05, 154.22, 152.07, 150.14, 140.70, 138.66, 130.08, 124.56, 118.42, 114.45, 69.83, 
31.20, 28.25, 28.20, 25.19, 22.02, 13.92. HRMS (ESI+) m/z calcd for C18H22N3O6 (MH)+: 
376.1503, found:  376.1494. 
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Me
O
O2N
NH
H
NO O
O  5-(3-nitro-4-
(nonyloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (37f) Obtained from the 
condensation of 36f with barbituric acid. Yield: 83 %. Yellow solid. 1H NMR (400 MHz, 
DMSO) δ 11.40 (s, 1H), 11.29 (s, 1H), 9.00 (d, J = 1.4 Hz, 1H), 8.37 (dd, J = 8.9, 1.5 Hz, 
1H), 8.25 (s, 1H), 7.45 (d, J = 9.0 Hz, 1H), 4.26 (t, J = 6.3 Hz, 2H), 1.77 – 1.69 (m, 2H), 
1.43 – 1.22 (m, 12H), 0.85 (t, J = 6.6 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 163.29, 
162.04, 154.20, 152.04, 150.13, 140.68, 138.67, 130.06, 124.56, 118.44, 114.46, 69.82, 
31.26, 28.91, 28.59, 28.55, 28.18, 25.19, 22.10, 13.94. HRMS (ESI+) m/z calcd for 
C20H26N3O6 (MH)+:  404.1816, found:   404.1810. 
4.2.6 Preparation of 2-(2,4-dioxothiazolidin-3-yl)acetic acid (40) 
Preparation of tert-butyl 2-(2,4-dioxothiazolidin-3-yl)acetate (39). The protocol was 
slightly modified as described in the literature.[82] Potassium hydroxide (61.5 mmol, 3.45 
g, 1.20 equiv.) was dissolved in absolute EtOH (20 mL) assisted by sonication. This 
solution was added dropwise into the solution of thiazolidine-2,4-dione (2, 6.00 g, 51.2 
mmol, 1.00 equiv.) in hot absolute EtOH (25 mL) at 55–60 °C. The reaction mixture was 
stirred at this temperature for 3 h before cooled to room temperature. The white precipitate 
was filtered off and washed with cold EtOH (25 mL × 3) and dried with infrared heat lamp. 
The potassium salt of thiazolidine-2,4-dione was thus obtained and used in the subsequent 
step without further purification (74% yield). The suspension of thiazolidine-2,4-dione 
potassium salt (2.97 g, 19.1 mmol) and tert-butyl bromoacetate (19.1 mmol, 3.73 g) in 
acetone was stirred at reflux for 5 h and then cooled to room temperature. The solid was 
removed by vacuum filtration and washed with acetone (25 mL × 3). The filtrate was 
concentrated and dried under vacuum overnight. The product was obtained as peach solid 
(3.63 g, 15.7 mmol, 82% yield). 
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S
N
O
O
CO2tBu
 tert-Butyl 2-(2,4-dioxothiazolidin-3-yl)acetate (39). Yield: 82%. Peach 
solid. 1H NMR (400 MHz, CDCl3) δ 4.23 (s, 2H), 4.01 (s, 2H), 1.45 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 171.29, 170.87, 165.25, 83.40, 42.98, 33.96, 28.07. 
Preparation of 2-(2,4-dioxothiazolidin-3-yl)acetic acid (40). The solution of 39 (3.50 g, 
15.1 mmol) in trifluoroacetic acid (15 mL) and dichloromethane (15 mL) was stirred at 
room temperature for 2 h.[83] The solvents were removed under reduced pressure and the 
residue was dried under vacuum overnight to obtain 40 as white solid (2.57 g, 14.7 mmol, 
97% yield). 
S
N
O
O
CO2H
2-(2,4-Dioxothiazolidin-3-yl)acetic acid (40). Yield: 97%. White solid. 1H 
NMR (400 MHz, DMSO) δ 13.30 (s, 1H), 4.32 (s, 2H), 4.20 (s, 2H). 13C NMR (101 MHz, 
DMSO) δ 171.90, 171.48, 168.11, 42.06, 34.04. HRMS (ESI+) m/z calcd for C5H4NO4S 
[M-H]+: 173.9867, found:173.9926. 
4.2.7 Preparation of 1-substituted isatins 43a–43m 
Preparation of 1-(cyclohexylmethyl)indoline-2,3-dione (43a). The protocol was slightly 
modified as described in the literature.[99] The suspension of isatin (41, 0.45 g, 3.06 mmol, 
1.00 equiv.), (bromomethyl)cyclohexane (1.20 equiv., 3.67 mmol, 0.65 g) and K2CO3 (2.00 
equiv., 61.2 mmol, 0.85 g) was stirred at room temperature in DMF for 24 h. The reaction 
mixture was poured into ice water with vigorous stirring. The precipitate was filtered off, 
washed with water (25 mL × 3) and cold EtOH (10 mL), air-dried and recrystallized from 
EtOH to obtain 43a as red crystals (0.64 g, 2.63 mmol, 86% yield). Compounds 43b–43m 
were prepared following the same protocol as described here. 
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N
O
O
1-(Cyclohexylmethyl)indoline-2,3-dione (43a). Yield: 87%. 1H NMR 
(400 MHz, CDCl3) δ 7.62 – 7.49 (m, 2H), 7.13 – 7.01 (m, 1H), 6.87 (d, J = 7.9 Hz, 1H), 
3.50 (d, J = 6.1 Hz, 2H), 1.82 – 1.57 (m, 6H), 1.22 – 0.96 (m, 5H). 13C NMR (101 MHz, 
CDCl3) δ 183.63, 158.44, 151.58, 138.38, 125.26, 123.56, 117.47, 110.56, 46.56, 36.20, 
30.91, 26.13, 25.65. HRMS (ESI+) m/z calcd for C15H18NO2 [M+H]+: 244.1332, found: 
244.1329. 
N
O
O
 1-(2-Cyclohexylethyl)indoline-2,3-dione (43b). Compound 43b was 
prepared from isatin (41) and 1-bromo-2-cyclohexylethane as described in the preparation 
of 43a. Yield: 81%. Red crystals. 1H NMR (400 MHz, CDCl3) δ 7.65 – 7.50 (m, 2H), 7.08 
(t, J = 7.5 Hz, 1H), 6.87 (d, J = 8.1 Hz, 1H), 3.71 (dd, J = 8.2, 7.2 Hz, 2H), 1.82 – 1.47 (m, 
7H), 1.38 – 1.06 (m, 4H), 1.03 – 0.87 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 183.77, 
158.06, 151.03, 138.41, 125.43, 123.64, 117.67, 110.21, 38.25, 35.46, 34.48, 33.14, 26.46, 
26.16. HRMS (ESI+) m/z calcd for C16H20NO2 [M+H]+: 258.1489, found: 258.1484. 
N
O
O
 1-(3-Cyclohexylpropyl)indoline-2,3-dione (43c). Compound 
11c was prepared from isatin (41) and 35 as described in the preparation of 43a. Yield: 
87%. Scarlet crystals. 1H NMR (400 MHz, CDCl3) δ 7.65 – 7.51 (m, 2H), 7.11 (t, J = 7.1 
Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 3.69 (t, J = 6.7 Hz, 2H), 1.74 – 1.55 (m, 7H), 1.30 – 1.07 
(m, 6H), 0.93 – 0.73 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 183.82, 158.24, 151.23, 
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138.42, 125.59, 123.71, 117.74, 110.28, 40.72, 37.51, 34.62, 33.38, 26.69, 26.42, 24.79. 
HRMS (ESI+) m/z calcd for C17H22NO2 [M+H]+: 272.1645, found: 272.1641. 
N
O
O
 1-(4-Cyclohexylbutyl)indoline-2,3-dione (43d). Compound 43d 
was prepared from isatin (41) and 23 as described in the preparation of 43a. Yield: 82%. 
Scarlet crystals. 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.53 (m, 2H), 7.11 (td, J = 7.6, 0.8 
Hz, 1H), 6.89 (d, J = 7.9 Hz, 1H), 3.75 – 3.67 (m, 2H), 1.74 – 1.51 (m, 8H), 1.42 – 1.31 
(m, 2H), 1.30 – 1.08 (m, 6H), 0.95 – 0.77 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 158.26, 
151.24, 138.40, 125.59, 123.71, 121.46, 117.77, 110.29, 40.44, 37.70, 37.18, 33.48, 27.72, 
26.79, 26.50, 24.35. HRMS (ESI+) m/z calcd for C18H24NO2 [M+H]+: 286.1802, found: 
286.1805. 
N
O
O
 1-(4-Phenylbutyl)indoline-2,3-dione (43e). Compound 43e was 
prepared from isatin (41) and 1-bromo-4-phenylbutane as described in the preparation of 
43a. Yield: 78%. Scarlet crystals. 1H NMR (400 MHz, CDCl3) δ 7.62 – 7.51 (m, 2H), 7.31 
– 7.23 (m, 2H), 7.23 – 7.05 (m, 4H), 6.83 (d, J = 7.9 Hz, 1H), 3.73 (t, J = 6.8 Hz, 2H), 2.67 
(t, J = 6.9 Hz, 2H), 1.78 – 1.68 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 183.65, 158.25, 
151.03, 141.63, 138.42, 128.50, 128.49, 126.06, 125.52, 123.72, 117.67, 110.24, 40.11, 
35.36, 28.53, 26.77. HRMS (ESI+) m/z calcd for C18H18NO2 [M+H]+: 280.1332, found: 
280.1334. 
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N
O
O
O
 1-(3-Phenoxypropyl)indoline-2,3-dione (43f). Compound 43f was 
prepared from isatin (41) and 34a as described in the preparation of 43a. Yield: 72%. Red 
crystals. 1H NMR (400 MHz, CDCl3) δ 7.63 – 7.47 (m, 2H), 7.35 – 7.24 (m, 2H), 7.10 (t, 
J = 7.6 Hz, 1H), 7.02 – 6.92 (m, 2H), 6.88 (dd, J = 7.8, 1.0 Hz, 2H), 4.05 (t, J = 5.7 Hz, 
2H), 3.96 (t, J = 7.0 Hz, 2H), 2.21 (p, 2H). 13C NMR (101 MHz, CDCl3) δ 183.53, 158.48, 
151.15, 138.55, 129.67, 125.55, 123.82, 121.22, 117.68, 114.56, 110.30, 64.81, 37.52, 
27.48. HRMS (ESI+) m/z calcd for C17H16NO3 [M+H]+: 282.1125, found: 282.1126. 
N
O
O
O
 1-(3-(Naphthalen-2-yloxy)propyl)indoline-2,3-dione (43g). 
Compound 43g was prepared from isatin (41) and 34b as described in the preparation of 
43a. Yield: 68%. Scarlet crystals. 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.67 (m, 3H), 7.63 
(d, J = 7.4 Hz, 1H), 7.57 – 7.44 (m, 2H), 7.41 – 7.28 (m, 1H), 7.23 – 7.03 (m, 3H), 7.00 (d, 
J = 7.9 Hz, 1H), 4.19 (t, J = 5.7 Hz, 2H), 4.02 (t, J = 6.9 Hz, 2H), 2.30 (p, 2H). 13C NMR 
(101 MHz, CDCl3) δ 183.53, 158.51, 156.42, 151.16, 138.56, 134.58, 129.68, 129.22, 
127.77, 126.90, 126.61, 125.58, 123.95, 123.84, 118.67, 117.69, 110.26, 106.92, 64.96, 
37.58, 27.47. HRMS (ESI+) m/z calcd for C21H18NO3 [M+H]+: 332.1281, found: 332.1289. 
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N
Me
O
O
1-Pentylindoline-2,3-dione (43h). Compound 43h was prepared from 
isatin (41) and 1-bromopentane as described in the preparation of 43a. Yield: 84%. Red 
cystals. 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.46 (m, 2H), 7.08 – 6.99 (m, 1H), 6.90 – 
6.83 (m, 1H), 3.69 – 3.60 (m, 2H), 1.75 – 1.52 (m, 2H), 1.50 – 1.21 (m, 4H), 0.82 (t, J = 
7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 183.61, 158.05, 150.97, 138.40, 125.21, 
123.53, 117.43, 110.23, 40.14, 28.89, 26.85, 22.21, 13.84. HRMS (ESI+) m/z calcd for 
C13H16NO2 [M+H]+: 218.1176, found: 218.1171. 
N
O
O
Me 1-Hexylindoline-2,3-dione (43i). Compound 43i was prepared from 
isatin (41) and 1-bromohexane as described in the preparation of 43a. Yield: 80%. Red 
crystals. 1H NMR (400 MHz, CDCl3) δ 7.63 – 7.51 (m, 2H), 7.09 (t, J = 7.5 Hz, 1H), 6.92 
– 6.85 (m, 1H), 3.70 (t, J = 7.4 Hz, 2H), 1.90 – 1.49 (m, 2H), 1.49 – 1.09 (m, 6H), 0.87 (t, 
J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 183.79, 158.23, 151.20, 138.41, 125.53, 
123.69, 117.71, 110.28, 40.39, 31.50, 27.34, 26.68, 22.62, 14.09. HRMS (ESI+) m/z calcd 
for C14H18NO2 [M+H]+: 232.1332, found: 232.1325. 
N
O
O
Me  1-Heptylindoline-2,3-dione (43j). Compound 43j was prepared 
from isatin (41) and 1-bromoheptane as described in the preparation of 43a. Yield: 80%. 
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Red solid. 1H NMR (400 MHz, CDCl3) δ 7.62 – 7.53 (m, 2H), 7.14 – 7.05 (m, 1H), 6.92 – 
6.85 (m, 1H), 3.70 (t, 2H), 1.78 – 1.60 (m, 2H), 1.46 – 0.97 (m, 9H), 0.86 (t, J = 6.9 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 183.77, 158.22, 151.19, 138.41, 125.51, 123.68, 
117.70, 110.28, 40.39, 31.77, 28.99, 27.37, 26.96, 22.65, 14.14. HRMS (ESI+) m/z calcd 
for C15H20NO2 [M+H]+: 246.1489, found: 246.1484. 
N
O
O
Me 1-Octylindoline-2,3-dione (43k). Compound 43k was prepared 
from isatin (41) and 1-bromooctane as described in the preparation of 43a. Yield: 72%. 
Red solid. 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.48 (m, 2H), 7.05 (td, J = 7.5, 0.8 Hz, 
1H), 6.90 – 6.83 (m, 1H), 3.70 – 3.61 (m, 2H), 1.71 – 1.58 (m, 2H), 1.35 – 1.14 (m, 10H), 
0.81 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 183.65, 158.08, 151.04, 138.38, 
125.28, 123.56, 117.51, 110.24, 40.23, 31.70, 29.14, 29.10, 27.22, 26.86, 22.57, 14.03. 
HRMS (ESI+) m/z calcd for C16H22NO2 [M+H]+: 260.1645, found: 260.1644. 
N
O
O
Me 1-Nonylindoline-2,3-dione (43l). Compound 43l was prepared 
from isatin (41) and 1-bromononane as described in the preparation of 43a. Yield: 74%. 
Red solid. 1H NMR (400 MHz, CDCl3) δ 7.60 – 7.47 (m, 2H), 7.07 (td, J = 7.5, 0.5 Hz, 
1H), 6.88 (d, J = 7.9 Hz, 1H), 3.67 (t, J = 7.3 Hz, 2H), 1.71 – 1.59 (m, 2H), 1.40 – 1.07 (m, 
12H), 0.82 (t, J = 6.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 183.69, 158.12, 151.07, 
138.41, 125.36, 123.60, 117.55, 110.26, 40.27, 31.81, 29.43, 29.23, 29.20, 27.26, 26.90, 
22.64, 14.11. HRMS (ESI+) m/z calcd for C17H24NO2 [M+H]+: 274.1802, found: 274.1793. 
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N
O
O
Me  1-Decylindoline-2,3-dione (43m). Compound 43m was 
prepared from isatin (41) and 1-bromodecane as described in the preparation of 43a. Yield: 
70%. Red solid. 1H NMR (400 MHz, CDCl3) δ 7.57 (t, J = 6.8 Hz, 2H), 7.09 (t, J = 7.5 Hz, 
1H), 6.89 (d, J = 8.3 Hz, 1H), 3.70 (t, J = 7.4 Hz, 2H), 1.77 – 1.59 (m, 2H), 1.44 – 1.14 (m, 
14H), 0.85 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 178.84, 153.26, 146.23, 
133.48, 120.56, 118.74, 112.73, 105.34, 35.43, 27.01, 24.65, 24.63, 24.42, 24.38, 22.41, 
22.05, 17.82, 9.28. HRMS (ESI+) m/z calcd for C18H26NO2 [M+H]+: 288.1958, found: 
288.1955. 
4.2.8 Preparation of (Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-2,4-dione 
derivatives 42 and 44a–44m 
Preparation of (Z)-2-(5-(1-(cyclohexylmethyl)-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (44a). The suspension of 43a (0.26 g, 1.07 mmol, 1.00 
equiv.), 40 (1.10 equiv.,1.18 mmol, 0.21g) and NH4OAc (2.00 equiv., 2.14 mmol, 0.16 g) 
in glacial AcOH (2 mL) was heated at 108 °C for 12 h or overnight. The reaction mixture 
was cooled to room temperature. The precipitate was filtered off, washed with cold EtOH, 
air-dried and recrystallized from EtOH. Compound 44a was thus formed as maroon 
crystals (0.36 g, 0.90 mmol, 84% yield). Compounds 42 and 44b–44m were prepared as 
described here with different 1-substituted isatins. 
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N
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O
CO2H
  (Z)-2-(5-(1-(Cyclohexylmethyl)-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (12a). Yield: 84%. Maroon crystals. 1H NMR (400 MHz, 
DMSO) δ 13.52 (s, 1H), 8.81 (dd, J = 7.9, 0.8 Hz, 1H), 7.50 (td, J = 7.8, 1.2 Hz, 1H), 7.25 
– 7.11 (m, 2H), 4.44 (s, 2H), 3.63 (d, J = 7.3 Hz, 2H), 1.81 – 1.56 (m, 6H), 1.19 – 0.94 (m, 
5H). 13C NMR (101 MHz, DMSO) δ 169.31, 167.86, 166.92, 164.83, 144.87, 133.02, 
129.34, 127.74, 126.91, 122.60, 119.02, 109.94, 45.90, 41.92, 35.85, 30.20, 25.78, 25.17. 
HRMS (ESI+) m/z calcd for C20H19N2O5S [M-H]-: 399.1020, found: 399.1027. 
N
H
O
S
N
O
O
CO2H
 (Z)-2-(2,4-Dioxo-5-(2-oxoindolin-3-ylidene)thiazolidin-3-yl)acetic acid 
(42). Compound 42 was prepared from isatin (41) with 40 as described in the preparation 
of 42a. Yield: 85%. Maroon crystals. 1H NMR (400 MHz, DMSO) δ 8.76 (d, J = 7.9 Hz, 
1H), 7.38 (t, J = 7.5 Hz, 1H), 7.04 (t, J = 7.7 Hz, 1H), 6.95 (d, J = 7.8 Hz, 1H), 4.04 (s, 
2H). 13C NMR (101 MHz, DMSO) δ 169.71, 168.27, 167.54, 165.37, 144.04, 132.66, 
129.76, 127.87, 127.05, 122.00, 119.83, 110.56, 44.51. HRMS (ESI+) m/z calcd for 
C13H7N2O5S [M-H]-: 303.0081, found: 303.0081. 
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N
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CO2H
  (Z)-2-(5-(1-(2-Cyclohexylethyl)-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (44b). Compound 44b was prepared from 43b with 40 
as described in the preparation of 44a. Yield: 81%. Maroon crystals. 1H NMR (400 MHz, 
DMSO) δ 13.54 (s, 1H), 8.84 – 8.77 (m, 1H), 7.51 (td, J = 7.8, 1.2 Hz, 1H), 7.21 – 7.11 (m, 
2H), 4.43 (s, 2H), 3.80 (t, 2H), 1.81 – 1.46 (m, 7H), 1.32 – 1.05 (m, 4H), 1.04 – 0.84 (m, 
2H). 13C NMR (101 MHz, DMSO) δ 169.32, 167.89, 166.51, 164.85, 144.26, 133.10, 
127.85, 126.96, 122.67, 119.18, 109.59, 42.00, 40.15, 39.94, 39.73, 39.52, 39.31, 39.10, 
38.89, 37.79, 34.69, 34.16, 32.50, 26.01, 25.66. HRMS (ESI+) m/z calcd for C21H21N2O5S 
[M-H]-: 413.1177, found: 413.1191. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(3-Cyclohexylpropyl)-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (44c). Compound 44c was prepared from 43c with 40 
as described in the preparation of 44a. Yield: 81%. Maroon crystals. 1H NMR (400 MHz, 
DMSO) δ 13.51 (s, 1H), 8.77 (dd, J = 7.9, 0.6 Hz, 1H), 7.49 (td, J = 7.8, 1.1 Hz, 1H), 7.21 
– 7.08 (m, 2H), 4.43 (s, 2H), 3.73 (t, J = 7.2 Hz, 2H), 1.81 – 1.42 (m, 7H), 1.31 – 0.98 (m, 
6H), 0.89 – 0.73 (m, 2H). 13C NMR (101 MHz, DMSO) δ 169.27, 167.85, 166.57, 164.77, 
144.38, 133.04, 129.23, 127.80, 126.97, 122.60, 119.08, 109.58, 41.91, 36.70, 33.81, 32.72, 
26.11, 25.78, 24.29. HRMS (ESI+) m/z calcd for C22H23N2O5S [M-H]-: 427.1333, found: 
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427.1345. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(4-Cyclohexylbutyl)-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (44d). Compound 44d was prepared from 43d with 40 
as described in the preparation of 44a. Yield: 77%. Maroon crystals. 1H NMR (400 MHz, 
DMSO) δ 8.78 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.17 – 7.07 (m, 2H), 4.20 (s, 
2H), 3.73 (t, J = 7.0 Hz, 2H), 1.67 – 1.51 (m, 7H), 1.32 – 1.04 (m, 8H), 0.88 – 0.74 (m, 
2H). 13C NMR (101 MHz, DMSO) δ 169.33, 167.69, 166.60, 165.01, 144.20, 132.74, 
130.01, 127.77, 126.38, 122.52, 119.13, 109.47, 43.44, 36.91, 36.41, 32.78, 27.20, 26.18, 
25.80, 23.50. HRMS (ESI+) m/z calcd for C23H25N2O5S [M-H]-: 441.1490, found: 
441.1520. 
N
O
S
N
O
O
CO2H
  (Z)-2-(2,4-Dioxo-5-(2-oxo-1-(4-phenylbutyl)indolin-3-
ylidene)thiazolidin-3-yl)acetic acid (44e). Compound 44e was prepared from 43e with 40 
as described in the preparation of 44a. Yield: 74%. Barn red crystals. 1H NMR (400 MHz, 
DMSO) δ 8.77 (dd, J = 7.9, 0.9 Hz, 1H), 7.46 (td, J = 7.8, 1.2 Hz, 1H), 7.28 – 7.20 (m, 2H), 
7.20 – 7.06 (m, 5H), 4.35 (s, 2H), 3.78 (t, J = 6.6 Hz, 2H), 2.59 (t, J = 7.2 Hz, 2H), 1.84 – 
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1.34 (m, 4H). 13C NMR (101 MHz, DMSO) δ 169.29, 167.83, 166.63, 164.85, 144.27, 
141.84, 132.88, 129.55, 128.26, 128.22, 127.79, 126.73, 125.69, 122.59, 119.12, 109.52, 
42.48, 34.62, 28.21, 26.57. HRMS (ESI+) m/z calcd for C23H19N2O5S [M-H]-: 435.1020, 
found: 435.1027. 
N
O
S
N
O
O
O
CO2H
  (Z)-2-(2,4-Dioxo-5-(2-oxo-1-(3-phenoxypropyl)indolin-3-
ylidene)thiazolidin-3-yl)acetic acid (44f). Compound 44f was prepared from 43f with 40 
as described in the preparation of 44a. Yield: 53%. Fire brick red crystals. 1H NMR (400 
MHz, DMSO) δ 8.80 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.28 – 7.11 (m, 4H), 
6.93 – 6.81 (m, 3H), 4.43 (s, 2H), 3.99 (dt, J = 13.4, 6.2 Hz, 4H), 2.12 – 2.03 (m, 2H). 13C 
NMR (101 MHz, DMSO) δ 169.32, 167.88, 166.76, 164.84, 158.27, 144.45, 132.99, 
129.41, 129.20, 127.80, 127.13, 122.62, 120.55, 119.24, 114.37, 109.54, 64.97, 42.01, 
37.30, 26.74. HRMS (ESI+) m/z calcd for C22H19N2O6S [M+H]+: 439.0958, found: 
439.0970. 
N
O
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(3-(Naphthalen-2-yloxy)propyl)-2-oxoindolin-3-
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ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (44g). Compound 44g was prepared from 
43g with 40 as described in the preparation of 44a. Yield: 38%. Fire brick red crystals. 1H 
NMR (400 MHz, DMSO) δ 13.51 (s, 1H), 8.85 – 8.78 (m, 1H), 7.83 – 7.70 (m, 3H), 7.50 
– 7.38 (m, 2H), 7.37 – 7.09 (m, 4H), 7.04 (dd, J = 8.9, 2.5 Hz, 1H), 4.43 (s, 2H), 4.15 (t, J 
= 5.8 Hz, 2H), 4.02 (t, J = 6.7 Hz, 2H), 2.22 – 2.10 (m, 2H). 13C NMR (101 MHz, DMSO) 
δ 169.27, 167.91, 166.80, 164.82, 156.17, 144.49, 134.17, 133.01, 129.19, 128.46, 127.48, 
127.16, 126.62, 126.35, 123.54, 122.64, 119.25, 118.55, 109.61, 106.72, 65.24, 41.95, 
37.41, 26.64. HRMS (ESI+) m/z calcd for C26H19N2O6S [M-H]-: 487.0969, found: 
487.1029. 
N
O
S
N
O
O
CO2H
Me   (Z)-2-(2,4-Dioxo-5-(2-oxo-1-pentylindolin-3-ylidene)thiazolidin-3-
yl)acetic acid (44h). Compound 44h was prepared from 43h with 40 as described in the 
preparation of 43a. Yield: 78%. Maroon crystals. 1H NMR (400 MHz, DMSO) δ 8.76 (d, J 
= 7.8 Hz, 1H), 7.47 (t, J = 7.4 Hz, 1H), 7.18 – 7.05 (m, 2H), 4.33 (s, 2H), 3.74 (t, J = 7.1 
Hz, 2H), 1.72 – 1.48 (m, 2H), 1.35 – 1.15 (m, 4H), 0.84 (t, J = 6.9 Hz, 3H). 13C NMR (101 
MHz, DMSO) δ 169.32, 167.86, 166.60, 164.88, 144.31, 132.92, 129.57, 127.79, 126.71, 
122.58, 119.10, 109.54, 42.57, 39.78, 28.40, 26.63, 21.78, 13.85. HRMS (ESI+) m/z calcd 
for C18H17N2O5S [M-H]-: 373.0864, found: 373.0900. 
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N
O
S
N
O
O
CO2H
Me   (Z)-2-(5-(1-Hexyl-2-oxoindolin-3-ylidene)-2,4-dioxothiazolidin-
3-yl)acetic acid (44i). Compound 44i was prepared from 43i with 40 as described in the 
preparation of 44a. Yield: 71%. Maroon crystals. 1H NMR (400 MHz, DMSO) δ 8.78 (d, J 
= 7.9 Hz, 1H), 7.52 – 7.43 (m, 1H), 7.19 – 7.09 (m, 2H), 4.33 (s, 2H), 3.75 (t, J = 7.1 Hz, 
2H), 1.65 – 1.53 (m, 2H), 1.31 – 1.21 (m, 6H), 0.83 (t, J = 6.9 Hz, 3H). 13C NMR (101 
MHz, DMSO) δ 169.32, 167.82, 166.60, 164.90, 144.31, 132.93, 129.60, 127.80, 126.71, 
122.59, 119.12, 109.55, 42.59, 40.15, 30.82, 26.88, 25.87, 21.98, 13.87. HRMS (ESI+) m/z 
calcd for C19H19N2O5S [M-H]-: 387.1020, found: 387.1077. 
N
O
S
N
O
O
CO2H
Me   (Z)-2-(5-(1-Heptyl-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (44j). Compound 44j was prepared from 43j with 40 as 
described in the preparation of 44a. Yield: 68%. Amber crystals. 1H NMR (400 MHz, 
DMSO) δ 8.81 (dd, J = 7.9, 1.1 Hz, 1H), 7.48 (td, J = 7.8, 1.2 Hz, 1H), 7.20 – 7.10 (m, 2H), 
4.21 (s, 2H), 3.76 (t, J = 7.1 Hz, 2H), 1.66 – 1.57 (m, 2H), 1.31 – 1.19 (m, 8H), 0.83 (t, J 
= 6.9 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 169.36, 167.53, 166.66, 165.06, 144.25, 
132.80, 126.40, 122.56, 119.18, 109.53, 43.45, 39.78, 31.14, 28.27, 26.92, 26.18, 22.00, 
13.92. HRMS (ESI+) m/z calcd for C20H21N2O5S [M-H]-: 401.1177, found: 401.1179. 
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N
O
S
N
O
O
CO2H
Me   (Z)-2-(5-(1-Octyl-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (44k). Compound 44k was prepared from 43k with 40 
as described in the preparation of 44a. Yield: 60%. Sangria crystals. 1H NMR (400 MHz, 
DMSO) δ 8.84 – 8.77 (m, 1H), 7.47 (td, J = 7.9, 1.1 Hz, 1H), 7.21 – 7.07 (m, 2H), 4.17 (s, 
2H), 3.75 (t, J = 7.1 Hz, 2H), 1.67 – 1.53 (m, 2H), 1.31 – 1.16 (m, 10H), 0.83 (t, J = 6.8 
Hz, 3H). 13C NMR (101 MHz, DMSO) δ 169.36, 167.55, 166.66, 165.09, 144.20, 132.72, 
130.24, 127.78, 126.27, 122.53, 119.17, 109.49, 43.72, 40.19, 39.99, 31.18, 28.56, 26.89, 
26.21, 22.04, 13.93. HRMS (ESI+) m/z calcd for C21H23N2O5S [M-H]-: 415.1333, found: 
415.1338. 
N
O
S
N
O
O
CO2H
Me   (Z)-2-(5-(1-Nonyl-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (44l). Compound 44l was prepared from 43l with 40 as 
described in the preparation of 44a. Yield: 75%. Sangria crystals. 1H NMR (400 MHz, 
DMSO) δ 13.52 (s, 1H), 8.78 (d, J = 7.9 Hz, 1H), 7.70 – 7.44 (m, 1H), 7.43 – 7.09 (m, 2H), 
4.43 (s, 2H), 3.75 (t, J = 7.0 Hz, 2H), 1.60 (s, 2H), 1.35 – 1.16 (m, 12H), 0.83 (t, J = 6.8 
Hz, 3H). 13C NMR (101 MHz, DMSO) δ 169.29, 167.87, 166.57, 164.78, 144.39, 133.03, 
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132.35, 129.23, 127.80, 126.96, 122.61, 119.08, 109.61, 41.92, 39.80, 39.79, 31.22, 28.84, 
28.59, 26.88, 26.18, 22.08, 13.93. HRMS (ESI+) m/z calcd for C22H25N2O5S [M-H]-: 
429.1490, found: 429.1502. 
N
O
S
N
O
O
CO2H
Me   (Z)-2-(5-(1-Decyl-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (44m). Compound 44m was prepared from 43m with 
40 as described in the preparation of 44a. Yield: 72%. Sangria crystals. 1H NMR (400 MHz, 
DMSO) δ 13.49 (s, 1H), 8.79 (d, J = 7.7 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.23 – 7.09 (m, 
2H), 4.44 (s, 2H), 3.76 (t, J = 7.1 Hz, 2H), 1.66 – 1.55 (m, 2H), 1.30 – 1.18 (m, 14H), 0.83 
(t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 169.30, 167.88, 166.60, 164.80, 147.95, 
144.41, 133.05, 129.26, 127.81, 126.98, 122.63, 119.10, 109.64, 41.92, 40.01, 39.80, 31.27, 
28.88, 28.65, 28.58, 26.87, 26.17, 22.09, 13.96. HRMS (ESI+) m/z calcd for C23H27N2O5S 
[M-H]-: 443.1646, found: 443.1657. 
4.2.9 Preparation of 2-(2,3-dioxoindolin-1-yl)acetic acid (46) from isatin (41) 
Preparation of tert-butyl 2-(2,3-dioxoindolin-1-yl)acetate (45). The protocol was 
slightly modified as described in the literature.[86] The suspension of isatin (41, 0.90 g, 6.12 
mmol, 1.00 equiv.,), tert-butyl bromoacetate (1.00 equiv., 6.12 mmol, 1.19 g) and K2CO3 
(2.00 equiv., 12.2 mmol, 1.69 g) was stirred in DMF (10 mL) at room temperature for 24 
h. Water (30 mL) was added and the reaction mixture was extracted with EtOAc (30 mL × 
3). The combined organic phase was washed sequentially with saturated NaHCO3 solution 
(30 mL), water (30 mL) and brine (30 mL), dried with anhydrous Na2SO4, and solvent was 
removed under reduced pressure. The solid residue was dried under vacuum to give 45 as 
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pumpkin powders (1.23 g, 4.71 mmol, 77% yield). 
N
O
O
CO2tBu   tert-Butyl 2-(2,3-dioxoindolin-1-yl)acetate (13). Yield: 77%. 
Pumpkin powders. 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.54 (m, 2H), 7.15 (t, J = 7.6 Hz, 
1H), 6.77 (d, J = 7.9 Hz, 1H), 4.39 (s, 2H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
182.75, 165.88, 158.20, 150.70, 138.49, 125.68, 124.22, 117.75, 110.29, 83.58, 42.19, 
28.11. HRMS (ESI+) m/z calcd for C14H16NO4 [M+H]+: 262.1074, found: 262.1067. 
Preparation of 2-(2,3-dioxoindolin-1-yl)acetic acid (46). The protocol was slightly 
modified as described in the literature.[86] Compound 45 (1.16 g, 4.28 mmol) was stirred in 
equal volumes of trifluoroacetic acid (10 mL) and DCM (10 mL) at room temperature for 
2 h. Solvents were evaporated under reduced pressure and the residue was dried under 
vacuum overnight to give 46 as a yellow solid (0.87 g, 4.24 mmol, 99% yield). 
N
O
O
CO2H 2-(2,3-dioxoindolin-1-yl)acetic acid (46). Yield: 99%. Yellow solid. 1H 
NMR (400 MHz, DMSO) δ 13.27 (s, 1H), 7.73 – 7.57 (m, 2H), 7.17 (dd, J = 14.2, 7.5 Hz, 
2H), 4.51 (s, 2H). 13C NMR (101 MHz, DMSO) δ 182.87, 168.84, 158.16, 150.64, 138.49, 
124.61, 123.58, 117.26, 111.10, 41.21. HRMS (ESI+) m/z calcd for C10H8NO4 [M+H]+: 
206.0448, found: 206.0446. 
4.2.10 Preparation of N-substituted thiazolidine-2,4-dione 47a–47b 
Preparation of 3-(4-cyclohexylbutyl)thiazolidine-2,4-dione (47a). The potassium salt of 
thiazolidine-2,4-dione (38, 0.28 g, 1.80 mmol) and 23 (1.80 mmol, 0.56 g) was stirred in 
acetone at reflux for 6 h. The reaction mixture was cooled to room temperature and the 
solid was removed by filtration. The filtrate was concentrated under reduced pressure and 
dried under vacuum overnight to obtain 47a as white solid (0.41 g, 1.61 mmol, 89% yield). 
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Compound 47b was synthesized with the same protocol as described here.[87] 
S
N
O
O 3-(4-Cyclohexylbutyl)thiazolidine-2,4-dione (47a). Yield: 89%. 
White solid. 1H NMR (400 MHz, CDCl3) δ 3.93 (s, 2H), 3.60 (t, 2H), 1.78 – 1.49 (m, 7H), 
1.37 – 1.03 (m, 8H), 1.00 – 0.70 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 171.88, 171.59, 
42.30, 37.62, 37.04, 33.85, 33.44, 28.00, 26.79, 26.49, 24.12. HRMS (ESI+) m/z calcd for 
C13H22NO2S [M+H]+: 256.1366, found: 256.1350. 
S
N
O
O 3-(4-Phenylbutyl)thiazolidine-2,4-dione (47b). Compound 47b 
was prepared from the potassium salt of thiazolidine-2,4-dione with 1-bromo-4-
phenylbutane as described in the preparation of 47a. Yield: 82%. White solid. 1H NMR 
(400 MHz, CDCl3) δ 7.40 – 7.01 (m, 5H), 3.93 (s, 2H), 3.65 (t, J = 6.7 Hz, 2H), 2.64 (t, J 
= 6.7 Hz, 2H), 1.76 – 1.58 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 171.90, 171.57, 141.89, 
128.53, 128.50, 126.02, 41.99, 35.43, 33.87, 28.58, 27.27. HRMS (ESI+) m/z calcd for 
C13H16NO2S [M+H]+: 250.0896, found: 250.0887. 
4.2.11 Preparation of (Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-2,4-dione 
derivatives 48a–48b 
Preparation of (Z)-2-(3-(3-(4-Cyclohexylbutyl)-2,4-dioxothiazolidin-5-ylidene)-2-
oxoindolin-1-yl)acetic acid (48a). The suspension of 47a (0.33 g, 1.29 mmol, 1.00 equiv.), 
46 (1.00 equiv., 1.29 mmol, 0.27 g) and NH4OAc (2.00 equiv., 2.58 mmol, 0.20 g) was 
stirred in glacial AcOH (2 mL) at 108 °C for 12 h or overnight. The reaction was cooled to 
room temperature and ice-water (40 mL) was added. The precipitate was filtered off, 
washed with water (10 mL × 3) and cold EtOH (10 mL), air-dried and recrystallized from 
EtOH. The product 48a was thus obtained as orange solid (0.39 g, 0.88 mmol, 68% yield). 
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N
O
S
N
O
O
CO2H   (Z)-2-(3-(3-(4-Cyclohexylbutyl)-2,4-dioxothiazolidin-5-ylidene)-2-
oxoindolin-1-yl)acetic acid (48a). Yield: 68%. Orange solid. 1H NMR (400 MHz, DMSO) 
δ 13.29 (s, 1H), 8.87 (d, J = 7.9 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.17 (d, J = 4.3 Hz, 2H), 
4.59 (s, 2H), 3.67 (t, J = 7.0 Hz, 2H), 1.77 – 1.51 (m, 7H), 1.48 – 1.04 (m, 8H), 0.91 – 0.69 
(m, 2H). 13C NMR (101 MHz, DMSO) δ 169.59, 167.05, 165.38, 146.19, 143.99, 132.59, 
131.38, 127.73, 125.40, 122.80, 119.14, 109.62, 41.21, 36.92, 36.40, 32.82, 27.29, 26.20, 
25.84, 23.48. HRMS (ESI+) m/z calcd for C23H25N2O5S [M-H]-: 441.1490, found: 
441.1588. 
N
O
S
N
O
O
CO2H   (Z)-2-(3-(2,4-Dioxo-3-(4-phenylbutyl)thiazolidin-5-ylidene)-2-
oxoindolin-1-yl)acetic acid (48b). Compound 48b was synthesized from 47b and 46 as 
described in the preparation of 16a. Yield: 74%. Yellow solid. 1H NMR (400 MHz, DMSO) 
δ 13.24 (s, 1H), 8.86 (dd, J = 8.1, 1.0 Hz, 1H), 7.47 (td, J = 7.8, 1.2 Hz, 1H), 7.37 – 6.95 
(m, 7H), 4.59 (s, 2H), 3.71 (t, J = 6.5 Hz, 2H), 2.60 (t, J = 7.1 Hz, 2H), 1.85 – 1.52 (m, 
4H). 13C NMR (101 MHz, DMSO) δ 169.64, 168.87, 167.04, 165.38, 143.93, 141.84, 
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132.57, 131.41, 128.31, 128.24, 127.73, 125.71, 125.36, 122.81, 119.14, 109.58, 41.39, 
41.03, 34.63, 28.22, 26.71. HRMS (ESI+) m/z calcd for C23H19N2O5S [M-H]-: 435.1020, 
found: 435.1118. 
4.2.12 Preparation of 1,5-disubstituted isatins (50, 54a–54d) through N-substitution 
Preparation of 1-(cyclohexylmethyl)-5-iodoindoline-2,3-dione (50). The protocol was 
slightly modified as described in the literature.[88] The suspension of 5-iodoisatin (49, 5.09 
g, 18.6 mmol, 1.00 equiv.), (bromomethyl)cyclohexane (1.20 equiv., 22.4 mmol, 3.96 g) 
and potassium carbonate (2.00 equiv., 37.3 mmol, 5.15 g) was stirred in DMF (20 mL) at 
80 °C overnight. The reaction mixture was cooled to room temperature and poured into 
ice-water. The precipitate was collected by filtration, washed with water (30 mL × 3), cold 
EtOH (10 mL), air-dried and recrystallized from EtOH. The product 50 was obtained as 
red crystals (0.62 g, 1.68 mmol, 90% yield). The synthesis of compounds 54a–54d 
followed the same protocol as described here. 
N
I
O
O
 1-(Cyclohexylmethyl)-5-iodoindoline-2,3-dione (50). Yield: 90%. 
Red crystals. 1H NMR (400 MHz, DMSO) δ 7.94 (dd, J = 8.3, 1.9 Hz, 1H), 7.77 (d, J = 1.8 
Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 3.46 (d, J = 6.9 Hz, 2H), 1.74 – 1.54 (m, 6H), 1.21 – 
0.89 (m, 5H). 13C NMR (101 MHz, DMSO) δ 182.09, 157.66, 150.52, 145.47, 131.99, 
119.47, 113.44, 85.92, 45.71, 35.74, 30.09, 25.79, 25.24. HRMS (ESI+) m/z calcd for 
C15H17INO2 [M+H]+: 370.0298, found: 370.0294. 
N
O
O
 1-(2-Cyclohexylethyl)-5-phenylindoline-2,3-dione (54a). 
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Compound 54a was synthesized from 53 and 1-bromo-2-cyclohexylethane as described in 
the preparation of 50. Yield: 81%. Sangria solid. 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.75 
(m, 2H), 7.58 – 7.32 (m, 5H), 6.96 (d, J = 8.1 Hz, 1H), 3.77 (t, J = 7.7 Hz, 2H), 1.80 – 1.55 
(m, 7H), 1.38 – 1.14 (m, 4H), 1.05 – 0.93 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 183.94, 
158.27, 150.15, 139.14, 137.28, 136.86, 129.22, 128.01, 126.68, 124.05, 118.22, 110.59, 
110.16, 38.48, 35.55, 34.64, 33.24, 26.54, 26.24. HRMS (ESI+) m/z calcd for C22H24NO2 
[M+H]+: 334.1802, found: 334.1802. 
N
O
O
 1-(3-Cyclohexylpropyl)-5-phenylindoline-2,3-dione 
(54b). Compound 54b was synthesized from 53 and 35 as described in the preparation of 
18. Yield: 76%. Sangria solid. 1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 14.1 Hz, 2H), 
7.65 – 7.28 (m, 5H), 6.97 (d, J = 8.1 Hz, 1H), 3.73 (t, J = 7.0 Hz, 2H), 1.77 – 1.60 (m, 7H), 
1.31 – 1.11 (m, 6H), 0.96 – 0.85 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 183.93, 158.37, 
150.25, 139.14, 137.29, 136.89, 129.22, 128.02, 126.68, 124.06, 118.16, 110.65, 40.86, 
37.52, 34.63, 33.39, 26.68, 26.42, 24.87. HRMS (ESI+) m/z calcd for C23H26NO2 [M+H]+: 
348.1958, found: 348.1957. 
N
O
O
 1-(4-Cyclohexylbutyl)-5-phenylindoline-2,3-dione (54c). 
Compound 54c was synthesized from 53 and 23 as described in the preparation of 50. Yield: 
71%. Sangria solid. 1H NMR (400 MHz, CDCl3) δ 7.87 – 7.77 (m, 2H), 7.57 – 7.33 (m, 
5H), 6.97 (d, J = 8.1 Hz, 1H), 3.75 (t, J = 7.3 Hz, 2H), 1.76 – 1.61 (m, 7H), 1.46 – 1.34 (m, 
2H), 1.25 – 1.07 (m, 6H), 0.91 – 0.79 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 183.92, 
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158.38, 150.25, 139.15, 137.30, 136.87, 129.22, 128.02, 126.69, 124.07, 118.18, 110.65, 
40.58, 37.69, 37.19, 33.47, 27.79, 26.78, 26.49, 24.37. HRMS (ESI+) m/z calcd for 
C24H28NO2 [M+H]+: 362.2115, found: 362.2103. 
N
O
O
Cl  1-(4-Chlorobenzyl)-5-phenylindoline-2,3-dione (54d). 
Compound 54d was synthesized from 53 and 4-chlorobenzyl bromide as described in the 
preparation of 50. Yield: 87%. Sangria solid. 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 
1.8 Hz, 1H), 7.72 (dd, J = 8.2, 1.9 Hz, 1H), 7.51 – 7.26 (m, 9H), 6.82 (d, J = 8.2 Hz, 1H), 
4.94 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 183.19, 158.47, 149.51, 138.98, 137.81, 
136.93, 134.34, 133.15, 129.46, 129.23, 129.00, 128.12, 126.70, 124.17, 118.28, 111.28, 
43.70. HRMS (ESI+) m/z calcd for C21H15ClNO2 [M+H]+: 348.0786, found: 348.0784. 
4.2.13 Preparation of 1,5-disubstituted isatins (51a–51e and 53) through Suzuki and 
Sonogashira coupling 
Preparation of 1-(cyclohexylmethyl)-5-phenylindoline-2,3-dione (51a). The protocol 
was slightly modified as described in the literature.[89b] The suspension of 50 (0.76 g, 2.06 
mmol, 1.00 equiv.), phenylboronic acid (1.50 equiv., 3.09 mmol, 0.38 g), 
Pd(dppf)Cl2·CH2Cl2 (0.03 equiv., 0.052 mmol, 0.05 g) and NaHCO3 (2.50 equiv., 5.15 
mmol, 0.43 g) in DME (8 mL) and distilled water (2 mL) was stirred at reflux under 
nitrogen atmosphere for 12 h (or overnight). The reaction mixture was cooled to room 
temperature and partitioned with EtOAc (30 mL) and 1 N HCl solution (30 mL). The 
organic layer was separated and the aqueous layer was extracted with EtOAc (30 mL × 3). 
The combined organic phase was washed with saturated NaHCO3 solution (30 mL), water 
(30 mL) and brine (30 mL), dried over anhydrous Na2SO4. The drying agent was filtered 
off and the filtrate was evaporated under reduced pressure. The residue was purified by 
flash chromatography using a mixture of hexanes and EtOAc (8:1) as eluent. The product 
51a was thus obtained as amber solid (0.50 g, 1.57 mmol, 76% yield).  The synthesis of 
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51b, 51c and 53 followed the same protocol as described here. 
N
O
O
 1-(Cyclohexylmethyl)-5-phenylindoline-2,3-dione (51a). 
Yield: 76%.  1H NMR (400 MHz, DMSO) δ 7.96 (dd, J = 8.3, 2.0 Hz, 1H), 7.80 (d, J = 1.9 
Hz, 1H), 7.72 – 7.64 (m, 2H), 7.50 – 7.27 (m, 4H), 3.53 (d, J = 6.9 Hz, 2H), 1.88 – 1.55 
(m, 6H), 1.28 – 0.86 (m, 5H). 13C NMR (101 MHz, DMSO) δ 183.81, 158.93, 150.87, 
139.01, 136.54, 135.63, 129.45, 127.99, 126.73, 122.63, 118.47, 111.92, 46.22, 36.26, 
30.59, 26.24, 25.69. HRMS (ESI+) m/z calcd for C21H22NO2 [M+H]+: 320.1645, found: 
320.1650. 
N
O
O
 5-([1,1'-Biphenyl]-4-yl)-1-
(cyclohexylmethyl)indoline-2,3-dione (51b). Compound 51b was synthesized from 50 
and 4-biphenylboronic acid as described in the preparation of 51a. Yield: 67%. Mahogany 
solid. 1H NMR (400 MHz, DMSO) δ 8.01 (dd, J = 8.2, 1.5 Hz, 1H), 7.87 – 7.69 (m, 7H), 
7.48 (t, J = 7.6 Hz, 2H), 7.38 (t, J = 7.3 Hz, 1H), 7.29 (d, J = 8.3 Hz, 1H), 3.53 (d, J = 6.8 
Hz, 2H), 1.80 – 1.56 (m, 6H), 1.24 – 1.09 (m, 3H), 1.06 – 0.94 (m, 2H). 13C NMR (101 
MHz, DMSO) δ 183.37, 158.50, 150.48, 139.47, 139.23, 137.53, 135.96, 134.60, 129.00, 
127.58, 127.23, 126.79, 126.55, 122.08, 118.08, 111.52, 45.82, 35.85, 30.18, 25.82, 25.27. 
HRMS (ESI+) m/z calcd for C27H26NO2 [M+H]+: 396.1958, found: 396.1948. 
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N
O
O
 1-(Cyclohexylmethyl)-5-(naphthalen-2-yl)indoline-2,3-
dione (51c). Compound 51c was synthesized from 50 and 2-naphthylboronic acid as 
described in the preparation of 51a. Yield: 65%. Sangria solid. 1H NMR (400 MHz, DMSO) 
δ 8.26 (d, J = 1.3 Hz, 1H), 8.11 (dd, J = 8.3, 2.0 Hz, 1H), 8.04 – 7.90 (m, 4H), 7.86 (dd, J 
= 8.6, 1.9 Hz, 1H), 7.60 – 7.47 (m, 2H), 7.33 (d, J = 8.3 Hz, 1H), 3.55 (d, J = 6.8 Hz, 2H), 
1.81 – 1.56 (m, 6H), 1.27 – 0.95 (m, 5H). 13C NMR (101 MHz, DMSO) δ 183.40, 158.54, 
150.49, 136.28, 135.83, 134.95, 133.30, 132.22, 128.56, 128.19, 127.47, 126.48, 126.19, 
124.84, 124.58, 122.47, 118.15, 111.54, 45.82, 35.88, 30.18, 25.82, 25.28. HRMS (ESI+) 
m/z calcd for C25H24NO2 [M+H]+: 370.1802, found: 370.1779. 
N
H
O
O
 5-Phenylindoline-2,3-dione (54). Compound 54 was synthesized 
from 5-iodoisatin (49) and phenylboronic acid as described in the preparation of 51a. Yield: 
62%. Barn red solid. 1H NMR (400 MHz, DMSO) δ 11.13 (s, 1H), 7.88 (d, J = 8.2 Hz, 1H), 
7.74 (s, 1H), 7.63 (d, J = 7.7 Hz, 2H), 7.44 (t, J = 7.5 Hz, 2H), 7.35 (t, J = 7.2 Hz, 1H), 
6.99 (d, J = 8.2 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 184.36, 159.56, 149.95, 138.73, 
136.46, 134.89, 129.01, 127.49, 126.23, 122.46, 118.43, 112.68. HRMS (ESI+) m/z calcd 
for C14H10NO2 [M+H]+: 224.0706, found: 224.0706. 
Preparation of 1-(cyclohexylmethyl)-5-(phenylethynyl)indoline-2,3-dione (51d). The 
suspension of 50 (0.67 g, 1.81 mmol, 1.00 equiv.), phenylacetylene (1.50 equiv., 2.72 mmol, 
0.28 g), Pd(dppf)Cl2·CH2Cl2 (0.03 equiv., 0.0543 mmol, 0.0443 g), CuI (0.02 equiv., 
0.0362 mmol, 0.0069 g) and DIPEA (5.00 equiv., 9.06 mmol, 1.17 g) in DMF (5 mL) was 
stirred at room temperature under nitrogen atmosphere for 24 h before the reaction mixture 
was partitioned with EtOAc (30 mL) and saturated NH4Cl solution (30 mL). The organic 
layer was separated and the aqueous layer was extracted with EtOAc (30 mL × 3). The 
combined organic phase was washed with saturated NaHCO3 solution (30 mL), water (30 
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mL)  and brine (30 mL), dried over anhydrous Na2SO4. The drying agent was filtered off 
and the filtrate was evaporated under reduced pressure. The residue was purified by flash 
chromatography using a mixture of hexanes and EtOAc (8:1) as eluent. The product 51d 
was thus obtained as mahogany solid (0.56 g, 1.63 mmol, 90 % yield). The synthesis of 
51e followed the same protocol as described here. 
N
O
O
 1-(Cyclohexylmethyl)-5-(phenylethynyl)indoline-2,3-
dione (51d). Yield: 90%. Mahogany solid. 1H NMR (400 MHz, CDCl3) δ 7.78 – 7.65 (m, 
2H), 7.55 – 7.44 (m, 2H), 7.39 – 7.31 (m, 3H), 6.89 (d, J = 8.2 Hz, 1H), 3.56 (d, J = 7.0 
Hz, 2H), 1.83 – 1.66 (m, 6H), 1.27 – 1.15 (m, 3H), 1.10 – 1.00 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 183.03, 158.46, 150.86, 141.20, 131.73, 128.79, 128.59, 128.37, 122.74, 
119.14, 117.61, 110.70, 90.47, 87.43, 46.89, 36.42, 31.05, 26.22, 25.76. HRMS (ESI+) m/z 
calcd for C23H22NO2 [M+H]+: 344.1645, found: 344.1620. 
N
O
O
 5-(Cyclohexylethynyl)-1-(cyclohexylmethyl)indoline-
2,3-dione (51e). Compound 51e was synthesized from 50 and ethynylcyclohexane as 
described in the preparation of 51d. Yield: 84%. Clay color solid. 1H NMR (400 MHz, 
CDCl3) δ 7.62 – 7.53 (m, 2H), 6.81 (d, J = 8.2 Hz, 1H), 3.53 (d, J = 7.3 Hz, 2H), 2.65 – 
2.48 (m, 1H), 1.86 – 1.68 (m, 10H), 1.56 – 1.46 (m, 3H), 1.37 – 0.98 (m, 9H). 13C NMR 
(101 MHz, CDCl3) δ 183.22, 158.52, 150.24, 141.14, 128.41, 120.06, 117.45, 110.46, 
95.71, 78.69, 46.79, 36.37, 32.67, 31.02, 29.72, 26.22, 25.98, 25.75, 24.97. HRMS (ESI+) 
m/z calcd for C23H28NO2 [M+H]+: 350.2115, found: 350.2090. 
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4.2.14 Preparation of (Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-2,4-dione 
derivatives 52a–52e, 54 and 55a–55d 
Preparation of (Z)-2-(5-(1-(Cyclohexylmethyl)-2-oxo-5-phenylindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (52a). The suspension of 51a (0.35 g, 1.10 mmol, 1.00 
equiv.) and 40 (1.10 equiv., 1.21 mmol, 0.21g) in the presence of NH4OAc (2.00 equiv., 
2.19 mmol, 0.17g) was stirred in glacial AcOH at 108 °C for 12 h (or overnight). The 
reaction mixture was cooled to room temperature and the precipitate was collected by 
filtration. The filter cake was washed with cold EtOH (10 mL), air-dried and recrystallized 
from a mixture of EtOH and DMF to give the product 52a as sangria crystals (0.38 g, 0.80 
mmol, 73% yield). The synthesis of 52b–52e, 54 and 55a–55d followed the same protocol 
as described here. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(Cyclohexylmethyl)-2-oxo-5-phenylindolin-3-
ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (52a). Yield: 73%. Sangria crystals. 1H 
NMR (400 MHz, DMSO) δ 9.20 (d, J = 1.8 Hz, 1H), 7.77 (dd, J = 8.2, 1.9 Hz, 1H), 7.68 – 
7.60 (m, 2H), 7.49 (t, J = 7.7 Hz, 2H), 7.41 – 7.25 (m, 3H), 4.06 (s, 2H), 3.65 (d, J = 7.3 
Hz, 2H), 1.88 – 1.52 (m, 6H), 1.27 – 0.90 (m, 5H). 13C NMR (101 MHz, DMSO) δ 169.35, 
167.13, 167.08, 165.39, 143.97, 139.81, 134.66, 131.23, 130.83, 129.07, 127.21, 126.24, 
126.03, 125.97, 124.30, 119.74, 110.17, 109.57, 46.01, 44.55, 35.94, 30.23, 25.81, 25.21. 
HRMS (ESI+) m/z calcd for C26H23N2O5S [M-H]-: 475.1333, found: 475.1344. 
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N
O
S
N
O
O
CO2H
  (Z)-2-(5-(5-([1,1'-Biphenyl]-4-yl)-1-
(cyclohexylmethyl)-2-oxoindolin-3-ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid 
(52b). Compound 52b was synthesized from 51b and 40 as described in the preparation of 
52a. Yield: 64%. Sangria crystal. 1H NMR (400 MHz, DMSO) δ 13.63 (s, 1H), 9.20 (d, J 
= 1.7 Hz, 1H), 7.85 (dd, J = 8.2, 1.6 Hz, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.72 (d, J = 8.4 Hz, 
4H), 7.49 (t, J = 7.6 Hz, 2H), 7.41 – 7.30 (m, 2H), 4.46 (s, 2H), 3.66 (d, J = 7.2 Hz, 2H), 
1.83 – 1.58 (m, 6H), 1.23 – 1.12 (m, 3H), 1.07 – 0.96 (m, 2H). 13C NMR (101 MHz, DMSO) 
δ 169.37, 168.02, 167.12, 165.06, 144.36, 139.63, 139.07, 138.78, 134.27, 131.25, 130.01, 
129.10, 127.65, 127.44, 127.01, 126.80, 126.64, 125.95, 119.76, 110.48, 46.14, 42.07, 
36.02, 30.29, 25.87, 25.29. HRMS (ESI+) m/z calcd for C32H27N2O5S [M-H]-: 551.1646, 
found: 551.1680. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(Cyclohexylmethyl)-5-(naphthalen-2-yl)-2-
oxoindolin-3-ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (52c). Compound 52c was 
synthesized from 51c and 40 as described in the preparation of 52a. Yield: 47%. Amber 
crystals. 1H NMR (400 MHz, DMSO) δ 13.53 (s, 1H), 9.24 (d, J = 1.7 Hz, 1H), 8.13 (s, 
1H), 8.06 – 7.89 (m, 4H), 7.78 (dd, J = 8.5, 1.6 Hz, 1H), 7.58 – 7.50 (m, 2H), 7.35 (d, J = 
8.3 Hz, 1H), 4.48 (s, 2H), 3.67 (d, J = 7.2 Hz, 2H), 1.88 – 1.50 (m, 6H), 1.20 – 0.95 (m, 
5H). 13C NMR (101 MHz, DMSO) δ 169.31, 167.93, 167.05, 164.95, 144.32, 137.23, 
134.68, 133.28, 132.10, 131.69, 129.97, 128.68, 128.11, 127.54, 126.91, 126.54, 126.30, 
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126.09, 124.85, 124.66, 119.69, 110.44, 46.06, 42.01, 35.97, 30.22, 25.81, 25.22. HRMS 
(ESI+) m/z calcd for C30H25N2O5S [M-H]-: 525.1490, found: 525.1530. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(Cyclohexylmethyl)-2-oxo-5-
(phenylethynyl)indolin-3-ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (52d). 
Compound 52d was synthesized from 51d and 40 as described in the preparation of 52a. 
Yield: 67%. Mahogany crystals. 1H NMR (400 MHz, DMSO) δ 13.54 (s, 1H), 8.95 (d, J = 
1.5 Hz, 1H), 7.69 (dd, J = 8.2, 1.6 Hz, 1H), 7.62 – 7.51 (m, 2H), 7.51 – 7.38 (m, 3H), 7.29 
(d, J = 8.3 Hz, 1H), 4.47 (s, 2H), 3.64 (d, J = 7.2 Hz, 2H), 1.78 – 1.57 (m, 6H), 1.18 – 0.95 
(m, 5H). 13C NMR (101 MHz, DMSO) δ 169.09, 167.87, 166.99, 164.85, 144.82, 135.92, 
131.36, 130.83, 130.23, 128.78, 128.71, 125.97, 122.33, 119.27, 116.29, 110.41, 89.15, 
88.50, 46.13, 42.03, 35.94, 30.19, 25.81, 25.21. HRMS (ESI+) m/z calcd for C28H23N2O5S 
[M-H]-: 499.1333, found: 499.1373. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(5-(Cyclohexylethynyl)-1-(cyclohexylmethyl)-
2-oxoindolin-3-ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (52e). Compound 52e was 
synthesized from 51e and 40 as described in the preparation of 52a. Yield: 72%. Mahogany 
crystals. 1H NMR (400 MHz, DMSO) δ 8.76 (s, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.16 (d, J = 
8.3 Hz, 1H), 4.45 (s, 2H), 3.59 (d, J = 7.0 Hz, 2H), 2.67 – 2.58 (m, 1H), 1.89 – 1.78 (m, 
2H), 1.72 – 1.42 (m, 11H), 1.38 – 1.06 (m, 6H), 1.03 – 0.90 (m, 2H). 13C NMR (101 MHz, 
DMSO) δ 169.15, 167.88, 166.94, 164.82, 144.11, 135.71, 130.45, 130.26, 126.16, 119.11, 
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117.43, 110.17, 93.48, 80.09, 46.06, 42.00, 35.92, 32.33, 30.19, 28.89, 25.81, 25.40, 25.22, 
24.45. HRMS (ESI+) m/z calcd for C28H29N2O5S [M-H]-: 505.1803, found: 505.1853. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(2-Cyclohexylethyl)-2-oxo-5-phenylindolin-3-
ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (55a). Compound 55a was synthesized 
from 54a and 40 as described in the preparation of 52a. Yield: 63%. Rust crystals. 1H NMR 
(400 MHz, DMSO) δ 9.11 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 7.6 Hz, 2H), 7.48 
(t, J = 7.6 Hz, 2H), 7.36 (t, J = 7.3 Hz, 1H), 7.21 (d, J = 8.2 Hz, 1H), 4.41 (s, 2H), 3.78 (t, 
J = 7.3 Hz, 2H), 1.80 – 1.46 (m, 7H), 1.33 – 1.09 (m, 4H), 0.98 – 0.85 (m, 2H). 13C NMR 
(101 MHz, DMSO) δ 169.24, 167.86, 166.56, 164.94, 143.53, 139.68, 134.75, 131.23, 
129.90, 129.05, 127.26, 126.88, 126.21, 126.08, 119.75, 109.86, 42.24, 37.91, 34.69, 34.22, 
32.50, 26.02, 25.67. HRMS (ESI+) m/z calcd for C27H25N2O5S [M-H]-: 489.1490, found: 
489.1546. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(3-Cyclohexylpropyl)-2-oxo-5-
phenylindolin-3-ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (55b). Compound 55b 
was synthesized from 54b and 40 as described in the preparation of 52a. Yield: 58%. 
Sangria crystals. 1H NMR (400 MHz, DMSO) δ 13.51 (s, 1H), 9.09 (s, 1H), 7.76 (d, J = 
8.2 Hz, 1H), 7.60 (d, J = 7.7 Hz, 2H), 7.48 (t, J = 7.4 Hz, 2H), 7.36 (t, J = 7.3 Hz, 1H), 
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7.23 (d, J = 8.2 Hz, 1H), 4.44 (s, 2H), 3.73 (t, J = 6.7 Hz, 2H), 1.77 – 1.45 (m, 7H), 1.35 – 
0.95 (m, 6H), 0.95 – 0.49 (m, 2H). 13C NMR (101 MHz, DMSO) δ 169.23, 167.89, 166.64, 
164.86, 143.71, 139.65, 134.72, 131.25, 129.70, 129.05, 127.27, 126.98, 126.20, 126.05, 
119.66, 109.92, 41.95, 36.73, 33.83, 32.74, 26.13, 25.81, 24.39. HRMS (ESI+) m/z calcd 
for C28H27N2O5S [M-H]-: 503.1646, found: 503.1704. 
N
O
S
N
O
O
CO2H
  (Z)-2-(5-(1-(4-Cyclohexylbutyl)-2-oxo-5-phenylindolin-
3-ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (55c). Compound 55c was synthesized 
from 54c and 40 as described in the preparation of 52a. Yield: 60%. Mahogany crystals. 
1H NMR (400 MHz, DMSO) δ 13.54 (s, 1H), 9.15 (s, 1H), 7.81 (d, J = 8.3 Hz, 1H), 7.64 
(d, J = 7.7 Hz, 2H), 7.50 (t, J = 7.6 Hz, 2H), 7.43 – 7.26 (m, 2H), 4.46 (s, 2H), 3.81 (t, J = 
6.9 Hz, 2H), 1.67 – 1.56 (m, 7H), 1.36 – 1.26 (m, 2H), 1.22 – 1.06 (m, 6H), 0.88 – 0.76 (m, 
2H). 13C NMR (101 MHz, DMSO) δ 169.28, 167.92, 166.70, 164.92, 143.74, 139.71, 
134.78, 131.28, 129.79, 129.09, 127.30, 127.00, 126.24, 126.09, 119.71, 110.01, 42.04, 
39.98, 36.96, 36.48, 32.83, 27.30, 26.21, 25.85, 23.53. HRMS (ESI+) m/z calcd for 
C29H29N2O5S [M-H]-: 517.1803, found: 517.1876. 
N
O
Cl
S
N
O
O
CO2H
  (Z)-2-(5-(1-(4-Chlorobenzyl)-2-oxo-5-phenylindolin-3-
ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid (55d). Compound 55d was synthesized 
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from 54d and 40 as described in the preparation of 52a. Yield: 69%. Mahogany crystals. 
1H NMR (400 MHz, DMSO) δ 13.52 (s, 1H), 9.16 (d, J = 1.6 Hz, 1H), 7.74 (dd, J = 8.3, 
1.7 Hz, 1H), 7.61 (d, J = 7.4 Hz, 2H), 7.54 – 7.32 (m, 7H), 7.17 (d, J = 8.3 Hz, 1H), 5.07 
(s, 2H), 4.48 (s, 2H). 13C NMR (101 MHz, DMSO) δ 169.08, 167.86, 167.01, 164.91, 
143.20, 139.69, 135.18, 134.75, 132.27, 131.23, 130.37, 129.21, 129.06, 128.72, 127.33, 
126.86, 126.28, 126.15, 119.90, 110.32, 42.63, 42.04. HRMS (ESI+) m/z calcd for 
C26H18ClN2O5S [M+H]+: 505.0619, found: 505.0621. 
4.2.15 Preparation of the meglumine salt of 52e (52e-MEG) 
Preparation of the meglumine salt of (Z)-2-(5-(5-(Cyclohexylethynyl)-1-
(cyclohexylmethyl)-2-oxoindolin-3-ylidene)-2,4-dioxothiazolidin-3-yl)acetic acid 
(52e-MEG). The protocol was slightly modified as described in the literature.[92] The 
suspension of 52e (1.85 g, 3.65 mmol, 1.00 equiv.) and meglumine (N-methyl-D-glucamine, 
1.20 equiv., 4.38 mmol, 0.86 g) in EtOH (50 mL) was heated at reflux for 5 h with rigorous 
stirring. The reaction mixture was stood at room temperature overnight. The precipitate 
was filtered off, washed with cold EtOH (25 mL × 3) and dried with infrared lamp and 
recrystallized from EtOH. The meglumine salt of 52e (52e-MEG) was thus obtained as 
brick red solid (2.08 g, 2.96 mmol, 81% yield). 
N
O
S
N
O
O
CO2
Me
H2
N
OH
OH
OH
OH
OH
•
The meglumine salt of (Z)-2-
(5-(5-(Cyclohexylethynyl)-1-(cyclohexylmethyl)-2-oxoindolin-3-ylidene)-2,4-
dioxothiazolidin-3-yl)acetic acid (52e-MEG). Yield: 81%. Brick red solid. 1H NMR (400 
MHz, DMSO) δ 8.84 (d, J = 1.6 Hz, 1H), 7.46 (dd, J = 8.2, 1.6 Hz, 1H), 7.17 (d, J = 8.3 
Hz, 1H), 5.27 (d, J = 447.2 Hz, 3H), 4.04 (s, 2H), 3.89 – 3.82 (m, 1H), 3.65 – 3.54 (m, 4H), 
3.50 – 3.35 (m, 4H), 3.00 (dd, J = 12.6, 3.2 Hz, 1H), 2.89 (dd, J = 12.5, 9.3 Hz, 1H), 2.69 
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– 2.58 (m, 1H), 2.50 (s, 3H), 1.88 – 1.43 (m, 13H), 1.39 – 1.28 (m, 3H), 1.18 – 0.91 (m, 
5H). 13C NMR (101 MHz, DMSO) δ 169.23, 168.09, 167.03, 165.27, 143.87, 135.26, 
131.87, 130.28, 125.17, 119.21, 117.28, 110.01, 93.33, 80.17, 71.27, 70.31, 68.46, 63.35, 
51.06, 45.97, 44.68, 35.88, 32.99, 32.29, 30.17, 28.85, 25.78, 25.36, 25.18, 24.41. HRMS 
(ESI+) m/z calcd for C28H31N2O5S [M+H]-: 507.1948, found: 507.1950. HRMS (ESI+) m/z 
calcd for C7H18NO5 [M+H]-: 196.1179, found: 196.1184. 
4.3 Crystallographic studies 
Single crystals of compound 42 suitable for X-ray crystallographic analysis were obtained 
by slow recrystallization from DMSO solution of 42 in the fume hood at room temperature. 
Maroon single crystals of 42 were placed in dry and degassed polyisobutene oil and 
mounted on a fiber loop[100] and used for X-ray diffraction analysis. Single crystal X-ray 
diffraction data were collected at 90.0 (2) K on a Bruker D8 Venture diffractometer with 
graded-multilayer focused Mo Kα X-rays. Raw data were integrated, scaled, merged and 
corrected for Lorentz-polarization effects using the APEX3 package.[101]  Corrections for 
absorption were applied using SADABS.[102]  The structure was solved by direct 
methods[103] and refinement was carried out against F2 by weighted full-matrix least-
squares.[104]  Hydrogen atoms were found in difference maps, but subsequently placed at 
calculated positions and refined using a riding model.  Non-hydrogen atoms were refined 
with anisotropic displacement parameters.  Non-merohedric twinning was diagnosed with 
APEX3, but later handled by TwinRotMat in Platon[105] as it gave a more complete dataset.  
Refinement progress was checked using Platon and by an R-tensor.[106] The final model 
was further checked with the IUCr utility checkCIF.  Atomic scattering factors were taken 
from the International Tables for Crystallography.[107] Crystallographic data are collected 
in Table 1.  All other details are included in the CIF, which is available free of charge from 
the CCDC, deposition code 1846371. 
Table 4-1. Crystallographic data for compound 42. 
Compound 42 
Moiety formula C13H8N2O5S, C2H6OS 
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Sum formula C15H14N2O6S2 
Crystal size (mm) 382.03 
Crystal system Triclinic 
Space group P
_
1  
a/Å 5.0022(10) 
b/Å 11.119(4) 
c/Å 14.996(5) 
α/° 75.785(8) 
β/° 86.220(8) 
γ/° 85.097(8) 
Z 2 
V/Å3 804.7(4) 
Dcalcd/g·cm-3 1.578 
T/K 90 
F(000) 396 
h,k,lmax 6,14,19 
R (reflections) 0.0642  
wR2 (reflections) 0.1790  
4.4 In vitro experimental tests 
4.4.1 Preparation of mPGES-1 enzymes 
Cloning of mPGES-1 and the protein preparation were described in our previous reports.[108] 
Briefly, FreeStyle Max Expression system was used to express wild-type human and mouse 
mPGES-1 enzymes separately. FreeStyle 293-F cells were cultured following 
manufacturer’s manual in FreeStyle 293 expression medium on orbit rotate shaker in 8% 
CO2 incubator at 37oC. Cells were transfected with 1.5 µg/mL of mPGES-1/pcDNA3 
construct using FreeStyle Max reagent at a cell density of 1 × 106 for 2 days. Transfected 
cells were collected, washed, and sonicated in TSES buffer (15 mM Tris-HCl, pH 8.0 plus 
0.25 M sucrose, 0.1 mM EDTA and 1 mM DTT) on ice. The broken cells were first 
113 
 
centrifuged at 12,500 × g for 10 min. The supernatant was further centrifuged at 105,000 
× g for 1 hr at 4oC. The pellet was washed and homogenized in PBS buffer. The crude 
microsomal mPGES-1 preparations were aliquoted and stored at -80 oC before use. 
4.4.2 Activity assays using a recombinant mPGES-1 
The enzyme activity assays were performed according to our previous reports.[76-77] Briefly, 
the mPGES-1-catalyzed reaction was carried out in 1.5 mL microfuge tubes with reaction 
mixture of 0.2 Na2HPO4/NaH2PO4, pH 7.2 (10 µL); 2.5 mM GSH (2.5 µL); diluted 
microsomal human or mouse mPGES-1 enzyme (80 µg/mL, 1 µL); inhibitor in DMSO 
solution (1 µL); 0.31 mM PGH2 in DMF (5 µL) and distilled deionized water in a final 
volume of 100 µL. An inhibitor was incubated with enzyme for 15 min at ambient 
temperature followed by the addition of cold PGH2 (stored in dry ice). The enzymatic 
reaction was initiated immediately upon adding PGH2. After 1 min of reaction, stop 
solution (40 mg/mL SnCl2 in absolute ethanol, 10 µL) was added to cease the reaction by 
converting excess PGH2 to PGF2α. The produced PGE2 from the enzymatic reaction was 
quantified by the PGE2 enzyme immunoassay.[109]  
4.4.3 Activity assays of COX-1/2 
The inhibition of COX isoenzymes was determined by using COX (ovine/human) inhibitor 
screening assay kit purchased from Cayman Chemical Company (Ann Arbor, MI). We used 
a mixture of equal amount COX-1 and COX-2 instead of single enzyme and followed the 
recommended protocol. 
4.5 In vivo experiments 
4.5.1 Animals 
Wild-type male CD-1 mice (28-35 g) were ordered from Harlan (Indianapolis, IN), and 
housed for a week prior to the experimental studies. All animals were allowed ad libitum 
access to food and water and maintained on a 12 h light/12 h dark cycle, with the lights on 
at 8:00 am at a room temperature of 21–22 oC. Experiments were performed in a same 
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colony room in accordance with the Guide for the Care and Use of Laboratory Animals as 
adopted and promulgated by the National Institutes of Health. The animal protocol was 
approved by the IACUC (Institutional Animal Care and Use Committee) at the University 
of Kentucky.  
4.5.2 Wild-type mice based air-pouch model of inflammation 
Air-pouches (cavities) were produced by duplicate injections of 3 mL of sterile air under 
the skin on the backs of mice. Following the formation of the air-pouch, six days after the 
initial air injection, 1 mL of 1% (w/v) solution of λ-carrageenan dissolved in sterile saline 
was injected directly into the pouch to produce an inflammatory response. Then, the mice 
treated with the test compound, celecoxib, or vehicle administered orally. 24 hours later, 
the mice were sacrificed by carbon dioxide (compressed gas) inhalation until visible 
respiration has ceased, followed by thoracotomy, and the air-pouch fluid and other tissues 
(including kidney) were collected. The collected samples were analyzed for their PGE2 
concentrations by using the PGE2 enzyme immunoassay.
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 Concluding Remarks 
5.1 Overall conclusion 
Generally, a traditional typical drug discovery and development process is largely focused 
on identifying ligands of human enzyme targets. The species distinction is not specifically 
taken into consideration during the early stage of drug design and discovery. Actually, some 
ligands identified in vitro turn out to be inactive in the in vivo mouse/rat models. 
Our study described in this thesis has demonstrated that it is a more effective strategy to 
rationally design a dual inhibitor of human and mouse target enzymes. We successfully 
designed and developed two series of compounds, substituted benzylidenebarbituric acid 
derivatives and (Z)-5-(2-oxoindolin-3-ylidene)thiazolidine-2,4-dione derivatives, as 
inhibitors potent against both human and mouse mPGES-1 enzymes. A number of these 
synthesized compounds were not only potent in in vitro assays, selective for mPGES-1 
over COX isozymes, but also effective in vivo using wild-type mouse carrageenan air-
pouch model. The results demonstrated that by focusing on the conserved region at the 
active site of both human and mouse enzymes, it is possible to design and discover dual 
inhibitors targeting enzymes in multiple species. The general strategy of our presented 
structure-based rational design of dual inhibitors of both human and mouse mPGES-1 
enzymes might also be employed for other drug targets with species difference in the 
ligand-enzyme bindings. 
5.2 Future directions 
The results shown in Fig. 2-4 and Fig. 3-4 indicated the effectiveness of compounds 25b 
and 52e in reducing PGE2 levels in both air-pouch fluid and kidney extract samples in 
mouse carrageenan air-pouch model. However, to further elucidate the in vivo activity and 
the pharmacological effects of these compounds, more animal experiments should be 
conducted. For the evaluation of anti-inflammatory effects, rat carrageenan-induced paw 
edema model and adjuvant arthritis model are frequently used. In addition, we may also 
evaluate the analgesic effects with these candidate compounds by performing carrageenan-
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induced hyperalgesia experiment, formalin test, and acetic acid-induced writhing 
experiment. 
Compounds 25b and 52e were identified as potent inhibitors against both human and 
mouse mPGES-1 enzymes, and these two compounds can be used as new leads for the 
design of inhibitors with the same scaffolds. In order to maintain the similar binding modes 
with human and mouse mPGES-1 enzymes, minor structural modification can be made on 
the original structures. We may pay particular attention in the improvement of aqueous 
solubility by introducing hydrophilic groups. In addition, virtual screening has emerged as 
a powerful approach widely employed in modern rational drug design. Using the recently 
disclosed human mPGES-1 structure and mouse mPGES-1 structure (derived by using 
human mPGES-1 crystal structure as a template), our group is able to screen compounds 
with a wide range of chemical scaffolds. Based on the binding modes, the identified hits 
with novel scaffolds are subjected to structural optimization via organic synthesis. The 
synthesized compounds are screened at single concentration (i.e. 10 µM) and those caused 
significant inhibition (≥ 70%) are further tested for their IC50 values. As described in 
Chapters 2 and 3, the selectivity of mPGES-1 over COX isozymes will be also tested. 
Similarly, mouse carrageenan air-pouch model can be used as the initial investigation of 
the in vivo activity of the inhibitors.
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